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The cytochrome P450 superfamily of enzymes are critical in the metabolism of endogenous 
and exogenous substrates. CYP1A1 and CYP1B1 have been found to be over-expressed in 
tumour cells whilst undetected or present in very low levels in corresponding normal tissue. 
This presented a novel target for the development of anti-cancer prodrugs, which would 
remain non-toxic until undergoing metabolism to toxic species by CYP1 enzymes over-
expressed at tumour sites. The chalcones have been shown to exhibit effective anti-cancer 
prodrug activity, but are labile to photoisomerisation reactions converting the potent trans 
isomer to the less toxic cis isomer. Several heterocyclic ring systems were incorporated 
across the α,β-unsaturated moiety of the chalcones to produce rigid structures, eliminating the 
possibility of photoisomerisation occurring whilst maintaining the substituted phenyl groups 
in a trans like geometry.  Lead compounds were identified using an in vitro MTT screening 
assay against a panel of tumour cell lines characterised for their constitutive or inducible 
CYP1 expression. These were the MDA 468, MCF7 and MDA 231 cell lines. The non-
tumour MCF10A cell line which has no basal CYP1 expression was used as the control.  
A library of eighteen 3,5-diarylpyrazoles were synthesised. The lead pyrazole DMU 10107 
(3-(2,3,4-trimethoxyphenyl)-5-(3,4-methylenedioxyphenyl)pyrazole) gave an IC50
 value of 
8µM towards the MDA 468 cell line. The MCF7 cells, TCDD induced and non-induced gave 
IC50 values of 10µM each. Although the pyrazoles showed plausible tumour toxicity, an 
investigation into six membered pyrimidine heterocycles was undertaken in an attempt to 
obtain enhanced cytotoxicities than those observed from the five membered pyrazoles. 
Therefore, a library of fifteen 2-amino-4,6-diarylpyrimidines was synthesised. The lead 
amino-pyrimidine DMU 10212 (2-amino-4-(2,4-dimethoxyphenyl)-6-(3,4-
methylenedioxyphenyl)pyrimidine) showed significant cytotoxicity towards the MDA 468 
cell line with an IC50 value of 0.01µM. Notable IC50 values of 0.3µM and 0.07µM were also 
observed towards the MCF7 and MCF7 cells induced with TCDD. The important toxicity 
seen from the 2-amino-4,6-diarylpyrimidines prompted the investigation of the 2-position of 
the pyrimidine ring, and to assess the tumour toxicities of the synthesised compounds.  
The 2-amino-4,6-diarylpyrimidines were converted to produce 4,6-diarylpyrimidones by a 
one-step conversion reaction using sodium nitrate. The pyrimidone DMU 10313 (4-(2-
methoxyphenyl)-6-(3,4-methylenedioxyphenyl)pyrimidin-2-one) showed high toxicity with 
an IC50 value of 0.07µM towards the MDA 468 cells and IC50 values of 1.8µM and 0.5µM 
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towards the MCF7 and MCF7 cells induced with TCDD. A library of nine 2-morpholino-4,6-
diarylpyrimidines was synthesised. The lead compound DMU 10405 (4-(2,4-
dimethoxyphenyl)-6-(4-methoxyphenyl)-2-morpholinopyrimidine) gave an IC50 value of 
10µM towards the MDA 468 cells. DMU 10600 (4-(2,4-dimethoxyphenyl)-6-(3,4-
methylenedioxyphenyl)-2-dimethylethylenediaminopyrimidine), showed an IC50 value of 
7µM towards the MDA 468 cells and an identical IC50 value of 10µM towards the MCF7 and 
MCF7 cells treated with TCDD. DMU 10700 (2-methyl-4-(2,4-dimethoxyphenyl)-6-(3,4-
methylenedioxyphenyl)pyrimidine), a substituted pyrimidine based on the phenyl 
substitutions of DMU 10212 gave an IC50 value of 2.5µM towards the MDA 468 cells. DMU 
10800 (4-(2,4-dimethoxyphenyl)-6-(3,4-methylenedioxyphenyl)pyrimidine), also based on 
the phenyl substitutions of DMU 10212 showed an IC50 value of 0.08µM towards the MDA 
468 cells and equal IC50 values of 0.2µM against the MCF7 and MCF7 cells induced with 
TCDD. All lead compounds did not show toxicity towards the non-tumour MCF10A cell 
line. 
DMU 10212 was selected as the overall lead compound due to the significant tumour 
toxicities recorded, and for the non-toxicity observed towards the MCF10A cells. Inhibition 
studies using the known CYP1 inhibitor α-naphthoflavone (α-NF) were conducted to show 
that DMU 10212 was a substrate of the CYP1 enzymes. The resulting data showed that the 
cytotoxicity of DMU 10212 was completely eliminated suggesting CYP1 enzymes play an 
activating role in the cytotoxic effect of DMU 10212. LCMS metabolism studies using 
isolated CYP1 isoforms were performed showing that DMU 10212 is metabolised to produce 
four metabolites (M1, M2, M3 and M4), determined from their individual retention times and 
molecular masses. The metabolites of DMU 10212 were also found to be generated at a 
greater rate with CYP1A1 than CYP1B1. Metabolite structures were proposed as CYP1 
enzyme reactions are known. The metabolite M2 was synthesised and was identified to be an 
authentic metabolite of DMU 10212 via LCMS and co-elution studies. Screening of M2 
against the tumour cells gave an IC50 value of 0.6µM towards the MDA 468 cells, and IC50 
values of 0.6µM and 1µM against the MCF7 and MCF7 cells induced with TCDD. In 
conclusion, DMU 10212, a novel CYP1 activated anticancer prodrug with selective high 
toxicity towards tumour cells has been identified. 
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Cancer is used to define the uncontrolled multiplication and spread of abnormal cells within 
the body.1 Hallmark characteristics of cancer cells include uncontrolled proliferation, 
insensitivity to negative and positive growth regulation, evasion of apoptosis, invasiveness, 
metastasis and loss of normal function.2 
A statistical report published by Cancer Research UK showed that 408,381 new cancer 
incidences and 156,723 cancer deaths occurred in the United Kingdom for the year 2008.3 
Breast cancer had the highest new incidence rate with 48,034 cases recorded, whilst the 
highest number of deaths were caused by lung cancer with 35,261 documented reports 
(Figure 1). 
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1.1 Cancer on a Cellular Level 
1.1.1 The Cell Cycle 
Normal cell proliferation can be illustrated by the cell cycle (Figure 2).1 Progression through 
the cell cycle is dependent on the balance of signalling pathways between positive growth 
factors and negative regulatory proteins. These are involved in the various phases of the cell 
cycle which are the G0, G1, S (DNA synthesis), G2 and M (mitosis) phases. Vital checkpoints 












Proto-oncogenes are responsible for positive growth factors such as cyclins and cyclin-
dependent kinases (CDKs), which stimulate the cell to enter the cell cycle and the 
progression through it. Cyclins bind to the CDKs forming complexes which control and 
regulate important enzymatic functions of the cell.  The cycle starts with the G1 phase in 
which the cell synthesises components necessary for DNA replication. This is regulated by 
cyclins D1, D2 and D3 associating with CDKs 4 and 6.4 In the later stages of G1, cyclins A 
and E are expressed which form complexes with CDK2 promoting the cell through the G1/S 
phase transition and the S phase itself.5, 6 The G2/M transition occurs with cyclins A1, A2, B1 
and B2 associating with CDK1. This also takes the cells through the M phase, a complex 
 





procedure divided into five stages consisting of the prophase, prometaphase, metaphase, 
anaphase and the telophase.7 This is followed by cytokinesis, and the complete progression of 
the cell through these stages results in the formation of a new daughter cell. The G0 phase is a 
resting period for cells. They exist in a quiescent state outside the cell cycle where they do 
not proliferate.8  
However, opposing the positive growth factors are cell cycle inhibitory proteins called CDK 
inhibitors. These act as ‘superbrakes’ by binding with CDKs alone or regulate CDK activity 
by binding with CDK-cyclin complexes. Two important CDK inhibitors have been 
established, the INK4 and Cip/Kip families. The INK4 family includes p15 (INK4b), p16 
(INK4a), p18 (INK4c) and p19 (INK4d). These specifically inactivate the G1 phase of the cell 
cycle by binding to CDK 4 and 6 preventing their association with cyclin D. The Cip/Kip 
family of inhibitors includes p21 (Waf1, Cip1), p27 (Cip2) and p57 (Kip2). These function 
by binding to CDK-cyclin complexes, inactivating their function. CDK inhibitors are 
regulated by tumour suppressor genes (TSG) including the p53 and retinoblastoma (Rb) 
proteins. For instance, if damaged cells are detected at the G2/M transition checkpoint the p21 
and p27 CDK inhibitors are expressed. These prevent the CDK1-cyclin B1 complex forming 
and prevent damaged cells from entering the M phase. This also allows damaged cells to be 
repaired if possible.9 If sufficient repairs to damaged DNA cannot be made the cell undergoes 
apoptosis, a cell-intrinsic programmed suicide mechanism that results in the controlled 
breakdown of the cell into apoptotic bodies. These bodies are recognised and engulfed by 
surrounding cells and subject to phagocytosis.10 Two main protein families are involved in 
apoptosis, the Bcl-2 family of proteins which control mitochondrial integrity, and the 
cysteinyl aspartate specific proteases, or caspases, which mediate the execution phase of 
apoptosis. Morphological characteristics of a cell undergoing apoptosis include cell 
shrinkage, chromatid condensation and membrane blebbing (bulging).11  
 
1.1.2 Carcinogenesis 
Carcinogenesis is the term used to define the transformation of a normal cell into a cancer 
cell. Carcinogenesis proceeds in three stages which are determined and defined by their 


























Initiation is the first stage of carcinogenesis and is characterised by permanent damage to 
DNA caused by a carcinogen. The formation of DNA-carcinogen adducts leads to mutations 
such as small deletions, transitions and transversions in the genome. The second stage is 
promotion, which involves the clonal replication of initiated cells in the presence of a 
promoting agent which can be either endogenous or exogenous. Promoting agents are 
generally non-mutagenic and are characterised by their ability to decrease the latency period 
of tumour formation once a cell has been exposed to an initiator. Progression is the final stage 
of carcinogenesis, established by an irreversible transition from the promotion stage. The 
tumour cells are formed and are characterised by the increasing aggressiveness and 
invasiveness of the cells. 
The invasiveness of cancer cells occurs with the aid of angiogenesis.13 This is the formation 
of new blood vessels, which provide the tumour with vital nutrients required for growth and 
replication. Angiogenesis is achieved by the stimulation of vascular endothelial cells through 
 





the release of angiogenic peptides including the potent vascular endothelial growth factor 
(VEGF). Cancer cells also secrete proteases, such as matrix metalloproteinases (MMPs), 
which degrade basement membranes and surrounding stroma exposing vital nutrients and 
blood vessel access, thus allowing further growth and sustainability for the tumour. 
Following the invasion of surrounding tissue tumours may metastasise. This is when 
cancerous cells break away from the original tumour. These enter the blood stream and 
lymphatic system and can travel to distant sites in the body resulting in the formation of 
secondary tumours. On the contrary, tumours may remain in a benign state in which they do 
not metastasise. 
 
1.2 Genetic Causes of Cancer 
1.2.1 Inactivation of Tumour Suppressor Genes (TSGs) 
TSGs are a critical part of the human body’s natural defences in the prevention of cancer 
development. TSGs are regulated and activated in response to a wide variety of biological 
stresses such as DNA damage, oncogene activation, ultraviolet radiation, hypoxia, nutrient 
deprivation, nucleotide imbalances and heat shock.14, 15  
The retinoblastoma (Rb) gene was the first tumour suppressor gene identified and is mutated 
in approximately 30% of all human cancers.16, 17 During the early stages of the G1 phase the 
Rb protein exists in an inhibiting hypo-phosphorylated state binding with E2F transcription 
factors such as E2F1, E2F2 and E2F3. The Rb-E2F complexes encode for products 
fundamental for the cell to enter the S phase.18, 19, 20 When the cell is ready to enter the S 
phase, CDKs hyper-phosphorylate the Rb protein causing the Rb-E2F complexes to 
disassociate. Free E2Fs subsequently activate the transcription of genes necessary for DNA 
synthesis. The Rb protein remains in a hyper-phosphorylated state throughout both the S and 
M phases.21 However, disruption of the Rb protein function is commonly linked with cancer 
originating from the over-expression of cyclin D1. This activates mutations in CDK-4 and the 
tumour suppressor p16Ink4a which becomes inactive in its role to prevent the association of 
CDKs and cyclins required for dephosphorylating Rb. This in turn prevents the Rb protein 
leaving the hyper-phosphorylated state allowing cells to replicate uncontrollably with the aid 
of free E2Fs.   
The important p53 TSG has been found to be mutated in approximately 50% of cancers 
studied.22 Normally, the p53 TSG responds to cell stress signals which are transduced into 
29 
 
transcribing genes such as the CDK inhibitor protein 21WAF1. This protein plays a part in 
controlling the G1/S and G2/M transition checkpoints, initiating growth arrest preventing 
damaged cells progressing further.16, 23 In addition, p53 also stimulates expression of genes 
involved in the apoptotic receptor pathway including KILLER/DR5, FAS and PIDD.  
In normal cells p53 is tightly regulated by the MDM2 protein. This pair function in an auto-
regulatory loop as MDM2 is itself a p53 target. The p53 positively regulates MDM2 
expression while MDM2 negatively regulates p53 levels and activity. However, p53 mutation 
prevents normal regulatory function at the vital transition checkpoints, inactivating the 
‘superbrake’ function of the cell. Approximately 90% of mutated p53 proteins in cancers are 
accredited to missense (single point) mutations of residues in the p53s genes.  
 
1.2.2 Activation of Proto-oncogenes to Oncogenes 
Oncogenes are altered versions of their normal cellular genes (proto-oncogenes), which are 
involved in the regulation of normal cell growth.24 Proto-oncogenes are converted to 
oncogenes by various processes such as structural or regulatory alterations, mutations, 
chromosomal rearrangements or gene amplification. These are usually somatic events but 
germ line mutations of proto-oncogenes can arise leading to predisposition to inheritable 
cancers. When proto-oncogenes involved in the proliferation of cells become activated to 
their oncogenes carcinogenesis is induced. The two essential G1/S and G2/M transition 
checkpoints in the cell cycle become ineffective leading to the formation of cancerous 
growths.25 The K-ras gene of the Ras super family of proteins involved in cellular signalling 
transduction is thought to be the most mutated gene to be detected in cancers, present in up to 
40% of colorectal adenomas and carcinomas.26  
 
1.2.3 Inherited Cancer Risk 
 
Cancers such as ovarian and breast cancers have been linked to occur due to the inheritance 
of mutated genes.27, 28 The BRCA1 and BRCA2 genes play an essential role in DNA repair, 
but the inheritance of these genes in their mutated forms have been linked to a higher chance 
of cancer occurring. This has been shown by family based linkage studies where strong 
variances have been discovered in the BRCA genes, with BRCA1 reported to be mutated in 
an estimated 52% and BRCA2 in 32% of breast cancer families.   
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1.3 Environmental Causes of Cancer 
1.3.1 Genotoxic Carcinogens 
Genotoxins are DNA damaging toxins such as polycyclic aromatic hydrocarbons (PAH), 
aromatic amines and heterocyclic amines.29 Genotoxic compounds are present in cigarette 
smoke, as by-products of burning fossil fuels and from the high temperature cooking of 
meats.30 It has been found that genotoxins have been directly associated with cancers of the 
lung, upper respiratory tract, pancreas, colon, breast and prostate.31 Genotoxins are 
metabolised by the cytochrome P450 system, converting them into electrophilic intermediates 
which then bind covalently with DNA forming carcinogen-DNA adducts. The carcinogen-
DNA adducts have also been identified as biomarkers for the prediction of cancer, especially 
in hepatocellular carcinomas.  If the adducts are not repaired appropriately, DNA becomes 
damaged leading to mutations and eventually cancer formation. For example, benzo[a]pyrene 
(BP) is a commonly known PAH.32 BP is metabolically activated into several highly reactive 
intermediates including (+)-anti-benzo[a]pyrene diol epoxide (BPDE). The reaction of BPDE 
with DNA produces the (+)-trans-anti-N2-benzo[a]pyrene deoxyguanosine adduct ((+)-ta-
[BP]G), the most mutagenic BP-DNA adduct that can form. The (+)-ta-[BP]G is regarded as 
a major initiator in the pathway of cancer (Figure 4).33  
 
1.3.2 Infectious Biological Agents (IBAs) 
Currently, six human viruses (Table 1) deemed carcinogenic to humans have been identified 






















hepatitis C and Kaposi’s sarcoma associated herpes viruses.34 Although the direct mechanism 
of virus induced carcinogenesis is not completely known, two pathways have suggested 
which may operate either simultaneously or independently.35 Direct oncogenesis can lead to 
malignancy as the IBAs infect the cell directly causing DNA damage. Indirect oncogenesis 
can occur in which the IBAs wield a circuitous effect on cell replication by affecting 
precursors involved in normal cell proliferation. 
 
 










































Carcinoma of the cervix, oral 























1.4 The Beginnings of Cancer Chemotherapy 
Research into the development of anti-cancer agents has been ongoing since the First World 
War where it was observed that soldiers being treated for exposure to sulfur mustard gas 
exhibited massive damage to the haematopoietic system, including lymphoid aplasia.36, 37, 38 
This is thought to have occurred due to the low activity of critical DNA repair enzymes 
combined with the high proliferation rates in bone marrow increasing susceptibility to 
alkylating agent based mutations.39, 40 The observed lymphoid and myeloid suppression 
indicated the potential use of alkylating agents as treatment for lymphomas and leukemias. 
Related nitrogen mustards were the first chemical agents to be clinically tested for the 
treatment of cancer. Resulting data showed successful regression of lymphomas in patients, 
through mustards forming covalent bonds with nucleophilic groups in DNA. This leads to 
single-strand or double-strand DNA breaks which subsequently causes inter-strand and intra-
strand DNA cross-linking halting DNA proliferation.41 Further advances came with 
compounds such as methotrexate and chlorambucil in the 1960’s which showed effectiveness 
against germ cell tumours, and cisplatin in 1965 which demonstrated the ability to inhibit 
cellular division.42, 43 The 1990’s produced two further important groups of anti-cancer 
agents; the taxanes and topoisomerase inhibitors. Drugs included the taxane paclitaxel and 





































1.5 Current Cancer Chemotherapy 
Several groups of chemotherapeutic drugs exist which are used to treat a wide range of 
cancers. These are categorised according to their mode of action and structural similarities. 
Selectivity of chemotherapeutic drugs is thought to occur due to the highly proliferative 
nature of tumour cells relative to normal cells, therefore the metabolism of drugs interacting 
with the tumour cells will be greater than normal.44  
 
1.5.1 Alkylating Agents 
Alkylating agents act by forming covalent bonds with DNA. This causes various lesions 
including mono-adducts formed through single bonds to DNA and bi-adducts in which the 
alkylating agent forms either interstrand or intrastrand DNA cross-links with DNA.45, 46, 47 
Mono-adducts constitute the major portion (approximately 90%) of total DNA lesions 
inflicted by alkylating agents. However, bi-adduct cross-links are more cytotoxic as these are 
associated with the anti-tumour ability of alkylating agents by blocking DNA replication. 
DNA alkylation has been shown to occur preferentially at the endocyclic nitrogen atoms 
including the N7 atom of guanine and the N1, N3, N6 and N7 atoms of adenine. N7-N7 
cross-linking of opposing guanine bases has been well documented.48  
Mechlorethamine was the first alkylating agent commonly used in chemotherapy.49 It is 
administered with other anti-cancer drugs in the MOPP (Mechlorethamine, Oncovin, 
Procarbazine and Prednisone) chemotherapy combination used to treat Hodgkins disease, and 
has been reported to be particularly effective against cutaneous T-cell lymphoma when 
administered topically. Mechlorethamine exerts its anti-cancer effects through the formation 
of aziridinium ion intermediates. These are formed by the sequential loss of the electron 
withdrawing chlorine atoms (Scheme 1). The aziridinium intermediates are highly reactive 
species which continue to alkylate multiple sites of DNA upon interaction.45 It has been 
shown experimentally that mechlorethamine reacts faster with nucleic acids and proteins than 






































































1.5.2 Platinum Containing Compounds 
Platinum compounds are widely used in chemotherapy to treat various cancers such as 
ovarian, lung, oesophageal, cervical and testicular cancers.50, 51 The anti-tumour mechanism 
of platinum based drugs mirrors that of the alkylating agents in that intrastrand adducts and 
interstrand cross-links are formed with DNA (Scheme 1). The major binding sites for 
platinum based agents on DNA are the N7 positions in guanine and adenine. Currently three 
platinum based anti-tumour drugs are in clinical use; cisplatin, carboplatin and oxaliplatin 








Cisplatin, introduced in the late 1970’s, was the first platinum based anti-cancer drug to be 
used clinically.52 The anti-tumour activity of cisplatin was discovered inadvertently when the 
inhibition of cell replication was observed during investigations into the effects of electric 
fields on the growth of Escherichia coli.53 This occurred as a result of platinum electrodes 
reacting with the chemical solution in which they were immersed (containing ammonium and 
chloride salts) forming the cisplatin complex through electrolysis. Cisplatin is now 
responsible for the cure of over 90% of testicular cancers, and is an important agent in the 
treatment of bladder, cervical, head, neck and ovarian cancers. The molecular anti-tumour 
mechanism of cisplatin occurs through numerous chemical reactions once it enters the body. 
Prior to DNA attack cisplatin undergoes activation through rapid aquation where the two 
chloride molecules are replaced by two water molecules. This occurs in intracellular regions 
where concentrations of chloride ions are significantly lower than in the blood plasma were 
the cisplatin complex remains stable. Once activated, the cisplatin complex forms DNA 
cross-links as the water molecules are displaced by the favourable N7 nitrogen atoms in the 
guanidine region of the DNA (Figure 7). The chelation of cisplatin and DNA causes the DNA 
to bend, and this abnormal shape is considered to be the critical lesion triggering the pathway 










































Antimetabolites are cytotoxic agents that structurally resemble naturally occurring purines 
and pyrimidines essential in the replication of DNA.41, 54 Their anti-cancer activity comes 
from both their ability to inhibit key enzymes involved in DNA synthesis, and their capability 
of incorporating into DNA and RNA. These properties of the antimetabolites cause strand 
breaks and the termination of cell proliferation (usually during the S phase of the cell cycle).  
Methotrexate the most commonly used antimetabolite in clinical use which is structurally 














































Methotrexate acts by inhibiting the enzyme dihydrofolate reductase (DHFR), which is 
responsible for the regeneration of oxidised folates into their reduced forms of 
tetrahydrofolates (THFA).35 Folate in the form of N5-methyltetrahydrofolate is essential for 
the conversion of homocysteine into methionine via methylation, which then undergoes 
further biological modification to become S-adenosylmethionine (SAM). This is an important 
universal methyl donor in a variety of biochemical reactions, especially methylating specific 
cytosines in DNA which regulate genome stability and gene transcription.55, 56 Depletion of 
SAM induces DNA hypomethylation and studies have shown abnormal methylation plays an 
integral role in carcinogenesis through various pathways including altered expression of 
TSG’s and proto-oncogene expression. 
N5, N10-methylenetetrahydrofolate is another important folate which methylates uracil to form 
thymine essential for DNA synthesis and repair. Deficient folate levels result in the 
disincorporation of thymine into DNA, leading to mutagenic effects and eventually cancer. 
Methotrexate usually causes cells to arrest in the G1 and/or the S phases of the cell cycle.
57, 58  
 
1.5.4 Anthracyclines 
The anthracyclines are broad-spectrum anti-cancer drugs which were originally isolated from 
the pigment producing Streptomyces peucetius.59, 60 Since the 1960’s, more than 200 
naturally occurring anthracyclines have been identified. Daunorubicin was the first 
anthracycline to be successfully isolated in 1963, but more important was the development of 
doxorubicin (DOX) in 1968 which is commonly used in the treatment of breast cancer and 





































The anthracyclines generally target the S phase of the cell cycle. They intercalate into the 
chromophore between DNA strands in a longitudinal orientation. This together with binding 
of the amino sugar with the DNA backbone causes DNA topoisomerase II malfunction. DNA 
topoisomerase II is a critical enzyme involved in breaking and re-joining DNA during cell 
proliferation.62 The disruption of this enzyme results in irregular DNA assembly leading to 
cell death. An alternative mechanism of action involves transfer of an electron from NADPH 
to the anthracycline. This results in a free radical intermediate of the anthracycline, which can 
readily transfer an electron to molecular oxygen forming free radicals capable of causing 
damage to DNA.63 In addition, anthracyclines can exert direct effects on cell membranes 
including the disruption of ion and electron transportation systems vital for cell proliferation. 
 
1.5.5 Tubulin Binding Drugs (TBDs) 
Tubulin is the basic sub-unit of microtubules which play an important and diverse role in the 
normal function of cells including mitosis, meiosis, intracellular transport and axonal 
function.41 Microtubules are hollow polymeric protein complexes built up of α and β tubulin 
heterodimers which consist of three domains; the N-terminal, the central and the C-terminal 
domain.64, 65 The dynamic nature of their ability to polymerise and depolymerise is critical in 
the formation of the mitotic spindle which is essential for cellular division and chromosome 
segregation during mitosis.66 Drugs which target tubulin act by suppressing the kinetics of the 
spindle microtubule dynamics, inhibiting the metaphase/anaphase transition which inhibits 
mitosis and induces apoptosis of tumour cells. Three binding sites have been categorised 
which are named after the ligands that occupy them; these are the taxane, vinca alkaloid and 
colchicine binding sites.67 TBDs are categorised according to the mechanism by which they 
affect the microtubules and to which site that they bind. 
The first category comprises of microtubule destabilising agents (MDSAs). These inhibit the 
assembly of microtubules by binding to the vinca alkaloid or colchicine binding sites 
preventing the formation of tubulin dimers. Drugs in this class include vincristine, a vinca 
alkaloid isolated from the periwinkle plant Catharanthus roseus, which is used in the 
















The second category of tubulin binding drugs is made up of microtubule stabilising agents 
(MSAs). These stabilise microtubules by binding to the taxane binding sites on polymeric 
tubulin, preventing its disassembly into α and β tubulin dimers. The taxane paclitaxel (Taxol) 
(Figure 11) was first isolated from the bark of the pacific yew tree (Taxus Brevifolia). Its 
ability to cause cell cycle arrest has subsequently gained clinical success in the treatment of 
ovarian, head, neck, lung and metastatic breast cancers.69, 70 Taxol inhibits cell proliferation 
by binding to the microtubule surface, especially to the β sub unit of tubulin heterodimers and 
preventing microtubule disassociation. It has also been accredited to induce the microtubule 
assembly which further disrupts the microtubule dynamics.71 However, unavailable ionisable 
functional groups make this drug extremely insoluble (<0.03 mg/mL) in aqueous 












Ixabepilone, an epothilone MSA received clinical approval in October 2007. It is used for the 
treatment of metastatic or locally advanced breast cancer that progresses after anthracycline 











































anthracycline therapy. Ixabepilone has also been approved as monotherapy in patients with 
metastatic and locally advanced breast cancer refractory to taxanes, anthracyclines, and 
capecitabine.73, 74  
The combretastatins are a group of antimitotic agents isolated from the bark of the South 
African tree Combretum caffrum.75 The most important of these, Combretastatin A4 (CA4) 
(Figure 12A), is a potent cytotoxic compound which strongly inhibits the polymerisation of 
tubulin by binding to the colchicine-binding site of the β-tubulin subunits.76 CA4 also 
displays powerful vascular disrupting and anti-angiogenesis properties leading to a significant 
reduction in tumour blood flow. However, CA4 showed poor bioavailability and low aqueous 
solubility but this was overcome by the development of a water soluble disodium-phosphate 
prodrug (Figure 12B), currently in clinical trials. This derivative is inactive as the phosphate 











1.5.6 Tyrosine Kinase Inhibitors 
Tyrosine kinases (TKs) are key components within the cellular communication network and 
function as “master switches” regulating signalling pathways pivotal to normal cell 
development and survival.78 Examples include the epidermal growth factor receptor 
(EGFR/ErbR), platelet derived growth factor receptor (PDGFR), vascular endothelial growth 
factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and the hepatocyte 
growth factor receptor (MET).  
In certain cancers, mutations causing the over-expression of TK’s appear to be the source of 
the disease causing carcinogenesis by altering normal downstream signalling which controls 





















fusion proteins. These are the combination of two or more genes which originally coded for 
separate proteins, resulting in increased abnormal kinase activity and eventually cancer. 
Fusion proteins are observed in chronic myeloid leukemia, and mutations or deletions 
directly in TK’s are seen in solid tumours. 
The human epidermal growth factor receptor 2 (HER-2) belongs to a family of receptor 
tyrosine kinases. Amplification of the HER-2 gene and consequent over-expression of the 
cell-surface receptor have been implicated in the pathogenesis in one out of four cases of 
breast cancer.81, 82 Herceptin was the first commercially available TK inhibiting antibody.83 It 
acts by down regulating HER2 expression (also known as ErbB2) by acting as a partial ligand 
for this receptor. This accelerates receptor endocytosis and degradation causing rapid de-
phosphorylation of ErbB2. This prevents downstream signalling proteins initiating signal 
transduction cascades responsible for DNA synthesis and cell proliferation resulting in the 
inhibition of cell cycle progression.84, 85 Experimental evidence suggests that herceptin may 
also affect the regulation of genes related to angiogenesis such as the vascular endothelial 
growth factor (VEGF) and angiopoietin-1.86  
Gleevec (Figure 13) is an inhibitor of the Abl protein-tyrosine kinases which are important in 
normal cell proliferation. Gleevec was clinically approved for the treatment of chronic 
myelogenous leukemia (CML) in May 2001. CML is usually detected and diagnosed by the 
presence of the Philadelphia chromosome, a fusion gene formed by the translocation of 




















1.6 The Side-effects of Chemotherapy 
Advances in chemotherapy have successfully provided remissive treatments for some types 
of cancers. For example, cisplatin provides testicular cancer patients with up to a 95% cure 
rate if the cancer is detected in its early stages.88 Unfortunately, chemotherapy comes with the 
cost of unwanted side-effects often as a result of the relatively narrow therapeutic index of 
anticancer agents. This is due to their poor selectivity and inability to differentiate between 
cancer cells and normal cells.89  
Cisplatin has been associated with the formation of new primary malignancies, infertility, 
renal toxicity and nephrotoxicity. These have been attributed to the direct toxic effects of 
secreted platinum species in the excretive system and reactive platinum species which have 
reached non target sites. Another common side-effect of cisplatin is bone marrow 
suppression, also observed in patients treated with anthracyclines and alkylating agents which 
cause white cell and platelet depletion and anaemia.90 Nausea and vomiting are observed in 
70-80% of patients receiving chemotherapy, alongside diarrhoea.91 The unfortunate apoptotic 
effect of chemotherapy on healthy hair follicles induces alopecia, which has been described 
as one of the most distressing side-effects observed in patients.92  
The administration of ifosfamide (Figure 14) to treat childhood tumours results in 
nephrotoxicity. This is severe in approximately 30% of cases where it is characterised by the 
Fanconi Syndrome. This is when damage to renal tubule cells occurs preventing the 
reabsorption of vital nutrients such as glucose, proteins, sodium, potassium and phosphates. 








Cardiomyopathies, including heart failure and arrhythmia have been induced by 
anthracyclines (especially DOX) during chemotherapy and have been reported many years 
after a course of treatment has finished.95, 96 Endomyocardial biopsy specimens suggest that 
DOX depletes cytosolic ATP crucial in supplying energy to the heart resulting in myocardial 
















Herceptin based chemotherapy was found to produce congestive heart failure in patients, 
especially when pre-treated with anthracyclines. This is due to ErbB receptors in the heart 
important for maintenance and survival interacting with the cytotoxic herceptin drug.98  
Other side-effects suffered by patients treated with chemotherapy include central nervous 
system toxicity resulting in seizures, cerebella dysfunction, inflammation, retinopathy, 
cerebral venous thrombosis, cognitive impairment and psychiatric symptoms.99, 100 
Chemotherapy is often combined with drugs such as prednisone, an anti-inflammatory agent 
which also reduces nausea in patients. Another protecting agent is dexrazoxane, administered 
alongside doxorubicin to protect heart damage occurring. However, with the combination of 
chemoprotective drugs the problem of unwanted side-effects is still a large problem amongst 
cancer patients.101, 102  
 
1.7 Prodrug Strategies in Chemotherapy 
The prodrug concept in chemotherapy was first introduced by Albert and Harper in the late 
1950’s to try and achieve a safer systemic approach for the treatment of cancer.103 A prodrug 
is a chemical with little or no pharmacological activity until it undergoes biotransformation in 
vivo into a therapeutically active metabolite.104 The aims of using the prodrug approach in 
chemotherapy are to produce compounds with improved pharmaceutical, pharmacokinetic 
and pharmacodynamic properties compared to existing drugs.105 In order to achieve this, the 
prodrug must reach and distribute efficiently across the tumour and undergo selective 
biotransformation to its cytotoxic form, without harming normal healthy cells.106 This in turn 
will reduce unwanted side-effects commonly observed with chemotherapy. Successful 
prodrug development relies in exploiting tumour properties which make cancer cells 
distinguishable from normal cells. Possible prodrug targets include hypoxic conditions 
observed in cancer cells due to the lack of vascular network development, specific or over-
expressed enzymes, pH differences, tumour specific antigens and the excretion of tumour 
specific enzymes.107   
 
1.7.1 Antibody Directed Enzyme Prodrug Therapy (ADEPT) 
ADEPT is an approach where tumour selectivity is achieved by using an antibody (non-
mammalian or mammalian) which is specific to an antigen on the tumour surface.108 
Enzymes which are essential for the biotransformation of the prodrug are attached to the 
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antibody and this conjugate is administered to the patient. Sufficient time is then allowed for 
this conjugate to accumulate at the site of the tumour and for it to clear from the blood supply 
and normal tissues.109 This is followed by the administration of the prodrug, which is stable 
under non-activating conditions but quickly activated to its cytotoxic form once it interacts 
with the target conjugate (Scheme 2).110  
Ideal prodrugs for use with ADEPT should be relatively small molecules which can easily 
diffuse within tumour tissues, including both antigen positive and antigen negative, and have 
the capability of producing the “bystander effect” (see GDEPT).111 The target antigen should 
be either expressed on the tumour cell membrane or be secreted into the extracellular matrix 
of the tumour. Conjugated enzymes should have no human homologue to prevent prodrug 





































The first pilot study of ADEPT was carried out at Charing Cross Hospital in London on 
patients with advanced colorectal cancers. An anti-CEAF(ab’)2 antibody conjugated to the 
bacterial enzyme carboxypeptidase G2 (CPG2) was used to target a benzoic acid mustard 
prodrug. The enzyme converted the prodrug to its toxic metabolite by cleavage of its 
glutamate terminal. Using this system, reduction in tumour masses of 50% were observed.  
Other systems used in ADEPT include the enzyme aminopeptidase which converts the 
prodrug 2-L-pyroglutamylmethotrexate to the toxic methotrexate, and the enzyme cytosine 
deaminase which converts 5-fluorocytosine into 5-fluorouracil. Disadvantages with ADEPT 
include the high cost and difficulties associated with the development and purification of 
antibodies, and unwanted immunogenic responses from the antibodies and antibody-enzyme 
conjugates.     
 
1.7.2 Gene Directed Enzyme Therapy (GDEPT) 
GDEPT requires the integration of a non-mammalian enzyme gene into the tumour of 
interest.112 This allows the tumour to express enzymes which will convert a specific prodrug 
into its cytotoxic metabolite, killing cells inside the tumour and by the “bystander” effect.113 
The “bystander effect” is observed as the cytotoxic drug leaves the tumour cells and kills 
surrounding cancerous tissue which may not have received the non-mammalian enzyme 
gene.114 Critical requirements for GDEPT are that the integrated non-mammalian enzyme 
gene is absent from the human genome or expressed in very low levels in healthy tissue. It 
must also have a high rate of catalytic activity in the biotransformation of the prodrug once 
expressed. The prodrug is also required to have an exceptionally high affinity for the targeted 
enzyme, be able to penetrate into tumours, exhibit virtually no toxicity in its prodrug form 
and have a half-life of the active metabolite sufficient to enable the “bystander” effect to 
occur.115 
Systems used in GDEPT include the enzyme nitroreductase (NTR), encoded for by the nfsB 
gene of Escherichia coli.116 NTR reduces the prodrug CB1954 to 2-HX and 4-HX, 
bifunctional alkylating agents which form interstrand cross-links with DNA resulting in cell 



























Also, Purine nucleoside phosphorylase has been used to convert 6-methylpurine 2-
deoxyriboside to the antimetabolite 6-methylpurine, currently in clinical trials (Figure 16).117, 
118, 119  
 
One of the major advantages of GDEPT is the higher concentrations of metabolised toxic 


































significantly in comparison with standard chemotherapeutic agents.114 However, 
disadvantages associated with this approach include the unwanted killing of normal 
neighbouring tissue via the bystander effect and systematic diffusion of the activated prodrug 
causing cytotoxicity to unwanted regions.111  
 
1.8 The Cytochrome P450s 
The cytochrome P450 enzymes (CYPs) are haem containing proteins originating from a gene 
super-family with over 1000 members found in humans, plants and bacteria.120 The name 
cytochrome P450 was given during investigations into the spectrophotometric properties of 
pigments in a microsomal fraction containing these proteins prepared from rat livers. The 
addition of the reducing agent sodium dithionite to the microsomal fraction which was 
previously gassed with carbon monoxide gave a unique absorbance band at 450 nm. This was 
due to the 5th cysteine thiolate anion ligand of the cytochrome enzymes.121, 122 Generally 
CYPs contain 500 amino acids with iron-protoporphoryrin IX as the prosthetic group, 
providing the electronic centre for the important activation of molecular oxygen. CYPs are 
bound to the endoplasmic reticulum or mitochondria in eukaryotic organisms.123  
In humans, 40 CYPs have so far been identified but research continues in the discovery and 
identification of further examples.120 A critical role played by CYPs in the human body is in 
the metabolism of xenobiotics, such as drugs and environmental pollutants. They are also 
important in the biosynthesis of cholesterol, endogenous steroidal hormones, bile acids and 
the metabolism of vitamin D3. 
Reactions catalysed by CYP enzymes include carbon hydroxylation, heteroatom oxygenation, 
dealkylation, epoxide formation and group migration.124 Substrates bind to CYPs when the 
iron containing haem is in its oxidised state (Fe3+).1 Donation of an electron from NADPH 
mediated by NADPH-cytochrome P450 reductase (CPR) reduces the iron haem to Fe2+ which 
then combines with molecular oxygen.125, 126 CPR is an electron transfer diflavoprotein and is 
widely expressed in all tissues but is most abundant in the endoplasmic reticulum of the 
liver.127 Donation of a second electron from NADPH activates the haem bound molecular 
oxygen, inserting one atom into the substrate and converting the other atom into water.128 
Regio and stereo selectivity of the oxygenation depend on the spatial orientation of the bound 
substrate relative to the position of the activated oxygen molecule on the haem. Hydrophobic 
substrates are preferred for a majority of CYPs, but some catalyse the oxygenation reactions 
of hydrophilic compounds such as ethanol and acetone.129 A prime example of CYP 
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hydroxylation is that of tamoxifen, which undergoes biotransformation to 4-
hydroxytamoxifen, a 100 times more potent than its parent compound.130 
Phase I drug metabolism involves the bio-transformation of xenobiotics by oxidative or 
reductive reactions carried out by CYPs in the liver.131 The CYP1, CYP2 and CYP3 families 
are responsible for over 90% of drug bio-transformations in humans and determine the 
elimination, systemic clearance and bioavailability of therapeutic compounds. CYP3A4 is the 
most abundant of the hepatic metabolising enzymes taking part in the metabolism of 50% of 
xenobiotics. The other CYPs involved in drug bio-transformations are CYP1A2 (4%), 
CYP2A6 (2%), CYP2C9 (10%), CYP2C19 (2%), CYP2E1 (2%), CYP2D6 (30%).132, 133 
 
1.8.1 The Over-Expression of CYPs in Tumours 
The identification of a novel subfamily of CYPs was made by Sutter et al in 1994.134 Using 
the P450 nomenclature system, the novel mRNA sequence was named CYP1B1. Since its 
discovery, it has been identified as a vital enzyme in the metabolism of 17β-estradiol.135    
Research into identifying xenobiotic metabolising enzymes in tumours has been ongoing for 
numerous years.136 Murray et al found that CYP1B1 was over-expressed in a wide range of 
tumour cells including lung, breast and bladder, whilst remaining undetected in the 
corresponding normal tissue.137 Specific monoclonial antibodies designed to detect CYP1B1 
in immunohistochemical studies were developed by Morag et al and used in the 
determination of the over-expression of CYP1B1 in breast tumours.138 It was found that 77% 
of breast tumours contained the over-expression of CYP1B1 enzymes, and were specifically 
localised to tumour cells. Colorectal tumours were found to over-express CYP1B1 enzymes 
by Gibson et al.139 However, they also detected the presence of CYP1B1 in normal colorectal 
tissue, but this was expressed to a far lesser degree than that observed in the tumour cell lines.  
It has also been reported that CYP1B1 expression is differential between tumours of different 
types.140 Pinpin et al elucidated that CYP1B1 was over-expressed in lung tumours, but to a 
higher degree in lung adenocarcinomas than in lung squamous cell carcinomas. 
However, contrary to the above finding it has been claimed that the over-expression of 
CYP1B1 occurs in normal tissue as well as tumour tissues. Leclerc et al studied non-tumour 
and tumour samples of lung tissue and found that the expression of CYP1B1 was to 
approximately the same extent in both tissue types.141 However, discrepancies in the finding 
of CYP1B1 expression in normal and tumour tissue may be attributed to the detection 
techniques used. It has been documented that CYP1B1 mRNA is commonly detected in 
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normal tissue but this does not necessarily indicate the expression of the enzyme protein.142 
For example, CYP1B1coded mRNA has been found in normal liver cells but the CYP1B1 
protein is undetectable. 
Interestingly, the CYP1A1 gene has been found to be amplified in tumour cells in contrast to 
its corresponding normal tissue.143 Studies conducted with ovarian cancers showed 
significant CYP1A1 over-expression.144  
Contrary theories suggesting the role of the CYP1 family of enzymes in tumour development 
exist. One theory is that the over-expression of CYP1 enzymes contributes towards tumour 
development, as the greater enzyme concentration produces a higher turnover of possible 
carcinogenic metabolites.145 Polymorphisms in CYP1A1 and CYP1B1 proteins have also 
been accredited to an increased risk of cancer.146, 147 The polymorphisms produce variant 
species of the CYP enzymes which have abnormal functionality, in turn displaying 
uncharacteristic metabolism of its substrates.148  
on the other hand, the over-expression of CYPs in tumours has generated an area of great 
interest for chemotherapeutic drug design and novel therapies to be developed.149, 150 CYPs 
have been categorised as targets for anti-cancer prodrugs as the over expression of these 
enzymes in tumours is still a legitimate concept. CYP based prodrugs have been designed to 
undergo selective metabolism by the over-expressed enzymes, producing cytotoxic 
metabolites killing the cancer cells. This allows for toxic differentiation between normal and 
tumour cells, which will give the drugs a greater therapeutic window and reduce problematic 
side-effects observed with current chemotherapy. Patents for CYP1B1 activated prodrugs, 
inhibitors and immunotherapies have already been issued and some are pending further 
investigation.151 
 
1.8.2 CYP Activated Prodrugs 
1.8.2.1 Cyclophosphamide 
The prodrug cyclophosphamide (CPA) belongs the oxazaphosphorine class of anti-cancer 
agents, and is used in the treatment of breast and ovarian cancers, certain leukemias and 
lymphomas (Figure 17).152, 153 CPA becomes biologically active after it undergoes hepatic 
biotransformation to 4-hydroxycyclophosphamide (4-OHCPA). This process is catalysed by 
several CYPs including CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A4. 
The 4-OHCPA exists in equilibrium with its ring opened tautomer aldophosphamide 
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(APH).154, 155 The equilibrium mixture diffuses from the hepatocytes into the blood plasma 
and is distributed throughout the body.156 At physiological pH the equilibrium lies in favour 
of 4-OHCPA and since it is relatively non-polar it readily enters cells via diffusion. APH 
undergoes further chemical transformations to yield the highly electrophilic aziridinium 
phosphoramide species which is the key cytotoxic entity as it forms DNA cross-links halting 
cell proliferation.  
In comparison to other alkylating agents, CPA produces less gastrointestinal and 
hematopoietic toxicity due to the enzyme aldehyde dehydrogenase which is responsible for 
the oxidation of APH to carboxyphosphamide, an inactive metabolite of CPA which is 
excreted in the urine and accounts for 80% of administered CPA. Aldehyde dehydrogenase is 
found in high concentrations in the hepatic cytosol, primitive hematopoietic cells, and in stem 











The anti-oestrogen tamoxifen (Figure 19, A) was first synthesised in 1963. It is a commonly 
used chemotherapeutic agent for the treatment of estrogen-receptive positive (ER+) breast 
cancers and has significantly decreased the mortality rate from this disease over the last 
decade.157  
It first began clinical trials in 1969 with patients diagnosed with advanced breast cancer. 
Tamoxifen undergoes hepatic phase I and II metabolisation by CYP2B6, CYP3A4 and 
CYP3A5 to produce the metabolites 4-hydroxytamoxifen (Figure 18, D), N-






































The mechanism of action of tamoxifen and its most important metabolite 4-
hydroxytamoxifen occurs through the competitive inhibition of the ER.158 Normally, estrogen 
binds with the ER and the estrogen–ER complex homodimerizes and binds to specific DNA 
sequences, known as estrogen response elements (ERE) in the regulatory regions of estrogen 
sensitive genes. Two transcriptional activation functions AF1 and AF2 located on the ER of 
the estrogen–ER complex interact with transcriptional co-activators to stimulate the activity 
of RNA polymerase II which catalyses the transcription of DNA precursors, thereby 
regulating gene activity and cell proliferation.159 Tamoxifen binds to the ER forming a 
tamoxifen–ER complex which homodimerizes and binds to the ERE of estrogen sensitive 
genes. However, only AF1 is active and the inactivity of AF2 results in reduced transcription 
of DNA precursors blocking the G1 phase of the cell cycle. This reduces the growth of 































Transforming Growth Factor-β1 (TGF-β1), a cytokine which inhibits mammary cell 
proliferation, induces apoptosis and influences morphogenesis (cell shape and spatial 
arrangement).161, 162, 163 Although blood plasma and tumour concentrations of 4-
hydroxytamoxifen are only 2% in relation to tamoxifen, it is 100 times more potent as an 
estrogen receptor antagonist.130  
Although tamoxifen is effective in the treatment of breast cancer, some tumours do not 
respond to tamoxifen treatment or become resistant to tamoxifen. This can be due to the 
absence of ER receptors in some breast cancers (known as ER- tumours), loss of ER 
expression, or mutations in ER genes and co-factors.157 A change in tamoxifen pharmacology 
may occur too, as cells can start to recognise tamoxifen as an agonist when previously acting 
as an antagonist.164  
 
1.8.8.3 AQ4N 
1,4-bis{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione (AQ4), is a 
potent topoisomerase II and DNA binding agent.107  In solid tumours, poorly defined vascular 
network usually exist which result in disrupted oxygen delivery creating cell subpopulations 
which are chronically or acutely hypoxic.165 Therefore, 1,4-Bis-{[2-(dimethylamino-N-
oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione (AQ4N), the bioreductively 
activated prodrug of AQ4 was specifically designed to target hypoxic tumour cells., 166 The 
mechanism of action of AQ4N relies on a four electron reduction to generate 1,4-bis{[2-
(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione (AQ4), an active 




























cytochrome P450 enzymes CYP3A4, CYP1A1, CYP1A2 and CYP2B6 which are present in 
the tumour (Figure 19).  
 
Importantly, AQ4N has shown selective tumour cytotoxicity as the AQ4N prodrug itself has 
a very low or un-measurable anti-proliferative effect on human tumour cell lines. This is due 
to the N-oxide groups preventing the interaction of the molecule with the sugar phosphate 
backbone of DNA, until converted to AQ4, the active cytotoxic metabolite.169 The selective 
cytotoxicity of AQ4N towards the tumour cells provides this compound with a high 
therapeutic index, a valuable quality required for the reduction of unwanted side-effects.    
It has also been reported that AQ4N, when administered alongside radiotherapy, significantly 
slows tumour growth by up to 40% when compared to treatment with radiation alone.170, 171 
This has been accredited to the active metabolite AQ4 killing hypoxic cells recruited into the 
cell cycle after being damaged by radiotherapy and chemotherapy.172 Other studies have 
shown that AQ4N enhances the anti-tumour effects of cisplatin and cyclophosphamide when 
administered in combination. This has been supported by human tumour xenograft studies 
with radio and chemotherapy.  
However, a contradicting report has stated that AQ4N acts as a DNA protecting agent and 
does not mediate enhanced DNA damage when administered alongside radiation therapy. The 
major destructive aspect of radiation is generated through DNA damage from hydroxy 
radicals formed through the dissociation of water. These cause damage to DNA by 
abstracting protons from DNA. The protective mechanism has been suggested to occur 
through AQ4N and AQ4 interacting with the hydroxy radicals forming drug radicals. This 
reduces the concentration of DNA damaging hydroxy radicals in cells. Although opposing 




A series of 2-(4-aminophenyl)benzothiazole’s were synthesised in the early 1990’s which 
showed promising antitumour activity.173 These were found to function as prodrugs which 
were metabolised to cytotoxic species by the cytochrome P450 enzyme CYP1A1. Of 
particular interest was 2-(4-amino-3-phenyl)benzothiazole (DF 203 or NSC 674495) (Figure 




DF 203 acts antagonistically on the aryl hydrocarbon receptor (AhR) which is directly 
involved in the expression of CYP1A1.174, 175 Once DF 203 binds to the AhR, activated AhR 
translocates to the nucleus, dimerises with the arylhydrocarbon receptor nuclear transporter 
(Arnt) and activates transcription of target genes by binding to specific enhancer sequences 
(xenobiotic response elements or XREs) in the regulatory region of the CYP1A1 gene. These 
influence the transcription of genes they are located on, and binding with the AhR/Arnt 
complex induces the transcription and expression of the CYP1A1 protein.176 Tumour cells 
which have shown a decrease in growth when treated with DF 203 have an increased level of 
CYP1A1 mRNA and enzymatic protein expression. The CYP1A1 mediated metabolites of 
DF 203 form adducts with DNA leading to irreparable single and double strand breaks 
triggering apoptosis when administered in doses greater than 100 nM. The binding of DF 203 
metabolites have been shown to occur on nuclear fractions, mitochondria, microsomal and 
cytosolic regions of the tumour cell. To validate DF 203 as a CYP1A1 substrate, inhibition 
studies using the CYP1 inhibitor α-naphthoflavone were conducted. The results showed that a 
decreased anti-tumour effect was observed, confirming that DF 203 does require CYP1A1 
metabolism to exhibit cytotoxicity. However, CYP1A1 has also shown to hydroxylate DF 
203, forming an inactive metabolite. Therefore, modifications to DF 203 were made to 
enhance the activity of this prodrug. The first step was to fluorinate the 5 position of the 
phenyl moiety to give the new drug 5F 203 (NSC 703786) (Figure 21, A), as fluorination of 
compounds has shown to inhibit their susceptibility to hydroxylation occurring. Overall, 5F 
203 showed improved cytotoxic activity in comparison to DF 203. The poor aqueous 
solubility of 5F 203 was overcome by conjugation of a lysyl-amide hydrochloride salt to the 
exocyclic primary amine function (Figure 21, B). The resulting lysyl prodrug Phortress (NSC 
710305) is both water soluble and chemically stable but undergoes rapid bioreversion in vitro 























The exact structures of the metabolites of phortress produced by CYP1A1 are yet to be 
established but the results of frontier molecular orbital studies have suggested the possible 
generation of nitrenium species. These structures suggest that nucleophilic centres in DNA 
bases might form adducts at the exocyclic nitrogen (via 1), or at carbon atoms in the 2-aryl 
group (via 2) or the benzothiazole moiety (via 3) (Figure 22).178 Phortress (NSC 710305) is 









1.9 Endogenous Steroids and the Development of Anticancer 
Prodrugs  
17β-estradiol is an endogenous human steroid which is metabolised by both CYP1A1 and 
CYP1B1, which have also shown to be over-expressed in tumours.179 CYP1A1 hydroxylates 











































C-4 position, and to a lesser extent at C-2. CYP1B1 is the most catalytically efficient of the 
estradiol hydroxylases as indicated by its low Km for 17β-estradiol, as a lower Km value 
indicates a higher affinity of the substrate for the enzyme.180, 181, 182 
Many naturally occurring phytoestrogens such as flavonoids, isoflavonoids, stilbenes, 
coumestans and lignans can be mapped on to the steroidal framework of estradiol.183, 184  
Compounds which share structural similarities to estradiol may in fact possess potential anti-
tumour ability. This can be an important tool in finding potential anti-cancer prodrugs which 
may be able to undergo CYP1 metabolism to toxic metabolites when reaching tumour sites. 
This can be determined by screening probable compounds against tumour cells and their 
corresponding normal tissues. Toxicity exclusive to tumour cells may be due to CYP1 
metabolism of the compound. Metabolite structures can also be predicted as the CYP1 
mediated metabolites of estradiol are known. 
 
1.9.1 Resveratrol 
Resveratrol (3,5,4'-trihydroxystilbene) (Figure 23 B) was first isolated from the roots of the 
White Hellebore (Veratrum album) plant. It is also present in red wine, grapes, peanuts and 
mulberries. In 1997 Jang et al published a paper showing resveratrol to be an effective agent 
for blocking the initiation, promotion and progression of carcinogenesis.185 Since then, the 
anti-cancer properties of resveratrol have been established on a range of cancers, including 
breast, prostate, colon, pancreatic, ovarian and thyroid cancers. It has been suggested that the 
anti-cancer ability of resveratrol occurs through the initiation of apoptosis and cell cycle 
arrest in the S and G2 phases of the cell cycle.
186, 187  The topical application of resveratrol 
was found to significantly reduce 7,12-dimethylbenz[a]anthracene (DMBA) initiated and 12-
O-teradecanoylphorbol-13-acetate (TPA) promoted skin tumours in female mice. Growth 
arrest in human epidermoid carcinoma (A431) cells was observed when these were treated 
with resveratrol. A down-regulation in the expression of cyclins D1, D2 and D3 was detected 
together with the inhibition in the expression and activities of CDKs 2, 4 and 6 and an up-
regulation of p21WAF/CIPI. A reduction in hyperphosphorylated Rb protein and decrease in 
E2F transcription factor expression were also observed. A number of other benefits have been 
reported for resveratrol. These include cardio-protective, anti-oxidant, anti-inflammatory and 
anti-infective properties.188, 189 
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Potter et al of the Cancer Drug Discovery Group (CDDG) studied the CYP1B1 metabolism 
of resveratrol and proposed that it is hydroxylated ortho to the 4'-hydroxyl group by CYP1B1 
generating piceatannol (Figure 23, D).190 This was achieved by mapping resveratrol on to 
estradiol (Figure 23, A), for which the CYP1B1 mediated metabolism is known to produce 4- 
hydroxyestradiol (Figure 23, B).  
 
To prove the hypothesis, the metabolism of resveratrol by CYP1B1 was carried out using a 
microsomal preparation of the human CYP1B1 enzyme. Using HPLC analysis with 
fluorescence detection the formation of two major metabolites (M1 and M2) and one minor 
metabolite M3 were observed. M1 has been suggested to be 3,4,5,4'-tetrahydroxystilbene 
formed through the hydroxylation of the other aromatic ring and M3 is thought to be 
3,4,5,3',4'-pentahydroxystilbene. Most importantly, the major metabolite M2 was identified 























Piceatannol is a known naturally occurring compound and has exhibited anti-leukemic 
properties, demonstrating an ability to inhibit a variety of tyrosine kinases involved in cell 
proliferation; including those involved in the phosphorylation of DNA transcription factors 
and tubulin. Due to their findings, Potter et al proposed that CYP1B1 functions as a “rescue 
enzyme” due to its over-expression in tumours and ability to metabolise resveratrol to the 
anti-tumour piceatannol. Therefore, CYP1B1 can be targeted by potential prodrugs which 
would only become toxic once present in tumour cells over-expressing the CYP1B1 
enzymes. Another relevant finding is that CYP1B1 is expressed in skin cells exposed to 
mutagenic UV light. The skin tumour reduction observed in mice by the topical application 
of resveratrol may be due to the formation of the CYP1B1 metabolite piceatannol, backing 
the theory for the role of this enzyme as a “rescue enzyme”.  
Contrary to the findings of Potter et al, it has been suggested that resveratrol is an inhibitor of 
CYP1A1, CYP1B1 and CYP1A2, and is also an antagonist of the AhR receptor. This theory 
implies that CYP1 enzymes help promote tumour development via the metabolism of PAHs 
to carcinogenic species. However, it is also known that carcinogens are metabolised by CYPs 
to make them into excretable species and the inhibition of these enzymes would cause the 
bioaccumulation of toxic species.  
Nonetheless, resveratrol is currently in phase I clinical trials being tested against colon cancer 
in the USA.  
 
1.10 Stilbenes and Chalcones as CYP1 Activated Prodrugs 
The Cancer Drug Discovery Group (CDDG) of the Leicester School of Pharmacy has 
developed and patented a number of low molecular weight anti-cancer prodrugs.191 They 
were designed to be metabolised by CYP1B1 as this is enzyme is a particularly attractive 
target for anticancer prodrugs, as it is often over expressed in tumours but rarely found in 
normal tissue. 
The stilbene DMU 212 (Stilserine) was found to overlay the structure of estradiol by 
structural mapping, in the same fashion as resveratrol and its metabolites were investigated 
(Figure 24). Exciting cytotoxicity was observed for DMU 212, which was screened against 
tumour cell lines characterised for their CYP1 enzyme expression. Included was an IC50 
value of 0.001µM observed against the MDA 468 cells, which constitutively expresses 

















Chalcones exhibiting anti-tumour abilities have also been investigated by the CDDG. 
Numerous chalcones have been shown to occur naturally and have been of interest since the 
establishment of their many benefits, including anti-cancer, anti-malarial, and anti-
inflammatory properties.192 They consist of two phenyl rings connected by a three carbon link 
which is α, β-unsaturated. The chalcone DMU 135 was designed to be activated by CYP1B1, 
over-expressed in tumour sites. The non toxic prodrug DMU 135 is activated to the catechol 
DMU 117 (Figure 25), a broad spectrum potent tyrosine kinase inhibitor that has been shown 









Studies on ApcMin/+ mouse gastrointestinal adenoma, an effective model for colorectal cancer 
showed that DMU 135 considerably reduced multiplication of tumours by 18.3% and showed 
no systematic side-effects. It has been reported that tyrosine kinase activity is essential for 
































1.11 Heterocyclic Analogues of Chalcone Prodrugs 
1.11.1 Cis and Trans Isomerisation of Chalcones 
Chalcones can exist as either cis or trans isomers as the α,β-double bond is labile for 
photoisomerisation.194 In general, the trans isomer is thermodynamically more stable and 
chalcones are usually isolated in this isomeric form. Photoisomerisation occurs as trans 
isomers absorb ultra-violet (UV) or visible light exciting an electron in the pi bonding 
molecular orbital to a pi-star anti-bonding orbital, yielding the cis isomer.195,196 
It has been shown that the rate of isomerisation and the equilibrium ratio depend on the 
substitutions on the aromatic rings and the solvents employed. It is also suggested that 
electron withdrawing groups and the chelating properties of the substituents in the 2-position 
have a significant effect on the degree of isomerisation. However, this theory is countered by 
researchers who have stated it is not possible to predict chalcone isomerisation. It was 
accepted that both these isomers were equipotent in their toxicities, but this was investigated 
by locking known anti-plasmoidal chalcones in cis and trans isomers and evaluating their 
activity. It was found that the trans locked isomer was the more active isomer, and the cis 
locked compounds showed virtually no activity. 
The cytotoxicities of the cis and trans isomers of DMU 407 and DMU 102 were investigated 
by the CDDG (Figure 26).197 They were screened against the CYP1 enzyme expressing MDA 
468 tumour cell line and the non-tumour control cell line of MCF10A which has no basal 
CYP1 expression. It was found that the cytotoxicities of the trans isomers were greater than 
that for the cis chalcones for both DMU 407 and DMU 102 when screened against the MDA 









































To eradicate the problem of cis isomerisation occurring, heterocyclic ring systems can be 
incorporated into chalcone prodrugs (Figure 27). This can be achieved by modifying the α,β-
double bond moiety of the chalcones, as this region is susceptible to nucleophilic attack by 
suitable nucleophilic reagents. The ring system would result in a more rigid compound 
maintaining the key functionalities of the chalcones by keeping the substituted phenyl groups 







1.12 Aims  
The primary aim of this project will be to modify chalcones to prevent the problematic factor 
of photoisomerisation occurring. This will be achieved by incorporating heterocycles across 
the α,β-double bond of the chalcones which will lock the phenyl groups in a trans like 
geometry. Heterocycles will be synthesised by reacting chalcones with selected heteroatom 
nucleophiles, to generate variant libraries of heterocyclic compounds. This approach is 
favourable as the carbonyl of the chalcone is a receptive nucleophilic attack site, which in 
turn will provide the foundation for the heterocyclic ring construction. 
The synthesised heterocyclic compounds will be screened against tumour cell lines 
characterised for their constitutive or inducible CYP1 expression. Cytotoxicity data will be 
compared throughout the libraries of compounds with the development of structure activity 
relationships being formulated. Resultant compounds with encouraging or significant 
toxicities will be investigated further to determine whether they are genuine CYP1 substrates. 
If successfully identified as CYP1 substrates, further studies involving the determination of 
possible metabolites formed will be made, from which proposed metabolites will be 
synthesised. Verification of the authenticity of the proposed metabolites will be investigated 
using LCMS techniques.  


























2.0 Synthesis of 3,5-Diarylpyrazoles via Chalcones and 
EpoxyChalcones 
To overcome the problem of chalcones undergoing photoisomerisation reactions, pyrazole 
heterocycles were introduced across the α,β-unsaturated region of chalcones locking the 
phenyl groups in a trans like geometry (Figure 28). Pyrazoles are five membered heterocyclic 
rings consisting of three carbon atoms and two adjacent positioned nitrogen atoms.  
 LeBlanc et al synthesised a library of pyrazoles from chalcones in good yields which were 





Bhat et al also synthesised pyrazole analogues from chalcones which were shown to exhibit 
anti-tumour activity on a number of cancer cell lines including colon, lung, liver, ovary, 
cervix and prostate.192 Results from cytotoxicity assays of these compounds were 
encouraging, with IC50 values including 0.48µM observed from the lead compound 4n 
(Figure 29) when screened against the colon tumour cell line HCT-15. This was a 25 fold 






Another route available for the synthesis of pyrazoles includes the conversion of diketones 
(Figure 30), which are treated with hydrazine hydrate in a one step reaction which forms the 



























The diketone conversion has been demonstrated by Shaw et al, who cyclised diketones with 
hydrazine to afford a range of substituted pyrazoles. They screened their library of 
compounds against four tumour cell lines, which were ovarian carcinoma cells (OVCA), 
colorectal adenocarcinoma cells (SW620), large lung carcinoma cells (H460) and gastric 
carcinoma cells (AGS). From the cytotoxicity results observed, they established compound 
26 (Figure 31) to be their lead compound as it displayed the most potent activity against the 









Pyrazoles have also been shown to be synthesised from intermediary epoxychalcones formed 
through the treatment of chalcones with hydrogen peroxide.198 Epoxychalcones are then 









Diketone Pyrazole  



























Two separate reaction conditions have been reported for the synthesis of pyrazoles via 
epoxychalcones, one by LeBlanc et al and the other by Bhat et al. For the synthesis of 
pyrazoles in this project, the method by LeBlanc et al will be used as yields of up to 94% 
were reported in their synthesis. 
 
2.1 The Synthesis of Chalcones 
The chalcones synthesised were selected based on their cytotoxicity results obtained by the 
CDDG in previous experimentations. DMU 135 was included in the selected chalcones 
which gave an IC50 value of 0.09µM when screened against the MDA 468 cell line which 
constitutively expresses CYP1A1 and CYP1B1. IC50 values of 0.2µM and 0.03µM were 
recorded against the MCF7 cells which show no basal CYP1 expression and MCF7 cells 







A number of reactions have been used to synthesise chalcones, but the most common 
approach is the Claisen-Schmidt condensation (CSC) reaction (Figure 33).200 This generally 
involves the reaction of equimolar quantities of benzaldehydes and acetophenones in 
alcoholic basic conditions. Common bases used for this reaction are sodium and potassium 
hydroxide, added either as solids or as aqueous solutions.201  Typically the reaction is carried 
out at room temperature with either methanol or ethanol as the solvent. When a phenolic 
group is present the CSC reaction is often slow and may require heating to proceed. 
Protecting the phenolic group as a tetrahydropyranyl (THP) ether using a 3,4-dihydro-2H-
pyran protecting group eliminates this problem, and has been shown to prepare several 












An acid catalysed version of the CSC reaction also exists.203, 204 Several acids, and lewis 
acids, have been used including hydrogen chloride, sulfuric acid and aluminium trichloride. 
Solvent free reactions using metal oxide catalysts impregnated onto zeolites and alumina 
have also been reported.205, 206 
The mechanism for the chalcone formation via the CSC reaction begins with the formation of 
an enolate ion of the acetophenone (Scheme 3). This occurs as the base abstracts an α proton 
from the acetophenone forming a resonance stabilised enolate. With bases such as sodium 
hydroxide, this equilibrium process lies very much towards the acetophenone side, however, 
sufficient enolate is generated for the reaction to proceed. The benzaldehyde cannot undergo 
enolisation as it does not have α protons. The nucleophilic enolate attacks the carbonyl of the 
benzaldehyde forming an intermediate β-hydroxy ketone or aldol. Although this intermediate 
can be isolated the reaction is generally allowed to proceed. The abstraction of an α-proton 
from the aldol generates another enolate which undergoes dehydration, via a conjugate base 
elimination mechanism to yield the chalcone. This elimination occurs in a regio-specific 
















































































































































































































































































































































































































































































































































































































































































































































All chalcones in Table 2 were synthesised in this project, using the base catalysed CSC 
reaction. Equimolar amounts of appropriate benzaldehydes and acetophenones were stirred in 
methanol at room temperature until fully dissolved.  A twenty fold excess of aqueous NaOH 
(50% w/v) was added to the solution resulting in an instant colour change from colourless to 
yellow. Reactions were closely monitored by thin layer chromatography (TLC), and the 
chalcone was identified as a new bright orange spot when stained with 2, 4-
dinitrophenylhydrazine (2,4-DNP). Reactions usually reached completion in less than four 
hours, as indicated by the disappearance of starting materials upon TLC analysis. Water was 
added to quench the reaction and the resulting mixture was extracted with dichloromethane 
(DCM). The organic extracts were combined and dried over MgSO4. The solvent was 
removed in vacuo resulting in the crude chalcone. Solids were recrystallised from either 
ethanol or methanol depending on the solubility of the chalcone. In three cases (Table 2, 
entries 9, 10 and 18), oils were obtained on removal of the solvent. These products were 
purified by flash chromatography on silica gel using a mixture of ethyl acetate and hexane 
(4:6) as eluent.  
Twenty four chalcones were synthesised in good yields ranging from 65% to 94%. In each 
case analytical data was consistent with the proposed structures. Nuclear magnetic resonance 
(1H NMR) confirmed the trans nature of the alkene double bonds which appeared as doublets 
between 7.40 and 7.60 ppm. Coupling constants were measured between 11-19Hz, typical for 
trans alkene protons as they range between 12-18Hz, whereas cis isomers range between 0-
12Hz.207 In accordance, no cis isomers were detected in any of the spectra analysed. Mass 
spectrometry (MS) gave either M+ or (M+1)+ ion peaks of correct mass, and infra-red (IR) 
spectra showed strong absorptions in the 1690-1750 cm-1 region consistent with the α,β-
unsaturated carbonyl group of a chalcone. All chalcones, apart from the three yellow oils, 




2.2 The Synthesis of Epoxychalcones 
The next stage in the synthetic route to the pyrazoles required the synthesis of 
epoxychalcones. Epoxides are important and versatile building blocks in organic synthesis 
commonly used as intermediate reagents for the synthesis of natural products.208 
Epoxychalcones are prepared by reacting hydrogen peroxide with chalcones, as shown in 
Scheme 4. Electrophilic epoxidising agents, such as m-chloroperbenzoic acid (MCPBA) give 
poor oxidising results with electron deficient double bonds such as those in chalcones, 

















The mechanism for the chalcone epoxidation (Scheme 4) initiates with the abstraction of a 
proton from hydrogen peroxide by NaOH, forming a hydroperoxide anion. The soft 
hydroperoxide nucleophile then undergoes conjugate addition to the chalcone generating an 
unstable enolate. The enolate intermediate undergoes intramolecular cyclisation to form the 
epoxychalcone with the loss of an OH group.  
The procedure used to synthesise compounds shown in Table 3 was the same as that used by 
LeBlanc et al in their synthesis of heterocyclic analogues of the combretastatins.198 Potassium 






























stirred solution of the chalcone in methanol. As the epoxidation progressed a visible colour 
change from the characteristic chalcone yellow to off-white was observed. The reactions 
generally took 3 hours for completion as indicated by TLC analysis. Water was added to 
quench the reaction, followed by the addition DCM to extract the organic phase. The 
combined organic extracts were dried over MgSO4 and the solvent removed in vacuo 
producing the crude epoxychalcones. Solids were recrystallised from either methanol or 
ethanol, resulting in white crystals. However, three compounds (Table 3, entries 4, 10 and 16) 
did not form solids but oils prior to and after recrystallisation.  

























































































































































































































































































































































































































































































































The epoxychalcones were synthesised with good yields ranging from 66 to 88%. The 1H 
NMR spectra showed the epoxide ring protons appearing as doublets between 3.8 and 4.4 
ppm. Coupling constants measured 3Hz, typical of trans epoxide protons (cis 4.5Hz).210 MS 
showed (M+1)+ peaks of correct ion masses, and IR spectra showed strong absorptions in the 
1690-1750 cm-1 region corresponding to the presence of the carbonyl group. However, three 
chalcones (Table 2, entries 5, 17 and 18) proved to be unsuccessful in the epoxidation 
reaction. TLC analysis showed that the starting material was still present, demonstrating that 
the chalcones had not reacted with the peroxide. As there was no obvious explanation for 
these results the reactions were repeated but in each case gave the same unsuccessful 
outcome. Zheng et al synthesised epoxychalcones via chalcones using t-butyl-hydroperoxide 
as the oxidising agent. Problems encountered showed that the presence of an isopropyl group 
on the β-side of the chalcone did not allow epoxidation to occur, accrediting this problem to 
the bulkiness of the isopropyl group. 211 It was also found that electron donating groups 
decreased reaction activity and electron withdrawing groups had the opposing effect. Also, 
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para positioned substituent’s on β-phenyl rings showed to influence yields as NO2>Cl>Me, 
indicating electron withdrawing groups favour greater yields than electron donating groups.  
The methoxy substituted A and B-rings of DMU 102 are electron donating by nature. As 
stated by Zheng et al, these groups have a negative effect on the epoxidation reaction which 
may be attributed by the resonance intermediates formed by DMU 102. The β-phenyl ring 
(A-ring) of DMU 102 also has the methoxy group in the para position, which can 
theoretically add to the negative reaction outcome based on the work of Zheng et al (Figure 
35).  These combined factors may act by lowering the reactivity of the α,β-unsaturated attack 







However, contrary to the above possible explanation for the non epoxidation of DMU 102, 
chalcones with para substituted electron donating groups on the B-rings have undergone 
successful epoxidation reactions (Table 2, DMU 2300 and DMU 2307). Therefore, the 
epoxidation reactions of DMU 2301, DMU 102 and DMU 2222 warrant further investigation 
to deduce the failing factor responsible for the unsuccessful reactions observed.  
 
2.3 Synthesis of 3, 5-Diarylpyrazoles 
The 3,5-diarylpyrazoles were designed to lock trans chalcone isomers in place by 
incorporating a pyrazole heterocycle across the α,β-unsaturated moiety of the chalcone. This 
reaction proceeded through epoxychalcone intermediates synthesised through the reaction of 
chalcones and hydrogen peroxide. It was anticipated that the conversion of the 
epoxychalcones to the desired 3,5-diarylpyrazoles could be achieved using the method of 





















The method of LeBlanc et al required heating a solution of the epoxychalcone, hydrazine 
hydrate and p-toluenesulfonic acid in xylenes at reflux for 3h. The xylenes were removed in 
vacuo and the obtained solid was washed with hexanes. The mechanism for this reaction is 
shown below (Scheme 5). Under weak acidic conditions the hydrazine reacts with the 
carbonyl group of the ketone to form a hydrozone. Intramolecular cyclisation then occurs 
with the primary amine group of the hydrazone opening the epoxide ring to generate a 
pyrazoline. Protonation of the alcohol group is followed by elimination of water to generate 














































Therefore, the epoxychalcone DMU 10006 (Table 3, entry 5) was stirred in a mixture of 
DCM and xylenes until the epoxychalcone fully dissolved. The addition of DCM was 
required to fully dissolve the solid epoxychalcone which was insoluble otherwise. Hydrazine 
hydrate (3 equivalents) and a catalytic quantity of p-toluenesulfonic acid monohydrate were 
added to the solution which was heated at reflux for 3h. The solvent was removed in vacuo 
yielding a brown oil. Attempts to solidify this product by trituration with hexanes were 
































































epoxychalcone, therefore the reaction time was increased. After several attempts at 
synthesising the pyrazoles the reaction time was optimised at 6h. The pyrazole DMU 10106 
was eventually isolated by flash chromatography using ethyl acetate and hexane (6:4) as 
eluent in variable yields of up to 63%. In view of these inconsistent results, a two-step 
approach based on the method of Bhat et al was investigated. This required stirring a solution 
of the epoxychalcone DMU 10006 with hydrazine hydrate (1.5 equivalents) in ethanol at 
reflux for 6h. TLC analysis showed the formation of the pyrazoline which appeared as a new 
fluorescent blue spot when viewed under ultra-violet (UV) light. The solvent was removed in 
vacuo and a brown residue was obtained which was dissolved in glacial acetic acid. 
Concentrated sulphuric (30 ml) acid was added to the solution which was then heated at 
reflux for 0.5h. After cooling, the reaction was neutralised by dropwise addition of 
concentrated ammonia solution resulting in the formation of a dark brown precipitate. 
Recrystalisation from ethanol gave DMU 10106 as brown crystals with a yield of 66%. 
Although this reaction gave a similar yield to the one pot method of LeBlanc et al, the two-
step synthesis provided consistent results and avoided the need for purification via flash 
chromatography. It was thus decided to use this method to prepare the library of compounds 
shown in Table 4. 
 






























































































































































































































































































































































































































































A library of eighteen 3,5-diarylpyrazoles was synthesised in yields ranging from 63-93%. 
With the exception of three compounds which produced oils (Table 4, entries 10, 16 and 23), 
the pyrazoles were obtained as brown crystals on recrystallisation from ethanol with melting 
points in the range of 71-242oC. The 1H NMR spectra were consistent with the expected 
structures, with the pyrazole ring proton at C4 (Figure 37) appearing as a broad singlet 
between 6-7.3ppm. The NH of the pyrazole ring was not apparent in the spectra as the 
pyrazole can undergo tautomerisation in which the NH proton can migrate between the two 
nitrogens in the heterocycle. This occurs at a rapid pace undetectable by the conditions used 
to conduct the 1H NMR analysis. Figure 38 shows the 1H NMR spectrum and Figure 39 







IR spectroscopy showed weak absorptions between 3300 and 3400cm-1 characteristic of the 
NH of the pyrazole heterocycle. MS spectra were consistent with the proposed structures 















































2.4 Cytotoxicity Screening 
2.4.1 MTT Assay 
The cytotoxicity of the compounds synthesised in this project were screened using the MTT 
assay by Dr. D. Ankrett of the CDDG (Appendix, 10.0). The MTT assay is a quantitative 
colorimetric assay based on the cleavage of the yellow water-soluble 3-[4,5-dimethylthiazol-
2yl]-2,5-diphenyltetrazolium salt (MTT) to form water-insoluble, dark blue formazan crystals 
(Figure 40).212 MTT cleavage occurs only in living cells by the mitochondrial enzyme 
succinate dehydrogenase. The formazan crystals are solubilised in organic solvent and the 
absorbance of the resulting solution is measured using a spectrophotometer. The absorbance 
is directly proportional to the concentration of the blue formazan solution, which is directly 
proportional to the number of metabolically active cells.  
 












2.4.2 Cell Lines Chosen for MTT Screening 
The human breast tumour cell lines MDA-MB-468 (MDA 468), MCF7 and MDA-MB-231 
(MDA 231) were selected for screening compounds synthesised in this project for their anti-
cancer prodrug ability. This was due to their capacity to express functioning CYP1 proteins, 
either constitutively or after exposure to 2,3,7,8-tetrachlorodibenzodioxin (TCDD), an 
agonist for the AhR widely used to induce CYP1 enzymes.213, 214 Experimentation techniques 
including western blotting were conducted by Dr. S. Surichan of the CDDG to determine the 
CYP1 expression in the MDA 468 and MCF7 cell lines. 
The MDA 468 cell line is estrogen receptor negative (ER-) as the levels of detection of the 
estrogen receptor are below 1 fmol/mg. The growth of this tumour is not dependent on the 
hormone estrogen, and this type of tumour cannot be treated with anti-estrogen drugs like 
tamoxifen, which exhibit their anti-tumour function by inhibiting the ER.215 MDA 468 cells 
have been shown through EROD (ethoxyresorufin-O-deethylase) assaying and western 
immunoblotting to constitutively express both CYP1A1 and CYP1B1 enzymes, with the 
latter at a lower concentration in comparison to CYP1A1.216 TCDD treatment amplifies the 
expression for both CYP1A1 and CYP1B1 with the ratio of CYP1A1 still remaining higher 
than that of CYP1B1.  
The MCF7 cell line is ER+ and is the most widely used breast cancer cell line in research.217 
This cell line does not constitutively expresses CYP1 enzymes, but treatment with TCDD 
























The MDA231 cell line is an ER- tumour cell line which constitutively expresses low levels of 
CYP1s. Treatment with TCDD primarily induces CYP1B1 but CYP1A1 is also expressed to 
a lesser extent.214, 218  
The control used in the MTT assay consisted of the non-tumourigenic MCF10A cell line. 
CYP1A1 or CYP1B1 enzymes are not constitutively expressed in this cell line, but it has 
been reported that MDA 468 exposure to TCDD induces the expression of CYP1A1 and 
CYP1B1.219, 220  
 
2.4.3 Biological Evaluation of the 2,4-Diarylpyrazoles 
A problematic factor associated with chalcones is their susceptibility to undergo 
photoisomerisation reactions producing both cis and trans isomers.  However, it has been 
shown that the trans isomers are more potent in their biological activities compared to the cis 
isomers. To eliminate this problem, pyrazole heterocycles were incorporated across the α,β-
double bond moiety of the chalcones to produce rigid structures invulnerable to 
photoisomerisation. The synthesised pyrazoles (Table 4) were screened for their prodrug 
activity against a panel of tumour cell lines including the MDA 468, MCF7 and MDA 231 
cells. To enable discussion of the cytotoxicity data observed, the phenyl groups at the 3 and 5 
positions have been assigned as A and B-rings (Figure 41), and compounds with similar 

























2.4.3.1 Methylenedioxy Substituted A-Ring 
Five compounds with constant 3,4-methylenedioxy substituted A-rings were synthesised 
































































































































































n=1, ND=No data 
 
DMU10104, with a 3,4,5-trimethoxy substituted B-ring (Table 5, entry 1) did not show 
toxicity towards the non-tumour MCF10A cells. In the MDA468 cancer cell line which 
constitutively expresses both CYP1A1 and CYP1B1, a relatively high IC50 value of 25µM 
was obtained. In the MCF7 cell line, which expresses very low levels of CYP1 enzymes, a 
lower IC50 of 8µM was achieved. Treatment of the MCF7 cells with TCDD to induce 
CYP1A1 expression made no significant difference to this value suggesting that CYP1 
prodrug activation does not play a role in the mode of action of this derivative. The MDA231 
cell line which principally expresses CY1B1 on induction with TCDD, gave an IC50 of 
20M. No change in cytotoxicity was observed on treatment of these cells with TCDD, again 
suggesting no prodrug action was occurring. DMU 10107, substituted with a 2,3,4-
trimethoxy B-ring (Table 5, entry 3) did not show toxicity towards the non-tumour MCF10A 
cells. Results from the MCF7 cell line gave IC50 values of 10M each for both the TCDD 
induced and non-induced cells. Unlike DMU 10104, DMU 10107 showed slight activity in 
the MDA 468 cell line with an IC50 value of 8M being recorded. No activity was seen in the 
MDA231 assays as IC50 values were greater than 100M. DMU 10106 (Table 5, entry 2), 
synthesised with a 2,3-dimethoxy substituted B-ring did not show toxicity towards the 
tumour cell lines as all IC50 values were above 50M. DMU 10108 and DMU 10109 (Table 
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5, entries 4 and 5) gave similarly disappointing results, with IC50 values of 30M and greater 
for each tumour cell line tested against.  
The pyrazoles DMU 10104, DMU 10107 and DMU 10108 were synthesised based on lead 
chalcones investigated in previous experimentations by the CDDG. DMU 135 (Table 6, entry 
1) showed significant cytotoxicity towards the MDA 468 cell line giving an IC50 value of 
0.09µM whilst having no toxic effect on the MCF10A cell line. However, the pyrazole 
analogue DMU 10104 (Table 6, entry 2) was approximately 280 times less toxic to the MDA 
468 cell line giving an IC50 value of 25µM, but showed the same non-toxic result towards the 
MCF10A cell line as DMU 135. A similar outcome was also apparent with the MCF7 and 
MDA 231 cells as DMU 135 showed greater toxicity towards these in comparison to DMU 
10104.    



















































































































































































































































































The chalcone DMU 419 (Table 6, entry 3) also gave greater toxicities across the cancer cell 
line panel in contrast to its pyrazole analogue of DMU 10107 (Table 6, entry 4). This was 
significantly more noticeable towards the MDA 231 cells as DMU 419 gave identical IC50 
values of 6µM for both the TCDD induced and non-induced cells but DMU 10107 did not 
show toxicity towards the MDA 231 cells in comparison. The chalcone DMU 407 (Table 6, 
entry 5) was far more toxic towards the MCF7 and MDA 231 cell lines in contrast to its 
pyrazole analogue of DMU 10108 (Table 6, entry 6), and over five times more toxic towards 
the MDA 468 cell line.  
 
2.4.3.2   4-Methoxy Substituted Pyrazoles 
Six 4-methoxy substituted pyrazoles were synthesised as shown in Figure 43. DMU 10103, 
DMU 10116 and DMU 10117 were synthesised from chalcones with 4-methoxy substituted 
B-rings, whilst DMU 10122, DMU 10112 and DMU 10111 were synthesised from chalcones 
substituted with 4-methoxy substituted A-rings. However, as pyrazoles are liable to undergo 
tautomerisation, a line of symmetry can be drawn through the centre of the pyrazole 
heterocycle making the A and B-rings interchangeable as long as all remaining substituents 
remain equal. Hence, the 4-methoxy substituted pyrazoles can be considered together for the 







































































































































































n=1, ND=No data 
The 4-methoxy substituted pyrazoles showed little toxicity towards the non-tumour MCF10A 
cell line with IC50 values of 70M or above being observed. Cytotoxicity was seen towards 
the tumour cell lines but not to a degree that would be considered noteworthy, as IC50 values 
were above 20M. DMU 102 (Table 8, entry 1), the chalcone analogue of DMU 10102 was 
another lead chalcone synthesised and investigated by the CDDG. An IC50 of 0.5µM was 
observed when DMU 102 was screened against the MDA 468 cell line, ten times more toxic 
in contrast to DMU 10102 (Table 8, entry 2). The chalcone analogue was also 15 times more 
toxic towards the MCF7 cell line, but interestingly 670 times more toxic against the MCF7 
































































































































The remainder of the chalcone analogues of the above 4-methoxy substituted pyrazoles were 
greater in toxicities than their pyrazole derivatives, but not to a degree of substantial interest. 
As the pyrazoles did not enhance their activity, further discussion of these compounds will 
not be undertaken.  
 
2.4.3.3   4-Propoxy and 4-Butoxy Substituted A-Ring 
The chalcone DMU 2216, substituted with a 4-propoxy A-ring and 3,4-dimethoxy substituted 
B-ring showed significant cytotoxicity towards the MDA 468 cell line. An IC50 value of 
0.6µM was observed whilst no toxicity was seen towards the non-tumour MCF10A cells. 
Hence, DMU 10123 was designed and synthesised based on DMU 2216 in an attempt to 
obtain comparable or better cytotoxic behaviour. Also, DMU 10114 (Figure 44) was 
synthesised with a 4-butoxy substituted A-ring and 3,4-dimethoxy substituted B-ring in order 
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n=1, ND=No data 
The results obtained from screening DMU 10123 against the tumour cells did not show to be 
more potent in comparison to DMU 2216 against the MDA 468 cell line, as DMU 10123 was 
30 times less toxic than DMU 2216 (Table 10, entry 1). DMU 10123 (Table 10, entry 2) also 
showed toxicity towards the non-tumour MCF10A cells unlike DMU 2216 and although it 
was not to a great degree the toxicity was undesirable nonetheless. DMU 10114 (Table 9, 
entry 1) exhibited less toxicity towards the MCF10A cell, but a similar toxicity towards the 
MDA 468 cells as DMU 10123 was recorded. DMU 10114 also proved to be more potent 
towards the MCF7 cells in contrast to DMU 10123, but not to an extent requiring further 
















































































































2.4.3.4   Other Substituted Pyrazoles 























Cl Cl  





It was deduced from structure activity relationship analysis of the lead chalcones that the 
occupancy of the 2, 3 and 4-positions on the A and B-rings have shown to be valuable for 
anti-cancer cytotoxicity. To further investigate this, methoxy groups were strategically placed 
in these positions on both the A and B-rings to see if any link or further enhancements of 
cytotoxicities could be seen. A chlorine substituted analogue was also synthesised, which 
would be a direct comparison to the methoxy substituted analogue of DMU 10103. 
 























































































n=1, ND=No data 
The pyrazoles shown in Table 11 did not show significant cytotoxicities against the panel of 
tumour cell lines screened against. However, an interesting result was obtained with 
DMU10121 (Table 11, entry 4) which was 4-chloro substituted on both of the A and B-rings. 
This derivative, although having an IC50 value of 65µM against the MDA468 cell line, 
showed activity at a much lower concentration with an IC25 value of 0.7µM being obtained 












In comparison to its methoxy analogue of DMU 10103, the chloro substituted DMU 10121 
only showed a slight increase in cytotoxicity towards the MDA 468 cell line but remained 
non-toxic towards the remaining cell lines alongside DMU 10103. 
 
2.5 Summary and Conclusions 
A library of eighteen pyrazoles were designed and synthesised using a two step method taken 
from Bhat et al, with yields of up to 93% being obtained. The rationale behind the synthesis 
was to lock the biologically active trans chalcone isomers in a rigid structure, preventing the 
problematic photoisomerisation reaction from occurring which produces the non-active cis 
isomers. The pyrazole heterocycle was incorporated across the α,β-unsaturated moiety of 
selected chalcones, including the lead compounds DMU 135 and DMU 102 via 
epoxychalcone intermediates.  
The synthesised pyrazoles were screened for their prodrug activity against a panel of tumour 
cell lines, consisting of the MDA 468, MCF7 and MDA 231 cells. DMU 10107, synthesised 
with a 3,4-methylenedioxy substituted A-ring and 2,3,4-trimethoxy substituted B-ring was 
concluded as the most toxic compound out of the pyrazoles synthesised. An IC50
 value of 
8µM was recorded from screening DMU 10107 against the MDA 468 cell line, whilst no 










































induced and non-induced gave IC50 values of 10µM each. However, the cytotoxicities 
observed from DMU 10107 were not as potent as the cytotoxicities seen from the chalcone 
analogue of DMU 419, which was twice as toxic towards the MDA 468 cell line and five 
times as toxic towards the MCF7 cell lines. DMU 10107 did not show toxicity towards the 
MDA 231 cells whereas DMU 419 exhibited a noticeable toxicity of 6µM towards the TCDD 
induced and non-induced cells.  
It was generally observed that the chalcone analogues of the pyrazoles synthesised were more 
cytotoxic across the tumour cell lines screened against, making the incorporation of the 
pyrazole heterocycle across the α,β-unsaturated moiety of the chalcones unfavourable in this 
case. 
The next stage of investigation would require the exploration of other heterocyclic ring 
systems which could be incorporated across the α,β-unsaturated moiety of the chalcones, 
resulting in rigid structures unable to photoisomerise. Also, comparable or increased 
cytotoxicities towards the tumour cell lines should be observed from modified compounds 





















3.0 Synthesis of 2-Amino-4,6-Diarylpyrimidines 
Photoisomerisation reactions occurring in chalcones are problematic as they convert 
biologically active trans isomers to the less potent cis isomer. To overcome this, pyrazole 
rings were incorporated across the chalcone α,β-double bond to lock the substituted phenyl 
groups in a trans like geometry. The pyrazole library was screened against a selected panel of 
tumour cell lines where it was experimentally concluded that DMU 10107 was the most 
effective cytotoxic compound synthesised. However, the cytotoxicity of DMU 10107 was not 
as potent as its chalcone analogue of DMU 419. Therefore, the investigation into alternative 
heterocyclic rings was required to achieve rigid, non-photoisomerisable structures with 
comparable or greater cytotoxicities towards the tumour cell lines in contrast to the parent 
chalcones.     
The incorporation of a pyrimidine heterocycle into the chalcones was investigated. 
Pyrimidines are 6-membered heterocycles with nitrogen atoms at positions 1 and 3 of the ring 







Pyrimidines have been shown to be important for the treatment of malaria, cancer, 
inflammation and tuberculosis.221 For example, 5-fluorouracil is a pyrimidine based anti-
cancer drug used to treat various cancers including breast and stomach cancers. A widely 
known synthetic route for the preparation of pyrimidines is via the Biginelli reaction which 
was discovered in 1893 (Figure 48).222 It involves the acid catalysed cyclo-condensation of 
ethylacetoacetate, benzaldehyde and urea in ethanol under reflux which affords 



















More importantly, a synthetic route using chalcones to yield pyrimidines has been reported 
by Varga et al, applied in experimentations investigating the oxidation of dihydro-pyrimidine 
intermediates to aromatised pyrimidines (Figure 49).224 Chalcones were stirred with 
guanidine in a basic alcoholic solution under refluxing conditions, followed by the 
subsequent addition of hydrogen peroxide solution. The synthesis of pyrimidines from 
chalcones occurs via dihydro-pyrimidine intermediates which require oxidation in order to 
form the aromatised pyrimidine heterocycle. The oxidation step can be achieved by stirring 
the dihydro-pyrimidines in the open air, but it has been reported that air alone is not sufficient 
enough for aromatisation to occur in larger scale reactions which require the addition of 
oxidative reagents. It was concluded by Varga et al that hydrogen peroxide was found to be 






























Figure 49. General reaction of the synthesis of pyrimidines (4) through the dihydro-pyrimidine (3) by reacting chalcones (1) 






















The mechanism for the pyrimidine synthesis is illustrated in scheme 6. Under basic 
conditions the guanidine reacts with the chalcone via 1,2-nucleophilic addition which forms 
an imine. Intramolecular cyclisation then follows forming the dihydro-pyrimidine which then 























The mechanism of hydrogen peroxide oxidation is considered complex, as this proceeds 
through the formation of free radicals via three stages.212 The first stage of initiation requires 
































































The second stage of propagation involves the formation of a new radical species through the 
first free radical formed through the initiation stage (Scheme 7). The last stage of termination 
sees the formation of a new bond through the joining of two radical species, ending the 
















All pyrimidines were synthesised by the method used by Varga et al. Guanidine 
hydrochloride (1.5 equivalents) was stirred with potassium hydroxide (4 equivalents, 50% 
w/v) in ethanol under reflux for thirty minutes to sufficiently yield the free guanidine. The 
chalcone (1 equivalent) was then added and the reaction was left to stir under reflux for six 
hours producing the dihydro-pyrimidine. Hydrogen peroxide (3 equivalents, 50% w/v) was 
added and the reaction continued to stir under reflux for one hour. TLC analysis was used to 
monitor the progress of the reaction and the pyrimidine product formed a single fluorescent 
blue spot when viewed under UV light. Water was added to quench the reaction and the 
resulting mixture was extracted with dichloromethane. The organic extract was dried over 
MgSO4 and the solvent removed in vacuo. The pyrimidine was purified by either 
recrystalisation from methanol or ethanol, or by flash chromatography on silica gel using 









































































































































































































































































































































































































































































































A library of fifteen pyrimidines were synthesised in yields ranging from 9-33% (Table 12), 
with melting points recorded between 119-183oC. The 1H NMR spectra showed characteristic 
broad signals between 5.00-6.02ppm corresponding to the NH2 protons at the 2-position of 
the pyrimidine heterocycle. The heterocyclic ring proton at C5 was observed between 7.30-
7.86ppm. MS data was correct upon interpretation with an (M+1)+ peak being observed and 
IR spectroscopy showed absorptions in the region of 3250-3400cm-1 as expected for the 















































Figure 51 illustrates the 1H NMR spectrum and Figure 52 shows the MS spectrum of DMU 
10212. 
Yields obtained for the synthesis of pyrimidines ranged from 9% achieved for DMU 10202 to 
33% gained for DMU 10203, which in general was not significantly high. This may be 
explicable by the way in which the initial nucleophilic addition step between the guanidine 
and chalcone occurs. The kinetically favoured 1,2-nucleophilic addition is required (Figure 
53) to enable the imine intermediate to form, and for the reaction to proceed to produce the 
pyrimidine heterocycle. 225 However, there is also the possibility that 1,4-nucleophilic 
addition can occur which is thermodynamically favoured. This would form an undesired 
























It has also been reported that the addition of hydrogen peroxide too early into the reaction 
resulted in the formation of a 5-membered heterocyclic by-product, which may also be 
formed if sufficient chalcone remains un-reacted with the free guanidine. Therefore it is vital 
for the chalcone and guanidine to be stirred without the presence of hydrogen peroxide in 
order to achieve the maximum amount of dihydro-pyrimidine possible to prevent further side-
products forming. 
The uses of several bases have been reported in the synthesis of pyrimidines from chalcones, 
including potassium hydroxide, sodium hydroxide, potassium carbonate and sodium 
isopropoxide.226, 227 
Agarwal et al have also reported the synthesis of similar substituted pyrimidines for the 
treatment of malaria, achieving yields between 59-77% for their compound library. This 
method employed the use of sodium isopropoxide as the base under anhydrous conditions, 
which is a stronger base than potassium hydroxide used in the synthesis of the pyrimidines in 
Table 12. The addition of an oxidising agent in order to achieve an aromatised heterocycle 
was not used in the reactions carried out. A more recent publication has shown the synthesis 
of pyrimidines from chalcones using potassium carbonate as the base stirred in DMF as the 
solvent.228 The reaction was carried out at room temperature with yields of up to 96% being 
recorded.  
Therefore, it could be possible that in order to achieve a higher yield of pyrimidine, the 
















Figure 53. Guanidine A shows the possibility of 1,4-nucleophilic addition and guanidine B shows 





future work. Also, an exploration can be made to see if the addition of hydrogen peroxide is 
required or not to achieve the final pyrimidine product, or whether stirring the reactions in air 
could suffice as there appears to be conflicting literature data. 
Another approach used to synthesise pyrimidine heterocycles from α,β-unsaturated 
compounds has been shown by Lin et al (Figure 54).229 S-methylisothiourea was reacted with 
α,β-unsaturated compounds using NaOMe in MeOH producing pyrimidines in yields ranging 
from 7-55%. The 2-positioned SMe on the pyrimidine heterocycle was then substituted with 
various amines to yield 2-amino substituted pyrimidines. This was achieved either using 1,4-
dioxane or THF as the solvent, with yields ranging from 25-55%. However, as this method 
uses a two step synthesis, the overall yield obtained may be lower than that achieved from the 














3.1 Biological Evaluation of the 2-Amino-4,6-Diarylpyrimidines  
Fifteen 2-amino-4,6-diarylpyrimidines were synthesised and evaluated for their cytotoxic 
properties against the MDA 468, MCF7 and MDA 231 breast cancer cell lines. This was 
achieved using the MTT assay described in Chapter 2, Section 2.4, with experimentations 



















pyrimidines will be discussed in accordance to the substitutions on the A and B-rings (Figure 










3.1.1 Methylenedioxy Substituted A-Ring 
Ten pyrimidines with constant 3,4-methylenedioxy substituted A-rings were synthesised with 
either single, double or triple methoxy groups on the B-rings, and one with a methylenedioxy 
substituted B-ring. These compounds will be further divided in respect to the B-ring 
substitutions in order to facilitate discussion of the cytotoxicity data achieved.  
 
3.1.1.1 Biological Evaluation of DMU 10213, DMU 10211 and DMU 10209 
Three amino-pyrimidines were synthesised with methylenedioxy substituted A-rings and 
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With a 2-methoxy substituted B-ring, DMU 10213 (Table 13, entry 3) displayed the greatest 
toxicity towards the tumour cell lines out of the mono methoxy substituted B-ring 
compounds. In the MDA468 cancer cell line which constitutively expresses both CYP1A1 
and CYP1B1 an IC50 value of 0.2µM was obtained, which was 250 times more toxic in 
comparison to the toxicity observed against the MCF10A cells (Figure 57). In comparison to 
its chalcone derivative of DMU 2265, DMU 10213 was 250 more potent towards the MDA 





















































IC50 values of 1µM were observed when DMU 10213 was screened against the TCDD 
induced and non-induced MDA 231 cells, the lowest IC50 results obtained from the 
methylenedioxy substituted A-ring pyrimidines. In the MCF7 cell line which constitutively 
expresses very low levels of CYP1 enzymes, IC50 values of 0.05µM and 0.06µM were 
recorded against the TCDD induced and non-induced MCF7 cells (Figure 58). This result 
was considerably lower than that observed from DMU 2265, as IC50 values of 50µM and 




















DMU 10211 (Table 13, entry 2) was synthesised bearing a 3-methoxy substituted B-ring. 
Unlike DMU 10213, DMU 10211 did not show toxicities of a considerable degree, as IC50 
values were 18µM and over towards the tumour cell lines. DMU 10209 (Table 13, entry 2) 
was synthesised with a 4-methoxy substituted B-ring. An IC50 value of 0.6µM was observed 
towards the MDA 468 cells, 83 times more toxic in contrast to the non-tumour MCF10A 
cells. However, results from the MCF7 and MDA 231 cells were not low enough to warrant 








































3.1.1.2 Biological Evaluation of DMU 10212, DMU 10214, DMU 10210                    
and DMU 10205 
Four pyrimidines were synthesised with dimethoxy substituted B-rings and methylenedioxy 















































































































































DMU 10212 DMU 10214
DMU 10205DMU 10210
 

























DMU 10212 (Table 14, entry 3), synthesised with a 2,4-dimethoxy substituted B-ring showed 
exciting toxicity towards the MDA 468 cell line giving an IC50 value of 0.01µM whilst 















The MCF7 cells, both induced and non-induced with TCDD also gave significant cytotoxic 
activity when screened with DMU 10212. The TCDD induced cells gave an IC50 value of 






















































































DMU 10212 was not as potent towards the MDA 231 cells in contrast to the results obtained 
from the MDA 468 and MCF7 cells. IC50 values of 20µM and above were observed which 
are not considered significantly toxic. In comparison to its pyrazole analogue of DMU 10108, 
DMU 10212 was 5500 times more toxic towards the MDA 468 cell line (Table 15, entry 2). 
It can also be seen that the toxicity of DMU 10212 against the MCF7 and MDA 231 cells was 
significantly greater than that of DMU 10108. DMU 10212 also proved to be more cytotoxic 
in comparison to its chalcone analogue of DMU 407 (Table 15, entry 3), showing 125 times 
more toxicity towards the MDA 468 cell line and increased toxicity towards the MCF7 cells.  
 











































































































































DMU 10214 (Table 14, entry 4) was designed with a 3,4-dimethoxy substitution on the B-
ring, however, IC50 results observed from screening this compound were not toxic enough for 
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this compound to warrant further investigation. DMU 10210 (Table 14, entry 2) was 
synthesised with a 3,5-dimethoxy substitution on the B-ring. A noticeable toxicity of 3µM 
was observed towards the MDA 468 cell line whilst no toxicity was seen against the 
MCF10A cells (Figure 62). The chalcone analogue DMU 160 was 4 times less toxic towards 
the MDA 468 cells and also showed toxicity towards the non-tumour MCF10A cells. A lower 
toxicity towards the MCF7 cells was also observed from the amino-pyrimidine in contrast to 
the chalcone derivative. DMU 10210 and DMU 160 also showed similar toxicity towards the 
TCDD induced MDA 231 cells, but results from the non-induced MDA 231 cells showed 














DMU 10205 (Table 14, entry 1) was synthesised with a 2,5-dimethoxy substitution on the B-
ring. The result from the MDA 468 cell line gave an IC50 value of 1.5µM whilst no toxicity 
was seen towards the MCF10A cell line. An IC50 value of 3µM was recorded for both the 
TCDD induced and non-induced MCF7 cells, and the MDA 231 TCDD induced and non-
induced cells also gave an identical result of 10µM. DMU 423, the chalcone analogue of 
DMU 10205 gave a considerably toxic IC50 value of 0.7µM when screened against the non-
tumour MCF10A cells compared to the non-toxic data observed from DMU 10205. The 
incorporation of the amino-pyrimidine heterocycle in this case has lowered the toxicity 
towards the non-tumour MCF10A cells significantly, while maintaining an encouraging 








































3.1.1.3 Biological Evaluation of DMU 10204 and DMU 10202 
Two amino-pyrimidines were synthesised with tri-methoxy substitutions on the B-rings and 


































































































DMU 10204 (Table 16, entry 2) showed interesting cytotoxicity when screened against the 
MDA 468 cell line, giving an IC50 value of 1µM whilst showing no toxicity towards the non-
tumour MCF10A cell line. This was encouraging as DMU 419, the chalcone analogue of 
DMU 10204 gave an IC50 value of 14µM when screened against the MCF10A cell line, 
showing the incorporation of the amino-pyrimidine heterocycle advantageous in this case. An 





















TCDD induced MDA 231 cells, whilst the non-induced cells showed a less potent effect with 
an IC50 value of 9µM being recorded. Toxicity was also observed in the MCF7 cell lines with 
an IC50 value of 10µM being achieved for the non-induced cells, whereas the TCDD treated 
MCF7 cells showed a five-fold increase in toxicity. This could be explained by the increased 
expression of CYP1 enzymes by TCDD metabolising DMU 10204 to its cytotoxic 
metabolites. DMU 10107, the pyrazole analogue was shown to be the most effective prodrug 
synthesised in chapter two. But DMU 10204 clearly exhibited enhanced toxicities towards 
the tumour cell lines in contrast to DMU 10107 (Table 17, entry 1), showing 8 times more 
cytotoxicity towards the MDA 468 cells, but more noticeably towards the MDA 231 cells 
induced with TCDD as an IC50 value of 0.6µM was recorded.   
 

















































































































DMU 10202, substituted with a tri-methoxy B-ring (Table 16, entry 1) did not show toxicities 
comparable to DMU 10204 as all IC50 values were 15µM and greater. This was a 
disappointing result as DMU 135, the chalcone precursor of DMU 10102 showed significant 
anti-tumour toxicities, especially towards the MDA 468 cell line with an IC50 value of 
0.006µM.   
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3.1.1.4 Biological Evaluation of DMU 10203 
The amino-pyrimidine DMU 10203 was synthesised with methylenedioxy substituted A and 









However, the results obtained from the MTT assays only appeared to show relative toxicity 
towards the MDA 231 cells, where IC50 values of 6µM for both the TCDD induced and non 
induced cells were observed. Undesirable toxicity was also seen towards the MCF10A cells 
hence this compound will not warrant further investigation.  
 
3.1.2 4-Methoxy Substituted A-Ring 























































































































































































DMU 10207 (Table 18, entry 1) synthesised with a 3,4-dimethoxy substituted B-ring  showed 
interesting toxicity towards the MDA 468 cells giving an IC50 value of 0.6µM.  The non-
tumour MCF10A cells gave an IC50 value of 30µM, showing DMU 10207 was 50 times more 
toxic towards the CYP1 expressing MDA 468 cell line. However, this compound was not 
particularly toxic to the MCF7 and MDA 231 cells, with IC50 values of 42µM and above 
being recorded. DMU 10208 (Table 18, entry 2) was synthesised with a 2,4-dimethoxy 
substituted B-ring. As observed with previous compounds, a methoxy group in the 2-position 
has shown to be important for cytotoxic activity of the compound. As expected, DMU 10208 
exhibited significant toxicity towards the MDA 468 cell line with an IC50 value of 0.2µM, 
and showed little toxicity towards the MCF10A cells (Figure 66). DMU 10208 was more 
toxic compared to its chalcone derivative of DMU 133 against the MDA 468 cell line but 





















Significant toxicity was recorded from screening DMU 10208 against the MCF7 cells, with 
IC50 values of 0.05µM and 0.2µM being observed for the TCDD induced and non-induced 














An IC50 value of 3µM was recorded when DMU 10208 was screened against the MDA 231 
cells with and without TCDD induction. It can been seen that DMU 10208 was more toxic in 


































IC50 >10 µM 









































further that a methoxy group in the 2-position of the B-ring is important for activity against 
the tumour cells. DMU 10201 (Table 18, entry 3) appeared to show its most effective 
cytotoxicity against the MDA 468 cell line achieving an IC50 value of 13µM. However, the 
chalcone analogue of DMU 10201, DMU 102 appeared to be more toxic towards the MDA 
468 cell line as an IC50 value of 0.5µM was recorded. IC50 values from screening DMU 
10201 against the MCF7 and MDA 231 were also not to a noteworthy degree, as values of 
30µM and above were seen.  
Modification of DMU 10201 by the addition of a methoxy group in the 4-position of the B-
ring gave DMU 10206 (Table 18, entry 4). Results from screening DMU 10206 against the 
MDA 468 cell line showed a 2-fold increase in cytotoxicty compared to DMU 10201, but no 
significant toxicities were observed from the MCF7 and MDA 231 cells as IC50 values were 
15µM and above.  
 
3.1.3 Non-Substituted A and B-Ring 









DMU 10200 showed considerable activity towards the MDA 468 cell line, with an IC50 of 
0.2µM whereas no toxicity was observed against the MCF10A cell line (Figure 69). The 
MCF7 cell line showed sufficient cytotoxicity as the TCDD induced cells gave an IC50 value 
of 7µM and the non-induced cells showed an IC50 value of 3µM. However, the MDA 231 cell 
line did not show toxicities to a noteworthy degree as IC50 values of 50µM were observed for 

























DMU 10200 showed comparative toxicity towards the MDA 468 cells with the results 
observed from DMU 10212 and DMU 10213 (Figure 70), but showed significantly less 
toxicity towards the MCF7 and MDA 231 cells. It can be seen from DMU 10200 that without 
substituted phenyl groups present the amino-pyrimidine is an effective anti-cancer prodrug 
against the MDA 468 cell line. But it appears that 3,4-methylenedioxy or methoxy substituted 
phenyl groups must be present in order for cytotoxicity to be seen towards the MCF7 and 








3.2 Summary and Conclusions 
In chapter two, pyrazole heterocycles were integrated into the α,β-unsaturated moiety of 
chalcones to yield 3,5-diarylpyrazoles. The pyrazoles were synthesised to lock chalcones in 

























































photoisomerisation, producing the less potent cis isomer. However, the pyrazoles were not as 
cytotoxic towards the tumour cell lines as their chalcone derivatives. Therefore, the α,β-
unsaturated moiety required further exploration in an attempt to produce compounds which 
solved the problem of photoisomerisation occurring and were comparatively similar or 
greater than the chalcones in cytotoxicity against the tumour cell.     
Therefore, fifteen 2-amino-4,6-diarylpyrimidines were synthesised from a method taken by 
Varga et al with yields ranging from 9-33%. The amino-pyrimidines were evaluated for their 
prodrug activity against a panel of tumour cell lines, which included the MDA 468, MCF7 
and MDA 231 cells. Exciting anti-tumour activity was observed from the amino-pyrimidines, 
especially with DMU 10212, DMU 10213 and DMU 10200 (Table 19). Out of these three 
compounds, DMU 10212 appeared to be the most effective anti-cancer prodrug as it provided 
the most effective IC50 values across the tumour panel of cell lines screened against. An IC50 
value of 0.01µM was recorded against the MDA 468 cell line, which constitutively expresses 
CYP1 enzymes. IC50 values of 0.07µM and 0.3µM were observed against the non-induced 
and TCDD induced MCF7 cells, which expresses CYP1A1 after exposure to TCDD. 
Importantly, no toxicity was observed towards the non-tumour MCF10A cells.   
 

































































































































Overall, improved cytotoxicities were observed from the amino-pyrimidines in comparison to 
their pyrazole derivatives synthesised in chapter two. DMU 10212 and DMU 10213 also 
showed greater toxicities in contrast to their chalcone analogues, whilst forming the rigid 
structures required to prevent photoisomerisation occurring. It can be stated that the 
incorporation of the pyrimidine heterocycle across the α,β-unsaturated chalcones have proved 































4.0 Synthesis of 4,6-Diarylpyrimidones 
The 2-amino-4,6-diarylpyrimidines synthesised in chapter three gave very exciting 
cytotoxicity results from screening against the MDA 468, MCF7 and MDA 231 cancer cell 
lines. Significant results were obtained from DMU 10212 (Figure 71) which showed an IC50 
value of 0.01µM when screened against the MDA 468 cells and IC50 values of 0.07µM and 







DMU 10204 (Figure 72) showed significant toxicity towards the MDA 231 cells induced 
with TCDD, giving an IC50 value of 0.6µM. To summarise, the amino-pyrimidine 
heterocycle has been shown to be important for better cytotoxicities to be observed across the 







The next stage of the project was to investigate whether the amino group at the 2-position of 
the heterocycle was important for the pyrimidines synthesised in chapter three to exhibit their 
cytotoxic activity, and to explore if other functional groups at the 2-position would alter the 






















2-position of the heterocycle. The lone pair of electrons on the amino group may be involved 
in electron interactions with CYP1 binding sites, by acting as a hydrogen bond acceptor, or 
on the other hand the amino protons may act as hydrogen donators. Carbonyl groups have 
two lone pairs of electrons available on the oxygen atom, which may also partake in 
electronic interactions between the CYP1 enzymes and the pyrimidones, consequently 
increasing selectivity and prodrug toxicity.     
Pyrimidones have been synthesised by the reaction of urea and chalcones under acidic 







The method involved stirring a mixture of chalcones, urea and hydrochloric acid in ethanol 
under reflux for 12h. Half of the solvent was removed in vacuo followed by the addition of 
ammonium hydroxide solution to neutralise the reaction. This formed a precipitate which was 
recrystallised from a mixture of DMF and water, producing the purified pyrimidones in a 
yield of 67%. However, an approach carried out by Borovik et al who converted 2-
aminopyrimidoindoles to 2-oxopyrimidoindoles (Figure 74) via diazotisation in a one step 
reaction using sodium nitrate was found.231 This reaction reportedly produced the 2-
oxopyrimidoindoles in greater than 90% yields, whereas the synthesis of pyrimidones by 
Fathalla et al gave yields of up to 67%. Borovic et al stirred 2-aminopyrimidoindoles with 
aqueous sodium nitrate in acetic acid under reflux, which resulted in the precipitation of the 







































This method of Borovic et al was used as the previously synthesised amino-pyrimidines 
could be directly converted to the pyrimidones through the diazotisation reaction without the 
need to re-synthesise chalcones as required for the method used by Fathalla et al. Also, direct 
comparisons in cytotoxicities of the amino-pyrimidines and pyrimidones could be made, 
indicating the more favourable functional group required for greater cytotoxicty to occur.   
 
The mechanism for the diazotisation of the amino-pyrimidines begins with the dissociation of 
sodium nitrate in water to give a nitrite ion, which then protonates to form nitrous acid 
(Scheme 8).210 The nitrous acid protonates again, resulting in dehydration and the creation of 
a reactive NO+ cation. The lone pair of electrons on the amine at the 2-position of the 
pyrimidine ring attack the nitrogen of the NO+ cation, followed by dehydration and formation 
of a diazonium salt. Nitrogen is lost forming a pyrimidine carbocation which undergoes 













































The pyrimidine conversion reaction was achieved by stirring the pyrimidines (1.31 mmol) in 
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w/v, 7.8 mmol) was then added and the reaction was stirred under reflux for a further three 
hours. Once the reaction cooled the glacial acetic acid was removed in vacuo resulting in the 
solid crude pyrimidone, recrystallised from ethanol to yield the pure pyrimidone.  
 




















































































































































































































































































































































































A library of fourteen pyrimidones were synthesised (Table 20) with yields ranging from 47-
85%. An exception was DMU 10302 which gave an overall yield of 3%. Melting points 
ranged between 142-308oC. The 1H NMR spectra of the amino-pyrimidines characteristically 
showed peaks for the NH2 group between 5.00-6.02ppm, but this was no longer present in the 
spectra of the pyrimidones. MS spectra were correct with either an M+ or (M+1)+ ion peak 
being observed. IR spectroscopy showed absorptions in the region of 1690-1750 cm-1 as 
would be expected for the presence of the carbonyl group. For example, the 1H NMR 
spectrum for DMU 10314 showed the C5 heterocyclic proton as a singlet at 7.42ppm. The 
MS spectrum showed an ion mass of 353 representing the [M+H]+ ion. An IR absorption at 
1630cm-1 was observed for the carbonyl group and a melting point range between 290-292oC 













































































4.1 Pyrimidone Synthesis via Thio-Pyrimidines 
Another method to synthesise the pyrimidones was discovered through the attempted 
synthesis of thio-pyrimidines (Figure 77). These were designed to investigate the 2-position 
of the heterocycle by the incorporation of a sulfur atom, to which comparisons in 








It was anticipated that thio-pyrimidines could have been synthesised by reacting thiourea with 
chalcones under the same conditions used to synthesise the amino-pyrimidines in chapter 3. 
DMU S16 was designed with a 4-methoxy substituted A-ring and 3,4-dimethoxy substituted 
B-ring. The synthesis required the corresponding chalcone to be stirred under reflux with 1.5 
equivalents of thiourea and 4 equivalents of aqueous NaOH in ethanol for 6h. Three 
equivalents of hydrogen peroxide were added and the reaction continued to stir under reflux 
for 1h. Water was used to quench the reaction and the organic phase was extracted with DCM 
and dried over MgSO4. The solvent was removed in vacuo producing the crude solid which 
was purified by flash chromatography using ethyl acetate and hexane (5:5) as eluent. A yield 
of 15% was obtained and a melting point range between 258-260oC was observed.     
However, after analysing the major product of this reaction the thio-pyrimidine was not 
present. MS results showed that the synthesised compound was 16 atomic mass units below 
what was expected and also signified the absence of the sulfur atom. DMU S16 was 
synthesised with a 4-methoxy substituted A-ring and 3,4-dimethoxy substituted B-ring. This 
compound should have given a mass of 354 but an actual mass of 338 was observed, the 
same as that observed for DMU 10307 (Table 20, entry 11). The 1H NMR produced peaks as 
expected giving a total of 8 protons, but this would be expected for both the thio-pyrimidine 
and pyrimidone. 
As hydrogen peroxide was used in the reaction to aid aromatisation of the heterocycle, it can 










to form pyrimidones (Figure 78). Subsequently, it was found that desulfurisation of thio-
pyrimidines has been shown to occur with hydrogen peroxide of pyrimidines by Samour et 









The synthesis of thio-pyrimidines warrants further investigation. Literature methods have 
been found which use the same method as used above but do not utilise hydrogen peroxide to 
aid the aromatisation of the compound.76  
 
4.2 Biological Evaluation of the 4,6-Diarylpyrimidones  
Pyrimidones were synthesised from the direct conversion of amino-pyrimidines via a one step 
diazotisation reaction. The rationale for the conversion was to investigate the importance of 
the amino group for the cytotoxicities observed in chapter two, and to determine 
cytotoxicities with the incorporation of the carbonyl function group in comparison.  
The synthesised pyrimidones were evaluated for their cytotoxicity against MDA 468, MCF7 
and MDA 231 breast cancer cell lines using the MTT assay as described in chapter two. The 
cytotoxicity data will be grouped and discussed in accordance to the substitutions on the A 





























4.2.1 Methylenedioxy Substituted A-Ring 
Ten pyrimidones with 3,4-methylenedioxy substituted A-rings were synthesised. These 
compounds will be further divided according to the B-ring substitutions present to facilitate 
discussion of the cytotoxicity data observed. 
 
4.2.1.1 Mono-Methoxy Substituted B-Rings 
DMU 10311, DMU 10309 and DMU 10313 were synthesised with mono-methoxy 










































































































































n=1, ND=No data 
DMU 10313 (Table 21, entry 3) was synthesised with a 2-methoxy substituted B-ring. The 
cytotoxicity of DMU 10313 towards the CYP1 expressing MDA 468 cell line was notable, 
with an IC50 value of 0.07µM (Figure 81). This was 700 times more toxic in comparison to its 
chalcone analogue of DMU 2265 (Table 21, entry 3), and 3 times more toxic than its amino-
pyrimidine analogue of DMU 10213 (Table 21, entry 2). Importantly, DMU 10313 did not 
appear to show cytotoxicity towards the non-tumour MCF10A cell line.  
 
 






IC50 values observed from DMU 10313 when screened against the MCF7 TCDD induced and 
non-induced cells were 0.5µM and 1.8µM. These values were significantly lower than that 
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With a 3-methoxy substituted B-ring DMU 10311 (Table 21, entry 2) showed encouraging 
toxicity towards the MDA 468 cells giving an IC50 value of 1.7µM, whilst showing no 
toxicity against the MCF10A cell line (Figure 82). Toxicity was also observed against the 
MDA 231 cells, where the TCDD induced cells gave an IC50 value of 2µM. This was over 
two times more toxic than the result obtained from the non-TCDD induced MDA 231 cells. 
Cytotoxicity was also observed towards the MCF7 cells, where the TCDD induced and non-
induced cells gave identical IC50 values of 8µM. In general, DMU 10311 showed higher 
toxicity in contrast to its amino-pyrimidine analogue of DMU 10211, with a ten-fold increase 
in activity against the MDA 468 cell line and up to a thirty five-fold increase in activity 












DMU 10309 (Table 21, entry 1) did not show cytotoxic effects of any interest as all IC50 
values were greater than 18µM, too high to be further evaluated. 
 
4.2.1.2 Di-Methoxy Substituted B-Rings 







































DMU 10305 DMU 10312
DMU 10314 DMU 10310
 







































































































































































n=1, ND=No data 
DMU 10312 (Table 23, entry 1) was synthesised with a 2,4-dimethoxy substituted B-ring. An 
IC50 value of 1.5µM was observed against the MDA 468 cell line whilst no toxicity was seen 


















































An IC50 value of 8µM was obtained for both the TCDD induced and non-induced MCF7 
cells. Also, identical IC50 values of 10µM were recorded for DMU 10312 when screened 
against both the TCDD induced and non-induced MDA 231 cells. 
 


















































































































DMU 10212, the pyrimidine analogue of DMU 10312 was shown to be the most cytotoxic 
prodrug synthesised in chapter two. It can be seen from Table 24 that the conversion of DMU 
10212 to its pyrimidone analogue did not improve its cytotoxicity towards the MDA 468 and 
MCF7 cell lines. An increase in cytotoxicity was observed in the MDA 231 cell line, but not 
to a substantial degree. DMU 10314 (Table 23, entry 2) was synthesised with a 3,4-
dimethoxy substitution on the B-ring. However, similarly to its amino-pyrimidine analogue 
of DMU 10214 little cytotoxicity was observed towards the tumour cell lines.  With a 3,5-
dimethoxy substituted B-ring, DMU 10310 (Table 23, entry 3) gave an IC50 value of 8µM 
from screening against the MDA 468 cell line whilst no toxicity was observed towards the 
MCF10A cell line. The toxicity of DMU 10310 in the MDA 468 cell line was significantly 
lower than that observed with DMU 10314. This suggests that the presence of a 3,4-
dimethoxy substituted B-ring is more favourable for cytotoxicity to occur in contrast to a 3,5-
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dimethoxy substituted B-ring, as this is was the only difference between DMU 10310 and 
DMU 10314.  DMU 10305 (Table 23, entry 4) was synthesised with a 2,5-dimethoxy 
substitution on the B-ring, but showed to be less potent than its amino-pyrimidine analogue 
of DMU 10205.  
 
4.2.1.3 Biological Evaluation of DMU 10304 and DMU 10302 































































































DMU 10304 (Table 25, entry1), with a 2,3,4-trimethoxy substitution on the B-ring 
demonstrated an IC50 value of 6µM towards the MDA 468 cells, whilst no toxicity towards 
the non-tumour MCF10A cells. An identical IC50 value of 7µM was observed for the TCDD 
induced and non-induced MCF7 cells. The MDA 231 cells gave IC50 values of 9µM and 























3,4,5-trimethoxy substituted B-ring showed to be less cytotoxic than DMU 10304 towards the 
tumour cell lines. There was a 5-fold decrease in toxicity towards the CYP1 expressing MDA 
468 cell line and 10-fold decrease in toxicity towards the MCF7 cell lines in contrast. It 
appears that a 2,3,4-trimethoxy substitution on the B-ring has a more potent cytotoxic effect 
than a 3,4,5-trimethoxy substitution on the B-ring towards the tumour cell lines. The amino-
pyrimidine analogues of DMU 10302 and DMU 10304 were more cytotoxic across the 
tumour cell lines in comparison.   
 
4.2.1.4 Biological Evaluation of DMU 10303 
DMU 10303 was synthesised with 3,4-methylenedioxy substitutions on both of the A and B-









Screening DMU 10303 against the MDA 468 cell line gave an IC50 value of 10µM, 
comparable to that observed from its amino-pyrimidine derivative of DMU 10203. However, 
unlike DMU 10203, the pyrimidone did not show toxicity towards the non-tumour MCF10A 
cells. results from the MCF7 and MDA 231 cells were not substantially toxic, as IC50 values 
of 25µM and above were recorded. 
  
4.2.2 4-Methoxy Substituted A-Ring 
DMU 10307 (Figure 87) was prepared with a 4-methoxy substitution on the A-ring and a 3,4-
dimethoxy substitution on the B-ring. However, there appeared to be no cytotoxic effect from 
this compound against the MDA 468 and MCF7 cells as IC50 values were greater than 
100µM. Slight cytotoxicity was observed on the MDA 231 cells but not to a great degree as 






















In contrast to its amino-pyrimidine analogue of DMU 10207, DMU 10307 showed a 
substantial decrease in activity towards the MDA 468 cells as toxicity towards this cell line 
from DMU 10207 was recorded at 0.8µM.  
 
4.2.3 4-Methoxy Substituted B-Ring 
































































































































With a 3,4,5-trimethoxy substituted A-ring, DMU 10301 (Table 26, entry 1) did not show 
toxicity towards the tumour cell lines, with IC50 values of 70µM and above being recorded. 
DMU 10306 (Table 26, entry 2), synthesised with a 3,4,5-trimethoxy substituted A-ring 
showed slightly increased toxicities towards the cancer cell lines in contrast to DMU 10301, 
but not to a significant degree. However, it can be noted that the increase in toxicity appears 
to occur due to the incorporation of the extra methoxy group in the 4-position of the A-ring. 
Also, the toxicities of DMU 10301 and DMU 10306 were not as potent as their 
corresponding amino-pyrimidine derivatives of DMU 10201 and DMU 10206 respectively.  
 
4.2.4 Non-Substituted A and B-Rings 



















Cytotoxicity results from the MDA 468 cells gave an IC50 value of 2µM whilst no toxicity 
was observed towards the non-tumour MCF10A cell line. The screening of DMU 10300 
against the MCF7 cells gave IC50 values of 3µM and 7µM for the TCDD induced and non-
induced cells. The IC50 results from the MDA 231 cells were recorded at 50µM each for the 
TCDD induced and non-induced cells. This result was not as potent as that observed towards 
the MDA 468 and MCF7 cells. 
 














































































































DMU 10200, the pyrimidine analogue of DMU 10300 (Table 27, entry 2) also gave exciting 
results when screened against the MDA 468 cells with an IC50 value of 0.2µM being 
recorded. Similarly to DMU 10200, DMU 10300 (Table 27, entry 1) showed no toxicity 
towards the non-tumour MCF10A cells but a ten-fold decrease in toxicity towards the MDA 
468 cells was seen. A three-fold increase towards the MCF7 cells induced with TCDD was 
observed also. The MDA 231 toxicities of both compounds appeared to be identical at 50µM 
for both the TCDD induced and non-induced cells. it is thought that the compounds designed 
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in this project undergo CYP1 metabolism to produce their cytotoxic analogues via 
dealkylation or hydroxylation reactions. As there are no substitutions on the phenyl groups 
present on the A or B-rings of either DMU 10200 or DMU 10300, hydroxylation by CYP1 
enzymes would most likely occur. This would produce hydroxy substituted metabolites of 
these two compounds which may be explicable for the anti-tumour activity seen. An example 
of this mode of hydroxylation can be seen with tamoxifen, which undergoes metabolism by 
CYP enzymes to produce 4-hydroxytamoxifen. The metabolite is 100 times more potent than 
its parent compound.  
   
4.3 Summary and Conclusions 
Fourteen pyrimidones were synthesised in good yields from a one-step diazotisation 
conversion reaction using the amino-pyrimidines synthesised in chapter three. The 
pyrimidones were synthesised to determine and evaluate the importance of the amino group 
at the 2-position of the pyrimidine ring for the cytotoxicities observed with the amino-
pyrimidines, and to observe the cytotoxic effect of the carbonyl group in comparison.  
Exciting results were observed from the pyrimidones when screened against the MDA 468, 
MCF7 and MDA 231 tumour cell lines, especially with DMU 10300, DMU 10311, DMU 
10313 and DMU 10312. 
Table 28. Comparison of toxicities of DMU 10300, DMU 10311, 























































































































































































































































































































































DMU 10300 (Table 28, entry 1) gave an IC50 value of 2µM against the MDA 468 cell line 
whilst showing no toxicity towards the non-tumour MCF10A cells. An IC50 of 3µM was 
recorded when screened against the TCDD induced MCF7 cells. DMU 10311 (Table 28, 
entry 3) did not show toxicity towards the non- tumour MCF10A cells but a potent IC50 value 
of 1.7µM was seen towards the MDA 468 cells. DMU 10313 (Table 28, entry 5) showed 
significant toxicity towards the MDA 468 cells giving an IC50 value of 0.07µM whilst no 
toxicity was observed towards the MCF10A cells. IC50 values of 1.8µM and 0.5µM were 
recorded when DMU 10313 was screened against the MCF7 and MCF7 cells induced with 
TCDD. DMU 10312 did not show toxicity towards the MCF10A cells but an IC50 value of 
1.5µM was observed against the MDA 468 cells.    
However, in general, the conversion of the amino-pyrimidines to pyrimidones did not 
enhance the cytotoxicity of the compounds comparatively even though notable results were 
seen from the pyrimidones. The pyrimidine DMU 10212 (Table 28, entry 8) was the most 
effective prodrug synthesised in chapter three. The pyrimidone analogue, DMU 10312 (Table 
28, entry 7) showed approximately a 20-fold decrease in cytotoxicity towards the MDA 468 
cell line compared to DMU 10212. The toxicity seen towards the MCF7 cells was 115 times 
less with DMU 10312 than that observed from DMU 10212, and approximately 30 times less 
towards the MCF7 cells induced with TCDD. 
On the contrary, DMU 10311 showed lower IC50 values across the tumour cell lines in 
contrast to DMU 10211, including a ten-fold increase in toxicity towards the MDA 468 cell 
line. More noticeable was the increased toxicity observed from DMU 10311 towards the 
MDA 231 cells, with 35 times more cytotoxicity recorded towards the TCDD induced cells 
than DMU 10211. 
Solubility of the pyrimidones in DMSO, a crucial solvent used in the MTT assay was poor. 
This was not apparent with the amino-pyrimidines, indicating the amino group is more 



















5.0 Synthesis of 2-Morpholino-4,6-Diarylpyrimidines 
The library of amino-pyrimidines synthesised in chapter three was valuable in providing 
compounds with exciting anti-cancer activity against tumour cell lines selected for their 
ability to constitutively or inductively express CYP1 enzymes. DMU 10212 (Figure 90) was 
shown to be the most cytotoxic prodrug synthesised, with significant IC50 values including 






The amino group at the 2-position of the pyrimidine ring was investigated for its importance 
in the cytotoxicity observed in chapter three. The amino-pyrimidines were converted by 
diazotisation to yield pyrimidones, allowing a contrast in cytotoxic properties of the amino-
pyrimidines and pyrimidones to be made. The pyrimidone ring was also selected as the lone 
pairs of electrons on the oxygen atom could possibly interact with CYP1 binding sites in the 
aim to increase binding towards CYP1 enzymes and in turn improving cytotoxicity. 
Significant toxicities were seen from the pyrimidones towards the tumour cell lines, with IC50 







The amino group has been shown to be important for pyrimidines to show toxicity towards 





















observed, the 2-position of the pyrimidine ring was further explored. On this occasion, a 
morpholine group was selected. Morpholine is a 6-membered heterocycle which consists of 
four carbon atoms, a nitrogen atom and oxygen atom (Figure 92). The heteroatoms are in the 
1 and 4-positions of the ring. Incorporation of morpholine maintained the presence of a 
nitrogen atom at the 2-position of the pyrimidine ring whilst introducing the bulkiness of the 
morpholine ring to explore the binding site of the CYP1 enzymes. The oxygen atom also 
present in the morpholine ring may participate in binding with the active site of the enzymes 






In order to form the morpholino-pyrimidine heterocycle, 4-morpholinylformamidine 
hydrobromide was reacted with chalcones. The reaction conditions and equivalents of parallel 
reagents were the same as that used to synthesise the pyrimidines in chapter three. Therefore, 
the synthesis of the 2-morpholino-4,6-diarylpyrimidines required the dissolution of 4-
morpholinylformamidine hydrobromide (1.5 equivalents) in ethanol using sodium hydroxide 
(4 equivalents). This mixture was stirred at reflux for thirty minutes producing the free 4-
morpholinylformamidine.  The required chalcone (1 equivalent) was added to the mixture 
and the reaction continued to stir under reflux for 6h. This was followed by the addition of 
hydrogen peroxide (3 equivalents, 50% w/v) to aromatise the heterocyclic ring and the 
reaction was stirred under reflux for a further 1h.  
TLC analysis showed the formation of the morpholino-pyrimidine as a fluorescent blue spot 
when viewed under UV light. The solvent was removed in vacuo and the product purified by 
recrystallisation from ethanol. Flash chromatography was used to isolate the 
morpholinopyrimidines if recrystallisation was unsuccessful using dichloromethane and 
methanol (9:1) as eluent. 
The first part of the mechanism for the formation of the morpholino-pyrimidines requires the 










hydroxide (Figure 93). Next, the free amidine forms an imine with the carbonyl group on the 
chalcone via 1,2-nucleophilic addition (Scheme 9). Intramolecular cyclisation then occurs 
forming the 6-membered dihydro-pyrimidine ring. The addition of hydrogen peroxide 





































































































































































































































































































































































































A library of nine 2-morpholino-4,6-diarylpyrimidines was synthesised with yields in the 
range of 12 to 36% and melting points between 121-215oC. The substitutions on the A and B-
rings were selected from the most effect amino-pyrimidines synthesised in chapter three.  
The 1H NMR spectra of the morpholino-pyrimidines were consistent with the expected 
structures. The pyrimidine ring proton at C5 appeared between 7.22-7.63ppm (Figure 94). 
The 8 protons bonded to the C19, C20, C21 and C22 carbons of the morpholine appeared as 
two separate triplets, each representative of four carbons between 3.75-4.20ppm. MS spectra 
were correct with either an M+ or (M+1)+ ion peak being observed. Figure 95 shows the 1H 

























Figure 94. Position of the C5, C19, C20, C21 and C22 















































The yields obtained for the library of compounds in Table 29 were relatively low, with the 
highest yield of 36% being obtained with DMU 10408. An optimisation of the synthetic route 
for the synthesis of DMU 10409 was carried out prior to the synthesis of the library 
synthesised. Variables investigated were the reaction time, equivalents of sodium hydroxide 
and 4-morpholinylformamidine hydrobromide (MBr) used. DMU 407 (Figure 97) was the 
constant chalcone used (one equivalent) in the optimisation reactions as the substitution on 



















It was concluded that a reaction time of 6 h, 4 equivalents of NaOH and 1.5 equivalents of 
MBr produced the highest yield of 12%. This was achieved with a reaction time of 6h, 4 
equivalents of NaOH and 1.5 equivalents of 4-morpholinylformamidine hydrobromide. 
However, DMU 10409 (Table 29, entry 9) the morpholino-pyrimidine analogue of DMU 407 
produced the lowest yield out of the substituted morpholino-pyrimidines synthesised, whilst 
DMU 10408 (Table 29, entry 8) non-substituted on either the A or B-rings produced the 
greatest yield. This could signify that the substitutions on the A and B-rings can affect the 
yield of the reaction, as it has already been shown that the substitutions on the A and B-rings 
can influence the yields of epoxides (Chapter 2, 2.2). Therefore, the substituted A and B-rings 
could either hinder the 1,2-nucleophilic addition process or increase the rate of 1,4-
nucleophilic addition occurring as discussed in chapter three (Figure 98). This is important as 
the reaction product required proceeds through 1,2-nucleophilic addition which is kinetically 
favoured, but there is also the possibility that 1,4-nucleophilic addition can occur which is 
thermodynamically favoured. The latter would form a heterocyclic product but would not 
provide the cyclised compound of interest, hence producing an undesired by-product 
lowering the yield. As this reaction also favours basic conditions, further investigations could 
be made experimenting with bases of varying strength including sodium isopropoxide, a 
stronger base than sodium hydroxide. However, if the pH of the reaction is too high, the 
protonation steps involved in the reaction mechanism may not occur hence inhibiting 





















5.1 Biological Evaluation of the 2-Morpholino-4,6-
Diarylpyrimidines 
The 2-position of the pyrimidine ring was investigated with the aim to achieve comparable or 
greater prodrug toxicities than those observed with the amino-pyrimidines in chapter two. 
Morpholine was incorporated into the pyrimidines yielding 2-morpholinopyrimidines (Table 
29) which were screened for their ability to inhibit cell growth against the MDA 468, MCF7 
and MDA 231 tumour cell lines as previously discussed in chapter two. To assist discussion, 
the aryl groups at the 4 and 6 positions have been assigned as A and B-rings (Figure 99). 
Also, the cytotoxicity results obtained have been grouped together according to the 









5.1.1 3,4-Methylenedioxy Substitution 
5.1.1.1 Biological Evaluation of DMU 10401, 10403 and DMU 10406 
Three morpholino-pyrimidine derivatives were synthesised with 3,4-methylenedioxy 


























Table 30. Cytotoxicity data for DMU 10401, DMU 10403 and DMU 10406 



































































































With a 3,4-methylenedioxy substitution on the B-ring, DMU 10401 showed no toxicity 
towards the MCF10A, MDA468 and MCF7 cell lines as IC50 values of greater than 100µM 
were recorded in each case. Slight toxicity towards the MDA231 cells was observed with 
identical IC50 values of 25µM recorded for both the TCDD induced and non induced cells. 
Substituted with a 2-methoxy B-ring, DMU 10403 showed the greatest toxicity towards the 
MCF7 cells out of the methylenedioxy substituted A-ring compounds. IC50 values of 7µM for 
the TCDD induced cells and 10µM for the non TCDD induced cells were observed. No 
toxicity towards the non-tumour MCF10A cell line was seen but an IC50 value of 22µM was 
obtained when DMU 10403 was screened against the CYP1 expressing MDA468 cell line. 
No toxicity was observed from screening DMU 10403 against the MDA231 cells as IC50 
values of 100µM and greater were seen in the TCDD induced and non-TCDD induced cells. 
DMU 10213, the amino-pyrimidine analogue of DMU 10403 showed exciting anti-tumour 
activity with an IC50 values significantly more potent than that of DMU 10403. The toxicity 
of DMU 10403 was 110 times less than that observed from DMU 10213 against the MDA 
468 cell line and over a 100 times less toxic towards the MCF7 cells. DMU 10403 did not 
show toxicity towards the MDA 231 cells whereas DMU 10213 gave IC50 values of 3µM 
each towards the TCDD induced and non-induced cells. DMU 10406, with a 3,5-dimethoxy 
substitution on the B-ring did not show to exhibit interesting toxicities against the tumour cel 











5.1.1.2 4-Methoxy A-Ring Substitution 














































































DMU 10404 (Table 32, entry 1) was synthesised with a 3,4-dimethoxy B-ring but this 
compound did not show any activity of interest towards the MCF10A, MDA 468 and MCF7 
cells as all IC50 values observed were above 100µM. Activity was observed towards the 
MDA 231 cell lines which primarily express CYP1B1 to a greater extent than CYP1A1. IC50 
values of 30µM were recorded for both the TCDD induced and non-induced cells, but this 
result was not toxic enough to warrant further investigation. DMU 10405 (Table 32, entry 2) 
was synthesised with a 2,4-dimethoxy substituted B-ring. This compound showed toxicity 
towards the MDA 468 cell line giving an IC50 value of 10µM whereas no toxicity was 
observed towards the MCF10A cells. IC50 values of 60µM were recorded for the TCDD 
induced and non-induced MCF7 cells, and no toxicity was observed towards the MDA 231 
cell lines. DMU 10208, the amino-pyrimidine derivative of DMU 10405 showed greater 
toxicities across the tumour cell lines in comparison to DMU 10405. DMU 10402, substituted 
with a 3,4,5-trimethoxy A-ring gave an IC50 value of 25µM towards the MDA 468 cell line 
whilst not showing toxicity towards the MCF10A cell line. The non TCDD induced MCF7 
cells gave an IC50 value of 55µM, but the TCDD induced MCF7 cells showed a two-fold 
increase in activity. Results from the MDA 231 cells did not show anything of interest as no 







































5.1.1.3 DMU 10400  
DMU 10400 (Figure 102) was designed with 3,4-dimethoxy substituted A and B. However, 
this compound did not prove to exhibit any type of prodrug or anti-cancer activity as all IC50 







5.2 Summary and Conclusions 
A library of nine morpholino-pyrimidines were synthesised from the same method used to 
yield the amino-pyrimidines in chapter three. The morpholino-pyrimidines were screened 
against a panel of selected tumour cell lines to assess their prodrug properties. DMU 10405 
(Figure 103) showed the most effective toxicity out of the synthesised morpholino-







DMU 10403 (Figure 104) showed the most effective toxicity towards the MCF7 cell lines 

































Overall, the incorporation of the morpholine group at the 2-position of the pyrimidine 
heterocycle did not show toxicities comparable to that obtained from the amino-pyrimidines 
synthesised in chapter three. Therefore it can be said that the morpholine group proves 
unfavourable compared with an amine group at the 2-position of the pyrimidine heterocycle. 
The amino group changes from a primary amine to a secondary amine when comparing the 
amino-pyrimidines and morpholino-pyrimidines. It may be a possibility that the two 
hydrogen atoms of the primary amine participate in hydrogen bonding when present in the 
active site of the CYP1 enzymes, increasing the metabolism and cytotoxicity towards the 
tumour cells. On the other hand, the bulk of the morpholine of the morpholino-pyrimidines 
may be problematic and prevent the compound from fitting correctly into the active site of 

























Synthesis and Biological 










6.0 Synthesis of Dimethylethylenediamino-4,6-Diarylpyrimidines 
The amino-pyrimidines synthesised in chapter two produced compounds with exciting anti-
tumour prodrug activity. In particular DMU 10212 (Figure 105), with a 3,4-methylenedioxy 
substitution on the A-ring and 2,4-dimethoxy substitution on the B-ring showed significant 
cytotoxicity towards the tumour cells. An IC50 value of 0.01µM was observed towards the 
MDA 468 cell line which constitutively expresses CYP1A1 and CYP1B1. Also, IC50 values 








With the aim to improve cytotoxicities of the pyrimidines and to explore the importance of 
the amino group at the 2-position, pyrimidones were synthesised. Significant toxicities were 
also obtained from screening the pyrimidones against the tumour cell lines but the amino 
derivatives proved more favourable with greater tumour toxicities. The 2-position of the 
pyrimidine ring was further investigated by incorporating a morpholine group. However, the 
toxicities towards the CYP1 expressing tumour cell lines of the morpholino-pyrimidines were 
not as potent as that observed from the amino-pyrimidines. The 2-position of the pyrimidine 
was subject to further investigation by the incorporation of dimethylethylenediamine. The 
notion of using the dimethylethylenediamine group was based on the fact that it is not rigid 
and is able to rotate and move whilst attached to the 2-position of the pyrimidine heterocycle. 
This may allow for the dimethylethylenediamine group to explore the CYP1 binding sites and 
orientate itself spatially in order for the dimethylethylenediamino-pyrimidines to gain 
optimum binding within the enzymes. This could occur via electronic interactions of lone 
pairs of electrons of the nitrogen atoms, and through hydrogen interactions with the 












The route used to synthesise the 2-dimethylethylenediamino-4,6-diarylpyrimidines was taken 
from Agarwal et al who prepared various substituted guanidines (Figure 106), by reacting 
their corresponding amines with S-methylisothiourea sulphate to produce guanidinium 
salts.233 The salts were then reacted with chalcones to produce the substituted pyrimidines. 
 
 







The first stage of this process required the synthesis of the dimethylethylenediamino-
guanidine. The procedure was taken from Andrews et al who synthesised 4-
amidinomorpholine hydrochloride by stirring S-methylisothiourea sulphate and morpholine 
in water under reflux for 5 minutes.234 This was followed by the addition of aqueous barium 
chloride and the reaction was stirred under reflux for a further 30 minutes. The mixture was 
then filtered through kieselguhr giving a colourless solution. The water was removed in 
vacuo leaving a white gum, which was recrystallised from ethanol with the addition of 
acetone, allowing the hydrochloride salt to separate out as solid white crystals. The solid was 
subject to further recrystallisation from a mixture of 2-ethoxyethanol and ethyl acetate. 
The above reaction was repeated in order to verify the successful synthesis of the morpholine 
salt, as the commercially available product used in chapter five was also available which 
could be used to compare analysis with the synthesised compound. The synthesis was 
successful but yields were very low of 5%, therefore an investigation into the length of time 





















was obtained when the reaction was allowed to reflux for one hour prior to the addition of the 
aqueous barium chloride solution.  
A problematic factor associated with the low yields can be accounted for by the 
recrystallisation process. The literature method requires dissolving the crude product in 
ethanol followed by the addition of acetone to precipitate out the guanidine hydrochloride. 
The separated guanidine hydrochloride solid is then collected by filtration and subject to a 
second recrystallisation with a mixture of 2-ethoxyethanol and ethyl acetate to yield the final 
purified product. However, it was found that the second recrystallisation process used by 
Andrews et al was not required as the compound was pure after undergoing recrystallisation 
with ethanol and acetone. It was also observed that recrystallising the solid with the 2-
ethoxyethanol and ethyl acetate reduced the yields as the compound did not solidify out 
completely. 
Dimethylethylenediamino-guanidine was then synthesised by a modified literature method of 
Andrews et al by removing the second recrystallisation step using 2-ethoxyethanol and ethyl 
acetate in preparation for the synthesis of the dimethylethylenediamino-4,6-
diarylpyrimidines. Therefore, N,N-dimethylethylenediamine (2 equivalents) was reacted with 
S-methylisothiourea sulphate (1 equivalent) in boiling water for 5 minutes. This was followed 
by the addition of aqueous barium chloride solution (1.5 equivalents, 50% w/v), producing 
BaSO4 precipitate as the side product almost instantaneously. The reaction continued to stir 
under reflux for 1h and was then filtered through kieselguhr giving a colourless filtrate 
solution. The solvent was removed in vacuo leaving a white gum. This was dissolved in 
ethanol with the addition of acetone of the same volume. The mixture was allowed to cool 
and the dimethylethylenediamino-guanidine hydrochloride separated out as white crystals, 






















The mechanism for the synthesis of the dimethylethylenediamino-guanidine proceeds as the 
nucleophilic amine attacks the central carbon of the S-methylisothiourea sulphate, leading to 
the loss of methanethiol (Scheme 10). The positively charged nitrogen becomes neutral as an 
extra proton is abstracted by the negatively charged SMe ion, forming methyl-mercaptan. 
BaSO4 was also produced as a white precipitate by-product, which also aids in the driving 
force for the reaction to proceed. 
The 1H NMR spectra of the dimethylethylenediamino-guanidine synthesised was consistent 
with the expected structure. The two CH2 groups of the dimethylethylenediamino chain were 
observed as triplets between 2.78-3.39 ppm. A singlet corresponding to the 6 methyl protons 
was seen at 2.39 ppm. MS data was consistent with the M+ ion peak observed at 166 m/z. 
The next phase of the synthesis was the reaction between the chalcone and the synthesised 
novel dimethylethylenediamino-guanidine to produce the dimethylethylenediamino-4,6-
diarylpyrimidines. Three chalcones were selected based on the best pyrimidine prodrugs 
 



























synthesised in previous chapters. Dimethylethylenediamino-guanidine (1.5 equivalents) was 
stirred with of sodium hydroxide (4 equivalents) under reflux in ethanol for 0.5h. Chalcone  
(1 equivalent) was then added and the reaction continued to stir under reflux for 6h. The 
product was observed by TLC analysis appearing as a fluorescent blue spot when observed 
under UV-light. The solvent was removed in vacuo and the compound purified by flash 
chromatography using DCM and methanol (8.5:1.5) as eluent. The three 
dimethylethylenediamino-4,6-diarylpyrimidines synthesised produced light brown oils. 
The mechanism for the above reaction begins with the formation of the free guanidine by 
stirring dimethylethylenediamino-guanidine with sodium hydroxide. The free nucleophilic 
guanidine then attacks the carbonyl of the chalcone forming an imine (Scheme 11). 
Intramolecular cyclisation then occurs forming the dihydropyrimidine heterocycle. 






































Three dimethylethylenediamino-4,6-diarylpyrimidines were synthesised with yields ranging 

























































expected structures, with the heterocyclic ring proton at C5 appearing between 7.43-7.60ppm. 
The four methylene protons appeared as two separate triplet peaks between 2.70-3.92ppm, 
each representative of two hydrogens. Figure 109 shows the 1H NMR spectrum and Figure 
110 shows the MS spectrum for DMU 10602. The six methoxy group protons appeared 
between 2.38-2.66ppm. MS data gave (M+H)+ ion peaks of correct masses. Due to the small 
scale of reagents used in the synthesis, hydrogen peroxide was not used in aiding the 
aromatisation of the pyrimidine heterocycle, as air was sufficient to achieve this. To support 
this, a parallel reaction with the synthesis of DMU 10600 was carried out which included the 
addition of hydrogen peroxide resulting in DMU 10600P (Figure 108). However, the addition 
of hydrogen peroxide unexpectedly did not produce the aromatised 
dimethylethylenediamino-4,6-diarylpyrimidine. MS data revealed that DMU 10600P had an 
additional mass of 16 in comparison to DMU 10600. As the only difference between the two 
reactions was the addition of the peroxide, an unwanted possible oxidation could have 
occurred and the extra mass of 16 would account for the incorporation of an oxygen atom in 
the compound at some point. NMR interpretation of DMU 10600P showed only 6 aromatic 
protons present when compared to the 7 aromatic protons present in DMU 10600. It was also 
observed that the heterocyclic proton at C5 was absent in the spectra, indicating that the C5 
position may have undergone oxidation and was bonded to an OH group (Figure 108). 
 








































































































































































6.1 Biological Evaluation of the 2-dimethylethylenediamino-4,6-  
diarylpyrimidines 
The three substituted 2-dimethylethylenediamino-4,6-diarylpyrimidines (Figure 111) were 
synthesised and screened for their cytotoxicities against the MDA 468, MCF7 and MCF10A 
cell lines as described in chapter 2. The substitutions on the A and B-rings were selected from 
the amino-pyrimidines DMU 10212, DMU 10313 and DMU 10200 as these exhibited the 






















Table 33. Cytotoxicities of DMU 10600, DMU 10601 and DMU 10602 







































































DMU 10601 DMU 10602
 





6.1.1 DMU 10601 
DMU 10601 (Figure 113) was synthesised without any functional groups on the A and B-
rings. The design was based on the amino-pyrimidine DMU 10200 (Figure 112) which 
showed exciting anti-tumour activity, especially against the MDA 468 cell line giving an IC50 







Screening DMU 10601 against the MDA 468 cell line gave an IC50 value of 15µM (Table 34, 
entry 2), 75 times less toxic than DMU 10200. Toxicity was also observed towards the 
MCF10A cells. The IC50 values recorded against the MCF7 and MCF7 cells induced with 
TCDD were 15µM and 21µM respectively. Again, the toxicities of the amino-pyrimidine 























6.1.2 DMU 10602 
DMU 10213 (Figure 114), synthesised with a 3,4-methylenedioxy substitution on the A-ring 







DMU 10602 (Figure 115) showed no cytotoxic activity towards the MDA 468 cell line which 
constitutively expresses the CYP1A1 and CYP1B1 enzymes. This was a disappointing result 
as DMU 10213 provided an IC50 value of 0.5µM when screened against the MDA 468 cells 








Screening of DMU 10602 against the MCF7 cell lines gave an IC50 value of 20µM for both 
























6.1.3 DMU 10600 
DMU 10600 was designed based on the amino-pyrimidine DMU 10212 (Figure 116), with a 








When screened against the MDA 468 cell line, DMU 10600 gave an IC50 value of 7µM. 
Slight toxicity was also observed towards the non-tumour MCF10A cells. However, DMU 
10600 was approximately 700 times less toxic towards the MDA 468 cells in comparison to 
DMU 10212 which was also non toxic towards the MCF10A cells. Identical IC50 values of 
10µM were observed when DMU 10600 was screened against the MCF7 cells, for both the 
TCDD induced and non-induced cells. This result was also less toxic than the cytotoxicity of 
DMU 10212 observed against the MCF7 cells.  
 
6.2 Synthesis of 2-methyl-4-(2,4-dimethoxyphenyl)-6-(3,4-     
methylenedioxyphenyl)pyrimidine, DMU 10700 
The synthesised 2-dimethylethylenediamino-4,6-diarylpyrimidines were synthesised to 
explore the 2-position of the pyrimidine ring. This was carried out in the aim to develop 
compounds with improved toxicities than those recorded with the amino-pyrimidines. DMU 
10600 showed the most effective anti-cancer activity from the 2-dimethylethylenediamino-
4,6-diarylpyrimidines synthesised, with an IC50 value of 7µM observed towards the MDA 
468 cell line. However, this result was not as significant as the cytotoxicity observed from the 












MDA 468 cell line and IC50 values of 0.07µM and 0.3µM recorded against the MCF7 and 
MCF7 cells induced with TCDD.  
Subsequently, DMU 10700 (Figure 117) was synthesised with a methyl group on the 2-
position of the pyrimidine ring. This was synthesised to observe the effect of a non-
conjugating electron donating group at the 2-position of the pyrimidine ring towards the 
cytotoxicity of this compound. The methyl group does not have lone pairs of electrons like 






The method used to synthesise DMU 10700 was the same as that used to synthesise the 
pyrimidines in chapter three, replacing guanidine hydrochloride with acetamidine 





Therefore, acetamidine hydrochloride (1.5 equivalents) was stirred with sodium hydroxide (4 
equivalents) in ethanol. The reaction was stirred at reflux for thirty minutes producing the 
free acetamide. DMU 407 (1 equivalent) was added to the mixture and the reaction continued 
to proceed for 6h. This was followed by the addition of hydrogen peroxide (3 equivalents, 
50% w/v) and the reaction was stirred under reflux for a further 1h to aromatise the 
pyrimidine ring. TLC analysis showed the formation of the 2-methylpyrimidine as a 
fluorescent blue spot when viewed under UV light. The solvent was removed in vacuo and 














































The mechanism for the synthesis of DMU 10700 is shown in Scheme 12. Under basic 
conditions the free acetamide reacts with DMU 407 via nucleophilic addition forming an 
imine. Intramolecular cyclisation then follows forming the dihydro-pyrimidine. The peroxide 
oxidises the pyrimidine ring forming the aromatised pyrimidine heterocycle. 
The reaction produced a yield of 10% with the melting point of DMU 10700 being recorded 
between 127-129oC. The 1H NMR spectrum gave a singlet at 2.80ppm for the three methyl 
protons at the 2-position of the pyrimidine ring. Seven aromatic protons, alongside the two 
methylenedioxy protons were also observed. The MS spectrum was correct upon 









































6.2.1 Biological Evaluation of DMU 10700 
DMU 10700 (Figure 119), was screened against the MDA 468, MCF7 and MDA 231 tumour 






Results from the MDA 468 cell line gave an IC50 value of 2.5µM (Figure 120), whilst no 
toxicity was observed towards the non-tumour MCF10A cell line. Unfortunately, no 











The cytotoxicity of DMU 10700 was 250 times less potent than that observed from DMU 
10212, the amino-pyrimidine analogue of DMU 10700 towards the MDA 468 cell line. 
However, the pyrimidone analogue DMU 10312 like DMU 10212 also showed greater 






















































6.3 Synthesis of 4-(2,4-dimethoxyphenyl)-6-(3,4-  
methylenedioxyphenyl)pyrimidine, DMU 10800 
The synthesis of substituted pyrimidines has produced compounds showing valuable toxicity 
against the tumour cell lines screened against, particularly towards the MDA 468 cell line. A 
further compound, DMU 10800 was designed without a functional group at the 2-position of 
the pyrimidine ring to show that the amino substitution at this position is important for the 
cytotoxicities observed from the pyrimidines in this project. The substitutions on the A and 
B-rings were identical to that of DMU 10212.The synthesis of DMU 10800 was parallel to 
that of DMU 10700 (6.2), with the replacement of acetamidine hydrochloride with 





Pale brown crystals with a yield of 10% were obtained for DMU 10800, with a melting point 
recorded between 132-134oC. The 1H NMR spectrum showed eight aromatic protons as 
expected with the structure. The MS spectrum was correct with a 337 (M+1)+ ion peak being 
observed.  
 
6.3.1 Biological Evaluation of DMU 10800 
DMU 10800 (Figure 122) was synthesised to display the importance of the 2-position of the 
pyrimidine ring and its effect on cytotoxicity when substituted with different functional 
groups. The amino group has proved to be the most favourable functional group providing 
significant cytotoxicities when substituted in the 2-position of the pyrimidine ring as shown 































The result from DMU 10800 when screened against the MDA 468 cell line was notably 
cytotoxic, showing an IC50 value of 0.08µM whilst remaining non-toxic towards the non-









The MCF7 cells, induced and non-induced with TCDD gave identical IC50 values of 0.2µM 
respectively (Figure 124). However, toxicity was not observed towards the MDA 231 cell 
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6.4 Summary and Conclusions 
Three dimethylethylenediamino-4,6-diarylpyrimidines were synthesised by methods used by 
Andrews et al and Agarwal et al. These compounds were screened for their prodrug activities 
against a panel of cell lines made up of the non-tumour MCF10A cell line, and the tumour 
MDA 468 and MCF7 cell lines. From the data obtained, it appeared that DMU 10600 (Table 
35, entry 4) was the most effective anti-cancer dimethylethylenediamino-4,6-
diarylpyrimidine synthesised. IC50 values of DMU 10600 included a value of 7µM towards 
the MDA 468 cell line. However, it was concluded that the incorporation of the 
dimethylethylenediamino group did not enhance the cytotoxicity of the pyrimidine 
compounds in comparison to the previously synthesised 2-aminopyrimidines in chapter three.  
DMU 10700 (Table 35, entry 2), an analogue of DMU 10212 was synthesised with a methyl 
group at the 2-position of the pyrimidine heterocycle to investigate the effect of a non-
conjugating electron donating group in contrast to the amino substituted pyrimidine DMU 
10212. Valuable toxicity was observed from this compound against the MDA 468 cell line, 
giving an IC50 value of 2.5µM, greater than that seen from the previously synthesised 
dimethylethylenediamino-4,6-diarylpyrimidineanalogue derivative of DMU 10600. No 
toxicity was recorded towards the non-tumour MCF10A cell line by DMU 10700. However, 
the amino-pyrimidine DMU 10212 (Table 35, entry 3) has shown to still be the most effective 
prodrug synthesised in comparison to its heterocyclic analogues. 
DMU 10800 (Table 35, entry 1), another analogue of DMU 10212 was synthesised without 
any functional group incorporated at the 2-position of the pyrimidine ring. Significant 
cytotoxicity was observed towards the MDA 468 cell line, with an IC50 of 0.08µM being 
observed. The MCF7 and MCF7 cells induced with TCDD gave IC50 values of 0.2µM each. 
These results were more potent than the pyrimidone analogue of DMU 10312 (Table 35, 
entry 5) and are comparable with DMU 10212, but the amino-pyrimidine showed to be more 











































































































































































































































Therefore, the functional group at the 2-position of the pyrimidine ring is important for 
cytotoxicity to occur towards the tumour cell lines whilst remaining non-toxic to non-tumour 
cells. It has been experimentally shown that the primary NH2 functional group integrated into 
the 2-position of the pyrimidine heterocycle is the most favourable for anti-cancer prodrug 
activity to be observed out of the pyrimidines synthesised in this project.  
Further work would entail an investigation to determine and synthesise the metabolites of 













Metabolism Studies on DMU 







7.0 Metabolism Studies on DMU 10212 
The 2-amino-4,6-diarylpyrimidine DMU 10212 (Figure 125) was found to be the most 







An IC50 value of 0.01µM was obtained from screening DMU 10212 against the MDA 468 
cell line whilst no toxicity was seen towards the non-tumour MCF10A cells, suggesting that a 
prodrug anti-cancer mechanism of action occurs. The MCF7 cells induced with TCDD gave 
an IC50 value of 0.3µM and the non-TCDD induced cells gave an IC50 value of 0.07µM. The 
significant cytotoxicity demonstrated by DMU 10212 motivated the further investigation of 
this compound in order to verify that the CYP1 enzymes were actually involved in the 
metabolism of DMU 10212, and to make an identification of the metabolites generated. The 
metabolism experimentations were conducted by Dr. D. Ankrett of the CDDG. 
 
7.1 Inhibition Studies of DMU 10212 
α-naphthoflavone (α-NF) is a well known CYP1A1 and CYP1B1 inhibitor due to its high 
binding affinity towards these enzymes (Figure 126).235, 236 It has been reported that the 
inhibition of the CYP1 enzymes occurs as the α-NF competitively binds to the active site or 
ferric haem of the CYP1 enzymes, preventing other substrates from binding to the CYP1 
enzymes.  Inhibition studies were conducted to demonstrate that DMU 10212 was a genuine 
substrate for the CYP1 enzymes. DMU 10212 was screened against the tumour cell lines 



















The MDA 468 cell line constitutively expresses both the CYP1A1 and CYP1B1 enzymes.216 
Screening of DMU 10212 against the MDA 468 cell line gave a notable IC50 value of 
0.01µM (Figure 127), which was the most cytotoxic result seen towards this cell line in 
comparison to the toxicities observed from the compounds in this project. Importantly, no 










When DMU 10212 was screened against the MDA 468 cells with the addition of the CYP1 
inhibitor α-NF, the previously observed toxicity of 0.01µM was completely eliminated 
(Figure 128). The control MCF10A cells were also screened against DMU 10212 with the 
























































The MCF7 cell line does not constitutively expresses CYP1 enzymes, but within five minutes 
of exposure to TCDD the expression of CYP1A1 is amplified.237 Screening of DMU 10212 
against the MCF7 cells and MCF7 cells induced with TCDD gave encouraging results, with 









DMU 10212 was screened against the MCF7 cells incubated with the CYP1 inhibitor α-NF. 
The results showed that the toxicity observed in Figure 129 was entirely eliminated as 
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The MDA231 cell line expresses very low levels of CYP1 enzymes. Treatment with TCDD 
primarily induces CYP1B1 expression but CYP1A1 is also expressed to a lesser extent. The 
screening of DMU 10212 against the MDA 231 and MDA 231 cells induced with TCDD 
showed reasonable toxicity with IC50 values of 20µM and 30µM being recorded 
correspondingly. The results observed from screening DMU 10212 with the incubation of α-
NF against the MDA 231 cells (Figure 131) did not show any cell death towards this cell line. 
This result is in line with the observed data from the MDA 468 and MCF7 cell lines 



































Figure 130. Cytotoxicity plot of MCF7 and MCF7 cells induced with TCDD treated with DMU 






10212 + α-NF 
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Figure 131. Cytotoxicity plot of MDA 231 and MDA 231 cells induced with TCDD treated 





10212 + α-NF 
IC50 >100µM 
MCF7 + TCD  




7.2 Metabolism Study of DMU 10212 
DMU 10212 was investigated in inhibition studies using the CYP1 inhibitor α-NF, which 
indicated that DMU 10212 was a substrate of the CYP1 enzymes. It was concluded that the 
CYP1 enzymes are responsible for the metabolism of DMU 10212, in turn producing its 
cytotoxic metabolite or metabolites important for the anti-cancer effect of DMU 10212 
observed against the CYP1 expressing tumour cell lines.   
The next stage of this study was to deduce the CYP1 metabolites of DMU 10212 formed. The 
affinity of DMU 10212 towards CYP1A1, CYP1A2 and CYP1B1 was also investigated 
alongside the rate of the metabolism of DMU 10212 by each enzyme. CYP3A4 was also 
explored in this study, as this enzyme is the most abundant in the liver. This would provide 
an insight if possible hepatic toxicity of this drug would occur if administered orally, as the 
liver would be the location of first pass metabolism which is undesired.  
To achieve the above, DMU 10212 was incubated with human recombinant CYP family 
enzymes; CYP1A1 CYP1A2, CYP1B1, CYP3A4 and the non-CYP expressing control 
Supersomes™. The LCMS mobile phase consisted of 33% acetonitrile acidified to pH5 with 
formic acid, 65% aqueous ammonium formate also acidified to pH5 with formic acid and 2% 
propan-2-ol.  A gradient was initiated at time zero.  The run time was 12.5 minutes with an 
additional 3 minute re-equilibration time.  The column compartment temperature was 
maintained at 50ºC.  The flow rate was 0.6mL.min-1.  LCMS analysis was carried out using 
positive mode electrospray ionization, (ESI) Standard-enhanced scan mode was employed 
(scan speed 8100 m/z /sec and scan range 50-450 m/z) and with drying gas 350ºC, flow rate 
of 9L/min-1, nebuliser pressure 40psi, MS/MS and MS3 fragmentation amplitude 3.5V. 
Incubations were carried out at 37ºC using the following final concentrations; PO4 buffer 
(20mM), MgCl2 (0.5mM), NADPH (0.5mM), DMU 10212 (10μM), enzyme 20pmol.mL-1 
and an appropriate volume of water to give a final incubate volume of 250μL.  Control 
incubations were carried out using either non-CYP-expressing insect Supersomes™ or with 
the omission of either DMU 10212, NADPH or the active enzyme.  At zero and 30 minutes, 
100μL of the incubate were removed and added to an equal volume of ice-cold acetonitrile to 
terminate the reaction.  Samples were then centrifuged at 3500rpm for 15 minutes at 4ºC, and 





The results showed that four metabolites (M1, M2, M31/M32 and M4) were produced by each 
of the CYP1A1, CYP1A2 and CYP1B1 enzymes which can be seen from the total ion 
chromatograms (TIC) in Figures 132, 133 and 134.  Encouragingly, no metabolites were 
detected in the CYP3A4 enzyme assay which is a strong indication that liver toxicity from 
DMU 10212 would not be observed if DMU 10212 was administered orally (Figure 135). 
Importantly, the metabolites from the CYP1 assays were not detected in the control assays 
(Figures 136 and 137) as these did not contain CYP1 enzymes, showing no other entity could 




















Figure 132. TIC of DMU 10212 incubated with CYP1A1 and extracted at time 0 and 30 mins 
 
 






1AA-0201.D: TIC +All MS, Smoothed (0.55,1,GA) 1AB-0301.D: TIC +All MS, Smoothed (0.55,1,GA)
61.2
79.1



































































































SIG1000015.D: TIC +All MS, Smoothed (0.53,1,GA) SIG1000016.D: TIC +All MS, Smoothed (0.54,1,GA)
61.2
79.1






























1AE-0601.D: TIC +All MS, Smoothed (0.55,1,GA) 1AF-0701.D: TIC +All MS, Smoothed (0.56,1,GA)
61.2
79.1





















































































































SIG1000018.D: TIC +All MS, Smoothed (0.59,1,GA) SIG1000017.D: TIC +All MS, Smoothed (0.54,1,GA) SIG1000019.D: TIC +All MS, Smoothed (0.55,1,GA)
 
Control 2: without NADPH 
Control 1: without 218 






The rate of metabolism of DMU 10212 by the CYP1A1, CYP1B1 and CYP1A2 enzymes 
was also measured. The rate of disappearance of DMU 10212 was measured over 15 minutes 
at 3 minute intervals. The calculated rates show that DMU 10212 was preferentially 
metabolised by CYP1A1, followed by CYP1A2 and then CYP1B1.   
The functions of the CYP family of enzymes are well known (Introduction, section 1.8). 
Reactions catalysed by CYP enzymes include carbon hydroxylation, heteroatom oxygenation 
and dealkylation. With the molecular weights known for each metabolite (Table 36), 
proposed structures were determined (Scheme 13). Each metabolite also produced its own 
specific retention time. This can be used as the proposed metabolites can be synthesised and 
co-eluted with the enzymatically produced metabolites which would give the same RT if they 











































7.2.1 Synthesis of Metabolites M2 and M32 
Proposed metabolite structures were synthesised to act as authentic standards for co-elution 
studies, which would allow for the confirmation of metabolite identity. The metabolites 
chosen for synthesis were M2 and M32, as these were the first structures identified as possible 
metabolites.  
The M2 metabolite, with a 3,4-dihydroxy substitution on the A-ring and 2,4-dimethoxy 


































































The method used to synthesise M2 was taken from Castro et al, who modified 
podophyllotoxin by demethylating the methylenedioxy group substituted on the A-ring using 
boron-trichloride.238 This resulted in the formation of a dihydroxy analogue of 









For the synthesis of M2, a solution of DMU 10212 and boron trichloride in dichloromethane 
was stirred at -5oC under nitrogen for 24 h. The reaction was quenched with water and 
extracted with ethyl acetate. The combined organic extracts were dried over MgSO4 and the 
solvent was removed in vacuo. The catechol was purified by flash chromatography using 
dichloromethane and methanol (9:1) as eluent.  
The purified catechol was collected as a brown oil with a yield of 17%. The 1H NMR 
spectrum of the compound synthesised was consistent with the expected structure, with the 

































6.03ppm for the methylenedioxy protons seen for DMU 10212 was no longer present, 
confirming the successful dealkylation of the methylenedioxy group. The MS spectrum gave 
an [M+H]+ ion peak of 340 which was correct for the catechol structure. 







The first step required the synthesis of the chalcone analogue, but due to the presence of the 
4-hydroxy group this could not be achieved immediately using the same Claisen-Schmidt 
reaction used to afford the previously synthesised chalcones in chapter two. It has been 
shown that hydroxy substituted chalcones require their hydroxy substituted precursors to be 
treated with protecting groups, or reactions rates are very slow producing low yields. This is 
due to the fact that the base involved in the Claisen-Schmidt reaction reacts with the hydroxy 
precursor delocalising the anion, slowing down the reactive steps required for the formation 
of the chalcone (Figure 141).239 
 




Therefore, the 4-hydroxy-2-methoxybenzaldehyde chalcone precursor was treated with 3, 4-
dihydro-2H-pyran as the OH protecting agent (Scheme 14).240, 197 The resulting 2-(methoxy-
4-tetrahydropyran-2-yloxy)-benzaldehyde was then reacted with 3,4-
methylenedioxyacetophenone to yield the protected chalcone via the Claisen-Schmidt 


























protected amino-pyrimidine. In order to gain the dihydroxy-pyrimidine, the tetrahydropyran 



















































7.2.1.1 Synthesis of 2-(methoxy-4-tetrahydropyran-2-yloxy)-benzaldehyde, 
DMU 10500       
A mixture of 4-hydroxy-2-methoxybenzaldehyde (1 equivalent) and pyridinium ρ-toluene 
sulfonate (0.024 equivalents, catalytic quantity) in dichloromethane was stirred at room 
temperature for 0.5 h. This was followed by the drop-wise addition of 3,4-dihydro-2H-pyran 
(3 equivalents) in dichloromethane and the reaction was stirred for a further 24 h. The 
reaction was quenched with water and the organic mixture extracted with dichloromethane. 
The organic extracts were dried over MgSO4 and the solvent was removed in vacuo. The 
protected benzaldehyde was purified by flash chromatography using dichloromethane – 















































The mechanism for the protection of the benzaldehyde is shown in (Scheme 15). The pyran 
protecting group requires activating which is achieved by the presence of the pyridinium ρ-
toluene sulfonate. This protonates the protecting tetrahydropyran group, forming a resonance 
stabilised carbocation intermediate. The nucleophilic alcohol of the benzaldehyde attacks the 
carbocation, which undergoes deprotonation to form the 2-(methoxy-4-tetrahydropyran-2-
yloxy)benzaldehyde. This produced a yellow oil with a yield of 49%. The 1H NMR spectrum 
showed the correct amount of protons required and MS analysis gave an (M+1)+ ion peak of 
237.   
 
7.2.1.2 Synthesis of (E)-1-(3,4-methylenedioxyphenyl)-3-(2-methoxy-4-           
tetrahydropyran-2-yloxyphenyl)-2-propen-1-one, DMU 10501       
The 2-methoxy-4-tetrahydropyran-2-yloxybenzaldehyde was stirred with 3,4-
methylenedioxyacetophenone and sodium hydroxide (4 equivalents) in methanol and stirred 
at room temperature 24h. The reaction was then quenched with water and the organic mixture 
was extracted with dichloromethane. The combined organic extracts were dried over MgSO4 
and the solvent was removed in vacuo. Flash chromatography was used to purify the 
protected chalcone, using ethyl acetate – hexane as eluent (5:5). The mechanism for this 







The protected chalcone (Figure 142) produced a yellow oil with a yield of 77%. The 1H NMR 
spectrum showed the correct number of protons required and MS analysis gave an ion mass 














7.2.1.3 Synthesis of 2-amino-4-(3,4-methylenedioxyphenyl)-6-(2-methoxy-4-
tetrahydropyran-2-yloxyphenyl)pyrimidine, DMU 10502 
The protected chalcone was stirred under reflux with guanidine hydrochloride (1.5 
equivalents) and sodium hydroxide (4 equivalents, 50% w/v) in ethanol for 24h. TLC 
analysis showed the formation of a new product spot, blue when viewed under UV light 
representing the 2-amino-4-(3,4-methylenedioxyphenyl)-6-(2-methoxy-4-tetrahydropyran-2-
yloxyphenyl)pyrimidine. The reaction was quenched with water and the organic mixture 
extracted with dichloromethane. The organic extracts were combined and dried over MgSO4. 
The solvent was removed in vacuo and the crude mixture was purified by flash 
chromatography using ethyl acetate − hexane (4:6) as eluent. A yield of 3% was obtained 
with the compound produced as a yellow oil. The appropriate protons were observed in the 
1H NMR spectrum and MS analysis gave the (M+1)+ ion mass of 422.    
The reaction followed the same mechanism as the synthesis to yield the amino-pyrimidines in 
chapter three, however, a yield of 3% was achieved for the protected pyrimidine (Figure 
143).  This was surprisingly low as a yield of 31% was achieved for DMU 10212. The cause 
for the low yield could be accredited to the additional protecting group involved in the 









7.2.1.4 Synthesis of 2-amino-4-(3,4-methylenedioxyphenyl)-6-(2-methoxy-4-
hydroxyphenyl)pyrimidine, DMU 10503     
The 2-amino-4-(3,4-methylenedioxyphenyl)-6-(2-methoxy-4-tetrahydropyran-2-














were stirred in methanol with at room temperature for 24h (Scheme 16). The solvent was 
removed in vacuo and the crude product was recrystallised from ethanol. The reaction gave a 
yield of 36% (5mg) which gave only enough compound to obtain a MS spectrum. The 
molecular weight observed from the MS spectrum gave an ion mass of 338 which 
corresponded to the [M+H]+ ion. However, this reaction was not repeated due to time 
restraints but warrants further investigation.  
The cyclisation step to form the pyrimidine heterocycle appeared to produce the lowest yield 
from the steps involved in the synthesis of DMU 10503. The addition of the protecting group 
may have decreased the reactivity of the carbonyl group of the chalcone, reducing the ability 
of the nucleophilic guanidine to form the imine. On the other hand, the intramolecular 
cyclisation step may have been hindered preventing the heterocycle from forming. These are 
concepts that can be investigated, alongside other protecting groups available which would be 








































7.2.2 LCMS Analysis of M2 
The proposed metabolites, M2 and M32 were synthesised to verify that they were authentic 
metabolites of DMU 10212. The synthetic M2 metabolite was analysed by LCMS and the 
results were compared to the data obtained from the enzymatically produced M2 metabolite. 
M32 could not be verified as the synthesis did not produce enough product for LCMS 
analysis to be conducted.  
The retention times (RT) and mass spectrum of the enzymatically produced and synthetically 
produced M2 were identical.  The TIC showed that the RT for the synthetically produced M2 









MS/MS analysis was conducted on the synthetically and enzymatically produced M2. This 
process further ionises the 340 M2 ion found which fragments to give distinctive molecules 
of M2. Identical fragmentation patterns were observed which verifies that both the 
enzymatically and synthetically produced M2 molecules were identical (Figures 145 and 
146). Fragments included masses of 135.1, 282.1 and 296.0.  
MS3 experimentation were conducted on the MS/MS analyte, which further ionises the 
fragments producing characteristic splitting patterns of the MS/MS ions. The data of the 
enzymatically produced and synthetic M2 compounds both showed the presence of fragment 
m/z 308 (Figures 147 and 148).   
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The next step was to confirm the synthetic M2 metabolite was indeed identical to the 
enzymatically produced M2 by co-elution. The sample produced from incubating DMU 
10212 with CYP1A1 was spiked with a sample of the synthetically produced M2. The LCMS 
analysis showed that the M2 peaks were identical, which can be seen from Figure 149. The 
red peaks show the CYP1A1 sample without the co-elution study. The grey peaks show the 
CYP1A1 enzyme sample co-eluted with the synthetically produced M2 metabolite, and it can 









The above result, alongside the data from the MS analysis, confirms that M2 is a genuine 
metabolite of DMU 10212 produced via CYP1A1, CYP1B1 and CYP1A2 metabolism. 
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1AB-0301.D: TIC +All MS, Smoothed (0.55,1,GA) SIG1000021.D: TIC +All MS
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7.2.3 Cytotoxicity of M2 
The confirmation of M2 as a CYP1 metabolite of DMU 10212 prompted the cytotoxicity of 
this compound to be determined. This was conducted to corroborate that M2 is in fact toxic 
and contributes towards the cytotoxicity observed from DMU 10212 towards the tumour cell 
lines.  
The results observed from screening M2 against the MDA 468 cell line gave an IC50 value of 
0.6µM (Figure 150). The IC50 values recorded from the MCF7 and MCF7 cells induced with 










As can be seen from Figure 138, no toxicity was observed towards the non-tumour MCF10A 
cells. A primary toxic metabolite would be expected to show toxicity towards the MCF10A 
cells as well as the tumour cells, but M2 only shows toxicity against the tumour cells. This 
may be explicable due to the fact that the primary metabolite M2 is non-toxic, but then 
undergoes further CYP1 metabolism forming a secondary toxic metabolite which exhibits the 
cytotoxicity observed towards the MDA 468 and MCF7 cells. M1 or M12 (Scheme 11) may 
be possible structures for the secondary metabolites formed. However, M1 and M12 would 
require synthesis to verify which metabolite is formed by CYP1 DMU 10212 metabolism. 







































the predicted metabolite M1 or M12 would require screening against the tumour and non-
tumour cell lines to establish whether it possesses cytotoxic capabilities. 
 
7.3 Summary and Conclusions 
DMU 10212 was investigated to determine whether the CYP1 family of enzymes were 
actually involved in the metabolism and cytotoxic effect of this compound, and to establish 
that DMU 10212 exhibits its anti-cancer ability via a prodrug mechanism.  
DMU 10212 was screened against the MDA 468, MCF7, MDA 231 and MCF10A cell lines 
with the included incubation of α-NF, a known CYP1 inhibitor. The results from the assays 
showed that α-NF completely eliminated the cytotoxic effect of DMU 10212. This strongly 
indicated that DMU 10212 is a substrate of the CYP1 family of enzymes. 
Metabolism studies to determine and identify the metabolites of DMU 10212 produced by 
CYP1A1, CYP1B1 and CYP1A2 were conducted using LCMS techniques. Six metabolites 
were detected and it was shown that CYP1A1, CYP1A2 AND CYP1B1 produced the same 
six metabolites. The structures of the metabolites were proposed from the molecular masses 
and retention times observed. It was also observed that the affinity of DMU was preferential 
towards the CYP1A1 enzyme, followed by CYP1A2 and CYP1B1.  
The proposed metabolites M2 and M32 were synthesised to verify their authenticity as DMU 
10212 metabolites through LCMS experimentations. It was successfully concluded that M2 
was a genuine metabolite of DMU 10212 produced through CYP1 metabolism, with a 
retention time of 3.8 mins. Co-elution of the synthetic M2 with the enzymatically produced 
M2 showed an identical match of the metabolite peak, confirming that they are equal. 
Screening of M2 against the MDA 468 and MCF7 tumour cells showed toxicities comparable 
to that observed from DMU 10212. However, as no toxicity was observed towards the non-
tumour MCF10A cells. It has been suggested that M2 is metabolised further by CYP1 
enzymes to produce a toxic secondary metabolite which exhibits the toxicity observed from 
screening M2 against the tumour cell lines. In order to confirm this theory, the suggested 
secondary toxic M1 and M12 metabolites would require investigation in the same techniques 












8.0 Conclusion and Future Direction 
Several groups of chemotherapeutic agents are currently used to treat cancer. Examples 
include alkylating agents, platinum containing compounds and antimetabolites. However, 
undesirable side effects are a major problem associated with chemotherapy due to the 
inability of the drugs to differentiate between tumour cells and normal cells. This narrow 
therapeutic index leads to patients experiencing debilitating problems such as nausea, 
alopecia, heart failure and the formation of secondary tumours to name a few.  
The cytochrome P450 is a superfamily of enzymes which are vital in the metabolism of 
endogenous and exogenous compounds. Importantly, the over-expression of CYP’s, 
including CYP1A1 and CYP1B1 have been detected in tumour cells whilst undetected or 
present at very low levels in their corresponding normal tissue. The over-expressed CYP1 
enzymes presented a legitimate target for anti-cancer prodrugs, which could be designed to 
undergo specific metabolism by over-expressed CYP1 enzymes to their cytotoxic entity 
whilst remaining non-toxic to normal cells. 
Chalcones have been shown to function as anti-tumour prodrugs which are selectively 
activated by CYP1 enzymes over-expressed in breast tumour cell lines. DMU 135 
synthesised by the CDDG was identified as a lead chalcone which gave an IC50 value of 
0.09µM when screened against the MDA 468 cell line and IC50 values of 0.2µM and 0.03µM 
against the MCF7 and MCF7 cells induced with TCDD. 
However, a problematic factor of the chalcones is their susceptibility to undergo 
photoisomerisation reactions, converting the more potent trans isomer to the less effective cis 
isomer. To overcome this problem, heterocyclic ring systems were incorporated across the 
α,β-unsaturated moiety of the chalcones locking the trans isomer in a rigid structure, 
preventing photoisomerisation occurring.   
The synthesised compounds were screened in vitro using the standard MTT assay against a 
panel of breast tumour cell lines characterised for their CYP1 expression. The panel consisted 
of the MDA 468 cell line which constitutively expresses CYP1A1 and CYP1B1, the MCF7 
cell line which expresses low levels of CYP1 enzymes, the MCF7 cells treated with TCDD 
which induces increased CYP1A1 expression, the MDA 231 breast tumour cell line which 
expresses low levels of CYP1 enzymes and TCDD treated MDA 231 cells which induces 
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increased CYP1 expression. The non-tumour MCF10A cell line which has no basal CYP1 
expression was included as the control cell line. 
A library of eighteen 3,5-diarylpyrazoles were synthesised starting from chalcones in good 
yields. Epoxychalcone intermediates were treated with hydrazine to form the pyrazole 
heterocycles. DMU 10107 (Figure 151), substituted with a 3,4-methylenedioxy A-ring and a 
2,3,4-trimethoxy substitution on the B-ring showed the greatest toxicity towards the MDA 
468 cell line with an IC50 value of 8µM, whilst proving non-toxic to the non-tumour 
MCF10A cells.  
 
        
 
 
DMU 10104 (Figure 152), with a 3,4-methylenedioxy substitution on the A-ring and a 3,4,5-
trimethoxy substitution on the B-ring gave IC50 values of 8µM and 5µM towards the MCF7 
and MCF7 cells induced with TCDD. This was the most potent result observed towards the 






The toxicities observed from the pyrazoles were not as potent as those recorded from their 
corresponding chalcone derivatives. Therefore, six membered heterocycles were investigated 
by incorporating a pyrimidine ring across the α,β-unsaturated moiety of the chalcones. A 
library of fifteen 2-amino-4,6-diarylpyrimidines were synthesised from the reaction of 
chalcones with guanidine hydrochloride. The cytotoxicity data from screening the 
aminopyrimidines showed significant cytotoxicities across the tumour cell lines. DMU 10212 
(Figure 142, 1), with a 3,4-methylendioxy substitution on the A-ring and 2,4-dimethoxy 























(Figure 153). IC50 values of 0.07µM and 0.3µM were recorded against the MCF7 and MCF7 















DMU 10213 (Figure 154, 2), with a 3,4-methylenedioxy substitution on the A-ring and 2-
methoxy substitution on the B-ring gave an IC50 value of 0.2µM towards the MDA 468 cell 
line and IC50 values of 0.06µM and 0.05µM against the MCF7 and MCF7 cells induced with 
TCDD. Equal IC50 values of 1µM were also observed towards the MDA 231 and MDA 231 
cells induced with TCDD. With a 4-methoxy substitution on the A-ring and 2,4-dimethoxy 
substitution on the B-ring, DMU 10208 (Figure 155, 1) gave an IC50 value of 0.2µM against 
the MDA 468 cells and IC50 values of 0.2µM and 0.05µM towards the MCF7 and MCF7 





























































DMU 10200 (Figure 155, 2), with no substitutions on either the A or B-rings gave an IC50 
value of 0.2µM towards the MDA 468 cell line and IC50 values of 7µM and 3µM against the 
MCF7 and MCF7 cells induced with TCDD. It was concluded that the incorporation of the 
pyrimidine ring into the chalcones showed greater toxicities towards the tumour cell lines in 
contrast to the chalcones. It was also observed that increasing the heterocycle from a 5-
membered pyrazole to a 6-membered amino-pyrimidine ring significantly improved the 
tumour toxicities of the compounds.   
The 2-amino-4,6-diarylpyrimidines were converted to 4,6-diarylpyrimidones via a one step 
diazotisation reaction. The rationale for the conversion was to investigate the importance of 
the amino group in the 2-position of the pyrimidine ring for the cytotoxicity observed from 
the aminopyrimidines. Also, the carbonyl functional group was evaluated for its tumour 
toxicity when incorporated in the 2-position of the pyrimidine ring. A library of fifteen 4,6-
diarylpyrimidones were synthesised in yields of up to 85%. In general, significant 
cytotoxicity from the pyrimidones was recorded when screened against the tumour cell lines. 
DMU 10313 (Figure 156, 1), with a 3,4-methylenedioxy substitution on the A-ring and 2-
methoxy substitution on the B-ring gave an IC50 value of 0.07µM towards the MDA 468 
cells. IC50 values of 1.8µM and 0.5µM were recorded against the MCF7 and MCF7 cells 
induced with TCDD. DMU 10312 (Figure 156, 2) was synthesised with a 3,4-
methylenedioxy substitution on the A-ring and 2,4-dimethoxy substitution on the B-ring. This 
compound showed an IC50 value of 1.5µM towards the MDA 468 cells. Tumour toxicities 
were also observed towards the MDA 468 cell line from DMU 10311 (Figure 156, 3) and 


























From the promising cytotoxicity results observed from the 2-aminopyrimidines and 
pyrimidones, the 2-position of the pyrimidine ring was explored by synthesising 2-
morpholinopyrimidines. Chalcones were reacted with morpholinoformamidine hydrobromide 
producing the 2-morpholinopyrimidines, from which DMU 10403 and DMU 10405 (Figure 
157) showed to be the most potent anti-cancer compounds. DMU 10403 showed an IC50 
value of 7µM towards the MCF7 cells induced with TCDD and 10µM towards the non-









However, the morpholine group did show greater tumour activity in contrast to the 2-









































morpholine group preventing the compound from fitting correctly into the active site of 
CYP1 enzymes.  
The investigation of the 2-position was continued with the synthesis of 2-
dimethylaminoethylamino-4,6-diarylpyrimidines. N,N-dimethylaminoethylguanidine 
hydrochloride was synthesised by reacting S-methylisothiourea with N,N-
dimethylethylenediamine. The guanidinium salt was reacted with the chalcone derivatives of 
the 2-aminopyrimidines DMU 10200, DMU 10212 and DMU 10213, as these compounds 
showed the most effective anti-tumour activity from the compounds synthesised. DMU 
10600, DMU 10601 and DMU 10602 were synthesised, from which DMU 10600 (Figure 
158) based on DMU 10212 showed the most cytotoxicity. Included was an IC50 value of 7µM 
against the MDA 468 cell line.   








Two final pyrimidines, DMU 10700 (Figure 159) and DMU 10800 (Figure 148) were 
synthesised based on the A and B-ring substitutions of the 2-aminopyrimidine DMU 10212. 
The 2-position of the pyrimidine ring of DMU 10700 was substituted with a methyl group, 
and this compound showed effective toxicity towards the MDA 468 cell line with an IC50 



























DMU 10800 (Figure 160) was synthesised with a proton at the 2-position of the pyrimidine 
ring. Significant tumour toxicities were recorded for this compound, with an IC50 value of 
0.08µM seen against the MDA 468 cells, and identical IC50 values of 0.2µM were observed 






Significant cytotoxicity data was observed from screening pyrimidine compounds 
synthesised in this project. The amino-pyrimidine DMU 10212 was selected as the lead 
compound due to its overall cytotoxicity towards the tumour cell lines. DMU 10212 was 
investigated further to prove it was a CYP1 enzyme substrate by conducting inhibition 
studies. DMU 10212 was screened using the MTT assay against the MDA 468, MCF7 and 
MDA 231 cells with the inclusion of the known CYP1 inhibitor, α-naphthoflavone (α-NF). 
The results obtained showed the complete elimination of the toxicity of DMU 10212 in 
contrast to screening DMU 10212 without α-NF (Figure 162), supporting the fact that DMU 
10212 is a genuine CYP1 enzyme substrate. This can be seen from Figure 161 which 
illustrates DMU 10212 screened against the MDA 468 cell line with the inclusion of α-NF, 


























































The inhibition studies prompted the investigation of identifying and determining the 
metabolites formed once DMU 10212 underwent metabolism by the CYP1 enzymes. DMU 
10212 was incubated with isolated CYP1 isoforms including CYP1A1, CYP1B1 and 
CYP1A2. Four metabolites were formed by each isoforms, which were identified by their 
unique retention times (RT) and molecular masses (MW) observed via LCMS analysis. It was 
also concluded that the metabolism of DMU 10212 by the CYP1 enzymes occurred at 
different rates, with CYP1A1>CYP1A2>CYP1B1. The functions of CYP1 enzymes, 
including oxidative and dealkylation reactions are known, therefore the structures of the 























































From the metabolites predicted in Scheme 17, M2 was selected for synthesis to determine 
that the proposed structure was a genuine metabolite produced from the metabolism of DMU 
10212 by CYP1 enzymes. 
Therefore, M2 was synthesised by treating DMU 10212 with boron trichloride. M2 was 
analysed via LCMS which showed that the synthetically produced M2 showed an identical 
RT and MW to the enzymatically produced M2 metabolite. The next stage involved co-
eluting the synthesised M2 compound with a sample of DMU 10212 metabolised by 
CYP1A1. As expected, the compounds were identical as the M2 peak of the CYP1A1 sample 
co-eluted with the synthesised M2 was amplified shown by the grey plot of the total ion 
chromatogram (TIC) in Figure 163. This study confirmed that the predicted M2 metabolite 




































































M2 was screened using the MTT assay to determine its cytotoxicity. An IC50 value of 0.6µM 
was observed towards the MDA 468 cells whilst no toxicity was observed towards the non-
tumour MCF10A cells (Figure 164). IC50 values of 0.6µM and 1µM were observed towards 
the MCF7 and MCF7 cells induced with TCDD. As no toxicity was observed towards the 
MCF10A cells, it can be suggested that M2 undergoes further metabolism to exhibit its toxic 










Therefore, through the inhibition and LCMS studies conducted, DMU 10212 was confirmed 
as a CYP1 activated anti-cancer prodrug. The 2-position of the pyrimidine ring proved 
pivotal in the cytotoxicity observed from the synthesised pyrimidine analogues. The primary 
 
Figure 163. TIC of the CYP1A1 produced metabolites of DMU 10212 (red plot) and the co-elution 














































amine derivatives showed the greatest toxicities than that observed from the other pyrimidine 
compounds.   
The future direction of work would require the synthesis of the remaining predicted 
metabolites in Scheme 15, which would also be evaluated through LCMS to conclude if they 
are CYP1 metabolites of DMU 10212. Once the metabolites were identified, they would 
require screening to assess their cytotoxicities. Another parameter to investigate would be the 
mechanism in which DMU 10212 and its metabolites exert their cytotoxic effect towards the 
tumour cells.  
This thesis has demonstrated that the over-expressed CYP1 enzymes in tumour cells are 

















9.1 Materials and Apparatus 
Chemicals were used as received from Sigma-Aldrich Chemical Company (Dorset, UK), Alfa Aesar 
(Lancashire, UK) or Fisher Scientific (Loughborough, UK). 
 The 1H and 13C-NMR spectra were recorded on a 400MHz super-conducting Bruker Spectrometer at 
30°C. TMS was used as an internal standard.  
Infra-red spectra were recorded on a Perkin-Elmer 298 Spectrophotometer as potassium bromide 
disks for solid samples and liquids as thin films using NaCl plates.  
Mass spectra were recorded on a Micromass Quattro II Low Resolution Triple Quadruple Mass 
Spectrometer (EPSRC National Mass Spectrometry Service Centre, Swansea UK).  
Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus.  
Thin layer chromatography was performed on Merck Aluminium Sheet- Silica Gel 60f254 coated 
plates. The TLC plates were visualised under Multiband UVGL-58 UV-254/366nm UV light and 
stained with either 2,4-dinitrophenylhydrazine, iodine absorbed on sand or phosphomolybdic acid. 
Flash Column Chromatography was conducted using silica gel (Fluka Silica 60; standard 30-45µ fine 





9.2 General Procedure for the Synthesis of Chalcones 
To a stirring mixture of the acetophenone (33mmol) and benzaldehyde (33mmol) in methanol 
(80 ml), aqueous sodium hydroxide solution (50 % w/v, 26 cm3, 0.33 mol) was added. The 
reaction was monitored by TLC and upon reaching completion was quenched with water (80 
ml) and the crude product extracted with dichloromethane (3 x 60 ml). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo. The crude product was 








Yellow crystals (8.00g, 74%), mp 111-113oC; H (CDCl3) 3.90 (12H, s, 4 x OCH3), 6.8-6.9 
(2H, m, Ar-H), 7.1 (1H, s, Ar-H), 7.18 (1H, d, Ar-H), 7.35 (1H, d, J=15.0Hz, C=C-H), 7.57 
(1H, s, Ar-H), 7.63 (1H, d, Ar-H), 7.71 (1H, d, J=15.0Hz, C=C-H); C (CDCl3) 56.0, 56.1, 
76.7, 77.0, 77.2, 77.3, 110.0, 110.4, 111.0, 111.2, 120.0, 123.0, 128.1, 131.6, 144.1, 149.3, 
151.3, 153.2, 188.7; m/z [MALDI]+ 329 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O). 
 













Yellow crystals (8.20g, 75%), mp 133-135oC; H (CDCl3) 3.90 (3H, s, OCH3), 3.95 (3H, s, 
OCH3), 3.98 (6H, s, 2 x OCH3), 6.88 (2H, s, Ar-H), 7.04 (2H, d, Ar-H), 7.45 (1H, d, 
J=15.0Hz, C=C-H), 7.74 (1H, d, J=15.0Hz, C=C-H), 8.05 (2H, d, Ar-H); C (CDCl3) 55.5, 
56.2, 61.0, 105.5, 113.8, 121.1, 130.6, 130.8, 131.1, 140.2, 144.1, 153.5, 163.4, 188.7; m/z 
[FAB]+ 313 ([M+H]+, 100%); max (KBr) /cm-1 1654 (C=O). 
 




Yellow crystals (5.94g, 68%), mp 107-109oC; H (CDCl3) 3.85 (3H, s, OCH3), 3.95 (3H, s, 
OCH3), 6.92-7.03 (4H, m, Ar-H), 7.44 (1H, d, J=15.0Hz, C=C-H), 7.61 (2H, Ar-H), 7.80 
(1H, d, J=15.0Hz, C=C-H), 8.05 (2H, d, Ar-H); C (CDCl3) 55.4, 55.5, 113.8, 114.4, 119.5, 
127.8, 130.1, 130.7, 131.3, 143.8, 161.5, 163.3, 188.8; m/z [MALDI]+ 269 ([M+H]+, 100%); 











Yellow crystals (7.34g, 65%), mp 133-135oC; H (CDCl3) 3.95 (9H, s, 3 x OCH3), 6.04 (2H, 
s, OCH2O), 6.86 (1H, d, Ar-H), 7.13 (1H, d, Ar-H), 7.20 (1H, s, Ar-H), 7.28 (2H, s, Ar-H), 
7.34 (1H, d, J=15.0Hz, C=C-H), 7.76 (1H, d, J=15.0Hz, C=C-H); C (CDCl3) 56.4, 61.0, 
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101.7, 105.9, 106.6, 108.7, 119.7, 125.3, 129.3, 133.7, 142.3, 144.6, 148.4, 149.9, 153.1, 








Yellow crystals (7.13g, 69%), mp 132-134oC; H (CDCl3) 6.05 (2H, s, CH2O2), 6.10 (2H, s, 
OCH2O), 6.87 (1H, d, Ar-H), 6.91 (1H, d, Ar-H), 7.14 (1H, d, Ar-H), 7.18 (1H, s, Ar-H), 
7.35 (1H, d, J=15.0Hz, C=C-H), 7.54 (1H, s, Ar-H), 7.65 (1H, d, Ar-H), 7.75 (1H, d, 








Yellow crystals (6.73g, 68%), mp 137-139oC; H (CDCl3) 4.00 (6H, s, 2 x OCH3), 6.05 (2H, 
s, OCH2O), 6.86 (1H, d, Ar-H), 6.94 (1H, d, Ar-H), 7.15 (1H, d, Ar-H), 7.19 (1H, s, Ar-H), 
7.41 (1H, d, J=15.0Hz, C=C-H), 7.62 (1H, s, Ar-H), 7.67 (1H, dd, Ar-H), 7.76 (1H, d, 
J=15.0Hz, C=C-H); C (CDCl3) 56.0, 56.1, 101.6, 106.6, 108.6, 110.0, 110.7, 119.6, 122.9, 
125.1, 129.5, 131.4, 143.8, 148.3, 149.2, 149.7, 153.1, 188.3; m/z [MALDI]+ 313 ([M+H]+, 












Yellow crystals (6.11g, 65%), mp 101-103oC; H (CDCl3) 3.90-3.98 (9H, m, 3 x OCH3), 6.02 
(2H, s, OCH2O), 6.76 (1H, d, Ar-H), 6.83 (1H, d, Ar-H), 7.1 (1H, d, Ar-H), 7.16 (1H, s, Ar-
H), 7.35 (1H, d, J=15.8Hz, C=C-H), 7.48 (1H, d, Ar-H), 7.62 (1H, d, J=15.8Hz, C=C-H); C 
(CDCl3) 56.1, 61.1, 62.1, 101.6, 106.7, 107.3, 108.6, 124.7, 125.0, 125.8, 126.9, 129.6, 142.1, 
143.0, 148.4, 149.7, 153.7, 156.9, 190.8; m/z [MALDI]+ 343 ([M+H]+, 100%); max (KBr) 











Yellow crystals (7.66g, 88%), mp 121-123oC; H (CDCl3) 3.86 (3H, s, 3 x OCH3), 3.90 (3H, 
s, 3 x OCH3), 6.00 (2H, s, OCH2O), 6.49 (1H, s, Ar-H), 6.55 (1H, dd, Ar-H), 6.81 (1H, d, Ar-
H), 7.07 (1H, dd, Ar-H), 7.11 (1H, s, Ar-H), 7.35 (1H, d, J=16.0Hz, C=C-H), 7.59 (1H, d, 
J=16.0Hz, C=C-H), 7.73 (1H, d, Ar-H); C (CDCl3) 55.6, 55.6, 98.7, 105.2, 106.6, 108.6, 
121.2, 122.4, 124.9, 125.4, 129.9, 132.8, 142.0, 148.3, 149.4, 160.3, 164.1, 190.4; m/z 











Yellow crystals (8.53g, 83%), mp 111-113oC; H (CDCl3) 3.83 (3H, s, 3 x OCH3), 3.88 (3H, 
s, 3 x OCH3), 6.03 (2H, s, OCH2O), 6.85 (1H, d, Ar-H), 6.97 (1H, d, Ar-H), 7.03 (1H, d, Ar-
H), 7.08 (1H, d, Ar-H), 7.14 (1H, s, Ar-H), 7.19 (1H, s, Ar-H), 7.30 (1H, d, J=16.0Hz, C=C-
H), 7.61 (1H, d, J=16.0Hz, C=C-H); C (CDCl3) 55.8, 56.5, 101.6, 106.6, 108.6, 113.8, 114.4, 
119.0, 125.1, 128.1, 128.7, 129.6, 129.8, 143.3, 148.7, 152.5, 153.6, 192.4; m/z [MALDI]+ 








Yellow oil (8.99g, 92%), H (CDCl3) 3.77 (6H, s, 2 x OCH3), 3.82 (3H, s, OCH3), 3.84 (3H, 
s, OCH3), 6.85 (1H, d, Ar-H), 6.85-6.94 (2H, m, Ar-H), 7.01 (1H, d, Ar-H), 7.14 (1H, d, Ar-
H), 7.19 (1H, d, Ar-H), 7.46 (1H, d, J=17.6Hz, C=C-H), 7.99 (1H, d, J=17.6Hz, C=C-H); C 
(CDCl3) 55.7, 55.8, 56.0, 57.2, 112.4, 113.4, 114.5, 117.0, 118.9, 119.8, 124.7, 127.6, 129.9, 
138.6, 152.5, 153.2, 153.5, 153.6, 199.8; m/z [MALDI]+ 269 ([M+H]+, 100%);max (KBr) 









Yellow oil (8.01g, 94%), H (CDCl3) 3.80 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.88 (3H, s, 
OCH3), 6.87 (1H, d, Ar-H), 6.90-6.94 (1H, m, Ar-H), 6.78 (2H, d, Ar-H), 7.16 (1H, d, Ar-H), 
7.58 (1H, d, J=15.0Hz, C=C-H), 8.00-8.08 (3H, m, C=C-H, Ar-H); C (CDCl3) 55.5, 55.8, 
56.1, 112.4, 113.8, 116.9, 123.0, 124.7, 130.8, 131.3, 139.3, 153.3, 153.5, 163.3, 189.3; m/z 
[MALDI]+ 299 ([M+H]+, 100%);  max (KBr) /cm-1 1735 (C=O). 
 






Yellow crystals (7.19g, 94%), mp 79-81oC, H (CDCl3) 3.85 (6H, s, OCH3), 3.89 (3H, s, 
OCH3), 6.52 (1H, s, Ar-H), 6.78 (2H, s, Ar-H), 6.98 (2H, s, Ar-H), 7.48 (1H, d, J=15.6Hz, 
C=C-H), 7.70 (1H, d, J=15.6Hz, C=C-H), 8.03 (2H, d, Ar-H); C (CDCl3) 50.8, 55.5, 102.5, 
106.3, 113.7, 122.4, 130.9, 137.0, 144.0, 160.4, 161.0, 163.5, 188.8; m/z [MALDI]+ 299 













Yellow crystals (7.21g, 77%), mp 121-123oC; H (CDCl3) 3.90 (3H, s, OCH3), 6.00 (2H, S, 
OCH2O), 6.83 (1H, d, Ar-H), 6.97-7.07 (3H, m, Ar-H), 7.10 (1H, s, Ar-H), 7.20 (1H, d, 
J=15.3Hz, C=C-H), 7.43-7.48 (1H, m, Ar-H), 7.53 (1H, d, J=15.3Hz, C=C-H), 7.59 (1H, dd, 
Ar-H); C (CDCl3) 55.8, 101.6, 106.6, 108.6, 111.7, 120.7, 125.0, 125.0, 125.3, 129.3, 129.5, 
130.2, 142.9, 143.3, 148.3, 149.7, 193.0; m/z (MALDI)+ Found 383.0962, C17H14O4 requires 
383.0965; m/z [MALDI]+ 283 ([M+H]+, 100%); max (KBr) /cm-1 1705 (C=O). 
 





Yellow crystals (6.10g, 65%), mp 125-127oC; H (CDCl3) 0.08 (3H, t, CH3), 1.50 (2H, m, 
CH2), 1.79 (2H, m, CH2), 3.95 (6H, s, OCH3), 4.00 (2H, t, CH2), 6.86 (3H, d, Ar-H), 7.41 
(1H, d, J=15.0Hz, C=C-H), 7.59 (2H, d, Ar-H), 7.61 (1H, s, Ar-H), 7.79 (1H, d, J=15.0Hz, 
C=C-H); C (CDCl3) 13.8, 19.2, 31.2, 56.1, 67.9, 110.1, 110.4, 114.9, 119.3, 122.8, 127.6, 
130.1, 131.7, 143.9, 149.2, 153.1, 161.2, 188.6; m/z [MALDI]+ 341 ([M+H]+, 100%); max 









Yellow crystals (7.30g, 66%), mp 89-91oC; H (CDCl3) 3.88 (3H, s, OCH3), 3.99 (6H, s, 
OCH3), 6.93-6.98 (3H, m, Ar-H), 7.45 (1H, d, J=14.3Hz, C=C-H), 7.60-7.66 (3H, m, Ar-H), 
7.69 (1H, dd, Ar-H), 7.80 (1H, d, J=14.3Hz, C=C-H); C (CDCl3) 55.4, 56.0, 56.1, 110.0, 
110.7, 114.4, 119.3, 122.9, 127.8, 130.1, 131.5, 143.8, 149.2, 153.1, 161.5, 188.6; m/z 
[MALDI]+ 299 ([M+H]+, 100%); max (KBr) /cm-1 1763 (C=O).  
 






Yellow crystals (7.90g, 76%), mp 101-103oC; H (CDCl3) 3.82 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.90 (3H, s, OCH3), 6.49 (1H, s, Ar-H), 6.56 (1H, dd, Ar-H), 6.90 (2H, d, Ar-H), 
7.38 (1H, d, J=16.0Hz, C=C-H), 7.54 (2H, d, Ar-H), 7.64 (1H, d, J=16.0Hz, C=C-H), 7.73 
(1H, d, Ar-H); C (CDCl3) 55.50, 55.70, 98.70, 105.10, 114.30, 122.50, 125.00, 128.20, 
129.90, 132.70, 142.10, 160.20, 161.20, 163.90, 190.70; m/z [MALDI]+ 299 ([M+H]+, 












Yellow crystals (8.32g, 70%), mp 65-67oC; H (CDCl3) 3.65 (3H, s, OCH3), 3.72 (9H, s, 
OCH3), 6.73 (2H, d, Ar-H), 7.06 (2H, s, Ar-H), 7.15 (1H, d, J=15.4Hz, C=C-H), 7.38 (2H, d, 
Ar-H), 7.57 (1H, d, J=15.4Hz, C=C-H); C (CDCl3) 55.1, 56.3, 60.9, 105.7, 114.0, 119.3, 
127.6, 130.3, 133.8, 142.2, 144.6, 153.0, 161.7, 189.1; m/z [MALDI]+ 329 ([M+H]+, 100%); 
max (KBr) /cm-1 1679 (C=O). 
 






Yellow crystals (8.52g, 90%), mp 126-128oC; H (CDCl3) 6.00 (2H, S, OCH2O), 6.85 (1H, d, 
Ar-H), 7.13 (1H, d, Ar-H), 7.16 (1H, s, Ar-H), 7.32 (1H, d, J=16.25Hz, C=C-H), 7.47 (2H, d, 
Ar-H), 7.74 (1H, d, J=16.25Hz, C=C-H), 7.94 (2H, d, Ar-H); C (CDCl3) 101.7, 106.7, 108.7, 
119.5, 125.5, 128.9, 129.2, 129.8, 136.7, 139.1, 145.3, 148.5, 150.1, 189.1; m/z [MALDI]+ 







(E)-1-(2-methoxyphenyl)-3-(2-methoxyphenyl)-2-propen-1-one, DMU 2308 
OOMe OMe
 
Yellow oil (8.72g, 88%); H (CDCl3) 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.88-7.05 (4H, 
m, Ar-H), 7.35 (1H, t, Ar-H), 7.38-7.47 (2H, d, J=16.0Hz, C=C-H), 7.59 (2H, t, Ar-H), 7.95 
(1H, d, J=16.0Hz, C=C-H); C (CDCl3) 55.5, 55.6, 111.2, 111.6, 120.7, 124.2, 127.7, 128.8, 
129.7, 130.3, 131.5, 132.5, 132.8, 138.8, 158.1, 158.7, 193.5; m/z [MALDI]+ 269 ([M+H]+, 
100%); max (KBr) /cm-1 1750 (C=O).  
 
(E)-1-(4-chlorophenyl)-3-(4-chlorophenyl)-2-propen-1-one, DMU 2309  
O
Cl Cl  
Yellow crystals (8.03g, 81%), mp 147-149oC; H (CDCl3) 7.37-7.41 (2H, d, J=16.0Hz, C=C-
H), 7.41-7.43 (1H, s, Ar-H), 7.46-7.50 (2H, d, Ar-H), 7.57 (2H, d, J=16.0Hz, C=C-H) 7.75 
(1H, d, Ar-H), 7.95 (2H, d, Ar-H); C (CDCl3) 122.0, 129.0, 129.3, 129.6, 129.9, 133.2, 
136.4, 136.7, 139.4, 143.6, 188.8; m/z [MALDI]+ 277 ([M+H]+, 100%); max (KBr) /cm-1 
1656 (C=O). 
 







Yellow crystals (7.02g, 72%), mp 103-105oC; H (CDCl3) 1.05 (3H, t, CH3), 1.72-1.85 (2H, 
m, CH2), 3.70 (2H, s, CH2), 3.95 (6H, s, OCH3), 6.90 (3H, d, Ar-H), 7.40 (1H, d, Ar-H), 
7.50-7.60 (3H, m, Ar-H), 7.65 (1H, dd, Ar-H), 7.75 (1H, d, Ar-H); C (CDCl3) 10.4, 18.3, 
22.5, 56.0, 69.7, 110.1, 110.9, 114.9, 119.2, 122.8, 127.6, 130.1, 131.6, 144.0, 149.2, 153.1, 








Yellow crystals (7.10g, 84%), m.p 126-128oC; H (CDCl3), 3.90 (3H, s, OCH3), 6.00 (2H, s, 
OCH2O), 6.85 (1H, d, Ar-H), 6.95 (2H, d, Ar-H), 7.10 (1H, d, Ar-H), 7.15 (1H, s, Ar-H), 
7.45 (1H, d, J=15.0Hz, C=CH), 7.70 (1H, d, J=15.0Hz, C=CH), 8.00 (2H, d, Ar-H); C 
(CDCl3), 55.84, 101.9, 109.0, 114.2, 120.4, 125.3, 129.9, 131.1, 138.5, 144.4, 148.8, 150.1, 
160.8, 163.7, 188.9; m/z (Electrospray)+ Found 283.0965, C17H14O4 requires 283.0965; m/z 





       
 












Yellow crystals (7.42g, 79%); m.p 104-106oC;; H (CDCl3) 3.95 (6H, s, OMe), 6.00 (2H, s, 
OCH2O), 6.75 (1H, s, Ar-H), 6.85 (1H, d, Ar-H), 7.05-7.15 (4H, m, Ar-H), 7.35 (1H, d, 
J=17.0Hz, C=CH), 7.85 (1H, d, J=17.0Hz, C=CH), C (CDCl3), 55.6, 101.6, 104.8, 106.3, 
106.7, 108.6, 120.1, 125.2, 129.4, 140.4, 144.7, 148.4, 149.94, 160.9, 189.9; m/z 
(Electrospray)+ Found 313.1070, C18H16O5 requires 313.1071; m/z (Electrospray)
+ 313 





     
 
 
Yellow crystals (6.55g, 77%), m.p 81-83oC, H (CDCl3) 3.79 (3H, s, OCH3), 6.50(2H, s, 
OCH2O), 6.85 (1H, d, Ar-H), 7.1 (3H, t, Ar-H), 7.31 (1H,d, J=15.6Hz, CH=CH), 7.41 (1H, d, 
Ar-H), 7.55 (2H, m, Ar-H), 7.75 (1H, d, J=15.6Hz, CH=CH); C (CDCl3), 56.18, 101.93, 
107.08, 108.98, 112.09, 121.12, 125.35, 129.68, 130.64, 133.08, 138.52, 143.58, 148.73, 
150.06, 158.43, 193.25; m/z (Electrospray)+ Found 283.0966, C17H14O4 requires 283.0965; 
m/z (Electrospray)+ 283 ([M+H]+, 100%); max (KBr) /cm-1 1659 (C=O). 
 
9.3 General Procedure for the Synthesis of Epoxychalcones 
To a stirring mixture of the chalcone (9.2 mmol) and potassium carbonate (27 mmol) in 
methanol (40 ml), hydrogen peroxide (50 % w/v, 12.4 cm3, 368 mmol) was added. The 
reaction was monitored by TLC and upon reaching completion was quenched with water (80 
ml) and the crude product extracted with dichloromethane (3 x 50 ml). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo. The crude product was 














White crystals (2.49g, 79%), mp 119-121oC; H (CDCl3) 3.85 (6H, s, 2 x OCH3), 3.90 (6H, s, 
2 x OCH3), 3.98 (1H, d, CHO), 4.20 (1H, d, CHO), 6.77 (1H, s, Ar-H), 6.82 (1H, d, Ar-H), 
6.84 (1H, d, Ar-H), 6.89 (1H, d, Ar-H), 7.52 (1H, d, Ar-H), 7.61 (1H, dd, Ar-H); C (CDCl3) 
50.7, 56.1, 59.3, 60.9, 108.2, 110.2, 111.3, 118.8, 123.4, 128.1, 128.8, 149.4, 149.5, 154.2, 
191.4; m/z (Electrospray)+ Found 345.1336, C19H20O6 requires 345.1333; m/z (Electrospray)
+ 
345 ([M+H]+, 100%); max (KBr) /cm-1 1800 (C=O). 
 






White crystals (2.40g, 76%), mp 118-120oC; H (CDCl3) 3.80 (12H, s, 4 x OCH3), 4.05 (1H, 
d, CHO), 4.21 (1H, d, CHO), 6.60 (2H, s, Ar-H), 7.00 (2H, d, Ar-H), 8.08 (2H, d, Ar-H); C 
(CDCl3); m/z (Electrospray)
+ Found 345.1336, C19H20O6 requires 345.1333; m/z 






















White crystals (2.49g, 79%), mp 119-121oC; H; C (CDCl3); m/z (Electrospray)+ Found 
285.1123, C17H19O4 requires 285.1121; m/z (Electrospray)
+ 345 ([M+H]+, 100%); max (KBr) 
/cm-1 1670 (C=O). 
 
1-(3, 4, 5-trimethoxyphenyl)-2,3-epoxy-3-(3, 4-methylenedioxyphenyl)propan-1-






Oil (2.40g, 68%), mp 118-120oC; H (CDCl3) 3.90 (6H, s, 2 x OCH3), 3.95 (3H, s, OCH3), 
4.01 (1H, d, CHO), 4.18 (1H, d, CHO), 6.00 (2H, s, OCH2O), 6.80 (1H, s, Ar-H), 6.88 (1H, 
d, Ar-H), 6.95 (1H, d, Ar-H), 7.35 (1H, s, Ar-H), 7.43 (1H, d, Ar-H); C (CDCl3); m/z 
























White crystals (2.04g, 68%), mp 161-163oC; H (CDCl3) 3.98 (6H, s, 2 x OCH3), 4.03 (1H, d, 
CHO), 4.25 (1H, d, CHO), 6.04 (2H, s, OCH2O), 6.83 (2H, d, Ar-H), 6.91 (2H, d, Ar-H), 
7.59 (1H, s, Ar-H), 7.68 (1H, d, Ar-H); C (CDCl3) 56.11, 59.3, 60.7, 101.4, 105.5, 108.7, 
110.7, 120.2, 123.4, 128.8, 129.5, 143.9, 148.3, 149.2, 154.2, 188.5, 191.4; m/z 
(Electrospray)+ Found 329.1024, C18H16O6 requires 329.1020; m/z (Electrospray)
+ 329 
([M+H]+, 67%); max (KBr) /cm-1 1680 (C=O). 
 
1-(3, 4, 5-trimethoxyphenyl)-2,3-epoxy-3-(3,4-methylenedioxyphenyl)propan-1-





White crystals (2.85g, 87%), mp 123-125oC; H (CDCl3) 3.75 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.95 (3H, s, OCH3), 4.00 (1H, d, CHO), 4.35 (1H, d, CHO), 6.00 (2H, s, OCH2O), 
6.77 (1H, d, Ar-H), 6.82 (2H, d, Ar-H), 6.90 (1H, d, Ar-H), 7.65 (1H, d, Ar-H); C (CDCl3) 
56.2, 59.8, 60.9, 61.8, 63.6, 95.0, 100.0, 101.3, 105.6, 107.5, 108.4, 120.4, 123.7, 126.0, 
130.1, 141.7, 148.2, 154.7, 158.5, 193.2; m/z (Electrospray)+ Found 359.1129, C19H18O7 

























White crystals (2.85g, 86%), mp 123-125oC; H (CDCl3) 3.65 (3H, s, OCH3), 3.89 (3H, s, 
OCH3), 3.90 (1H, d, CHO), 4.30 (1H, d, CHO), 6.01 (2H, s, OCH2O), 6.43 (1H, d, Ar-H), 
6.59 (1H, dd, Ar-H), 6.83 (2H, d, Ar-H), 7.90 (1H, d, Ar-H); C (CDCl3) 55.5, 59.3, 64.4, 
98.2, 101.3, 105.0, 105.6, 108.3, 119.2, 120.1, 130.6, 132.9, 150.0, 161.6, 165.5, 192.7; m/z 
(Electrospray)+ Found 329.1025, C18H16O6 requires 329.1020; m/z (Electrospray)
+ 329 









White crystals (2.75g, 82%), mp 124-126oC; H (CDCl3) 3.55 (3H, s, OCH3), 3.74 (3H, s, 
OCH3), 3.86 (1H, d, CHO), 4.23 (1H, d, CHO), 5.92 (2H, s, OCH2O), 6.76 (2H, d, Ar-H), 
6.83 (2H, d, Ar-H), 7.01 (1H, dd, Ar-H), 7.27 (1H, d, Ar-H); C (CDCl3) 55.9, 56.2, 59.9, 
64.3, 101.3, 105.6, 108.3, 113.2, 113.5, 120.2, 122.0, 126.0, 130.4, 148.1, 153.7, 154.2, 
194.5; m/z (Electrospray)+ Found 329.1023, C18H16O6 requires 329.1020; m/z (Electrospray)
+ 






















White crystals (2.88g, 86%), mp 113-115oC; H (CDCl3) 3.64 (3H, s, OCH3), 3.80 (3H, s, 
OCH3), 3.81 (3H, s, OCH3), 3.83 (3H, s, OCH3), 4.27 (1H, d, CHO), 4.32 (1H, d, CHO), 6.86 
(3H, s, Ar-H), 6.90 (1H, d, Ar-H), 7.10 (1H, dd, Ar-H), 7.38 (1H, d, Ar-H); C (CDCl3) 55.9, 
64.1, 110.6, 111.7, 113.3, 113.5, 114.3, 121.8, 126.3, 152.7, 153.7, 153.9, 154.2, 194.8; m/z 
(Electrospray)+ Found 345.1137, C18H16O6 requires 345.1333; m/z (Electrospray)
+ 345 









Oil (2.33g, 81%), H (CDCl3) 3.78 (6H, s, 2 x OCH3), 3.88 (3H, s, OCH3), 4.12 (1H, d, CHO) 
4.37 (1H, d, CHO), 6.86 (3H, d, Ar-H), 6.95 (2H, d, Ar-H), 8.04 (2H, d, Ar-H); C (CDCl3) 
55.4, 55.8, 56.0, 60.5, 111.1, 111.7, 113.6, 114.5, 123.5, 125.1, 125.5, 130.8, 152.5, 153.7, 























White crystals (1.98 g, 69%), mp 100-102oC; H (CDCl3) 3.83 (6H, s, 2 x OCH3), 3.90 (3H, 
s, OCH3), 4.03 (1H, d, CHO) 4.22 (1H, d, CHO), 6.48 (1H, t, Ar-H), 6.55 (2H, d, Ar-H), 6.99 
(2H, d, Ar-H), 8.04 (2H, d, Ar-H); C (CDCl3) 55.4, 59.0, 60.0, 101.2, 103.6, 114.1, 128.5, 









White crystals (1.98 g, 70%), mp 100-102oC; H (CDCl3) 3.68 (3H, s, OCH3), 3.94 (1H, d, 
CHO) 4.27 (1H, d, CHO), 5.98 (2H, s, OCH2O), 6.81-6.83 (2H, m, Ar-H), 6.90 (1H, d, Ar-
H), 6.94 (1H, d, Ar-H), 7.05 (1H, t, Ar-H), 7.52 (1H, t, Ar-H), 7.81 (1H, d, Ar-H); C 
(CDCl3) 55.7, 59.9, 64.3, 94.9, 101.3, 105.6, 108.3, 111.6, 120.2, 121.0, 126.0, 130.4, 130.7, 
134.9, 148.1, 148.1, 159.6, 194.9; m/z (Electrospray)+ Found 299.0909, C17H14O5 requires 






















White crystals (2.14 g, 66%), mp 153-155oC; H (CDCl3) 0.98 (3H, t, CH3), 1.45-1.57 (2H, 
m, CH2), 1.74-1.81 (2H, m, CH2), 3.89-3.95 (9H, m, CH2, CHO, OCH3), 4.24 (1H, d, CHO), 
6.87-6.92 (3H, m, Ar-H), 7.27 (2H, d, Ar-H), 7.65 (1H, s, Ar-H), 7.68 (1H, d, Ar-H); C 
(CDCl3) 13.8, 19.2, 31.3, 56.1, 59.3, 60.9, 67.9, 110.2, 114.8, 123.3, 127.1, 128.9, 149.4, 








White crystals (2.20 g, 77%), mp 82-84oC; H (CDCl3) 3.84 (3H, s, OCH3), 3.95 (6H, s, 2 x 
OCH3), 4.03 (1H, d, CHO) 4.26 (1H, d, CHO), 6.90 (1H, d, Ar-H), 6.95 (2H, d, Ar-H), 7.30 
(2H, t, Ar-H), 7.59 (1H, d, Ar-H), 7.68 (1H, dd, Ar-H); C (CDCl3) 50.8, 56.0, 56.1, 59.2, 
60.9, 110.2, 114.2, 123.3, 127.2, 127.6, 128.9, 149.4, 154.2, 160.3, 191.6; m/z 
(Electrospray)+ Found 315.1231, C18H18O5 requires 315.1227; m/z (Electrospray)
+ 315 




















White crystals (2.74 g, 92%), mp 81-83oC; H (CDCl3) 3.61 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.88 (3H, s, OCH3), 3.94 (1H, d, CHO) 4.33 (1H, d, CHO), 6.43 (1H, d, Ar-H), 6.59 
(1H,d d, Ar-H), 6.93 (2H, d, Ar-H), 7.30 (2H, d, Ar-H), 7.90 (1H, d, Ar-H); C (CDCl3) 55.4, 
55.6, 59.5, 64.5, 98.1, 105.8, 114.0, 116.8, 127.2, 128.6, 132.8, 159.6, 161.6, 165.5, 192.9; 
m/z (Electrospray)+ Found 315.1222, C18H18O5 requires 315.1227; m/z (Electrospray)
+ 315 
([M+H]+, 65%); max (KBr) /cm-1 1774 (C=O). 
 





White crystals (2.74 g, 92%), mp 81-83oC; H (CDCl3) 3.61 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 3.88 (3H, s, OCH3), 3.94 (1H, d, CHO) 4.33 (1H, d, CHO), 6.43 (1H, d, Ar-H), 6.59 
(1H,d d, Ar-H), 6.93 (2H, d, Ar-H), 7.30 (2H, d, Ar-H), 7.90 (1H, d, Ar-H); C (CDCl3) 55.4, 
55.6, 59.5, 64.5, 98.1, 105.8, 114.0, 116.8, 127.2, 128.6, 132.8, 159.6, 161.6, 165.5, 192.9; 
m/z (Electrospray)+ Found 315.1222, C18H18O5 requires 315.1227; m/z (Electrospray)
+ 315 



















White crystals (2.08 g, 78%), mp 129-131oC; H (CDCl3) 4.07 (1H, d, CHO) 4.18 (1H, d, 
CHO), 7.32 (2H, d, Ar-H), 7.40 (2H, d, Ar-H), 7.49 (2H, d, Ar-H), 7.98 (2H, d, Ar-H); C 
(CDCl3) 58.6, 61.0, 127.1, 129.3, 129.8, 133.6, 135.1, 140.8, 191.7; m/z (Electrospray)
+ 
Found 293.0136, C15H10O2Cl2 requires 293.0131; m/z (Electrospray)
+ 293 ([M+H]+, 100%); 
max (KBr) /cm-1 1803 (C=O). 
 





White crystals (2.11 g, 65%), mp 123-125oC; H (CDCl3) 1.04 (3H, t, CH3), 1.77-1.86 (2H, 
m, CH2), 3.92-3.96 (8H, m, CH2, OCH3), 4.01 (1H, d, CHO), 4.24 (1H, d, CHO), 6.87-6.93 
(3H, m, Ar-H), 7.27 (1H, d, Ar-H), 7.58 (1H, s, Ar-H), 7.67 (1H, d, Ar-H); m/z 




      
O
O








9.4 General Procedure for the Synthesis of Substituted Pyrazoles 
Hydrazine hydrate (0.18 cm3, 5.7 mmol) was added drop-wise to a refluxing solution of the 
epoxide (3.8 mmol) in ethanol (40 cm3). After 6 h at reflux the solution was allowed to cool 
to room temperature and the solvent removed in vacuo. The residue was dissolved in glacial 
acetic acid (30 cm3). Concentrated sulphuric acid (0.25 cm3) was added and the solution 
heated at reflux for 0.5 h. After cooling (ice bath) the solution was neutralised with 
concentrated ammonia solution and poured onto ice. The resulting brown precipitate was 
isolated by vacuum filtration. The pyrazole was purified by either recrystalisation from 
ethanol, or flash chromatography on silica gel using ethyl acetate − hexane (7:3) as eluent. 
 






Brown crystals (1.12g, 87%), mp 84-86oC; H (CDCl3) 3.94 (6H, s, 2 x OCH3), 3.97 (6H, s, 2 
x OCH3), 6.71 (1H, s, Ar-H, C4-H), 6.94 (2H, d, Ar-H), 7.25-7.28 (4H, m, Ar-H); C (CDCl3) 
55.7, 55.9, 98.8, 108.6, 111.2, 118.1, 124.2, 148.6, 149.0, 149.1; m/z (CI, NH3)
+ Found 
341.1499, C19H22N2O4 requires 341.1499; m/z (CI, NH3)
+ 341 ([M+H]+, 100%); max (KBr) 
/cm-1 3330 (N-H). 
 





Brown crystals (1.05g, 81%), mp 80-82oC; H (CDCl3) 3.84 (3H, s, OCH3), 3.84-3.88 (3H, s, 
OCH3), 3.88-3.90 (6H, s, 2 x OCH3), 6.70 (1H, s, Ar-H, C4-H), 6.86-6.89 (4H, m, Ar-H), 
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7.60 (2H, d, Ar-H); C (CDCl3) 55.2, 55.8, 60.9, 98.9, 102.7, 114.2, 123.1, 126.8, 127.7, 
137.8, 153.4, 159.6; m/z (CI, NH3)
+ 341 ([M+H]+, 100%); max (KBr) /cm-1 3150 (N-H). 
 
3-(4-methoxyphenyl)-5-(4-methoxyphenyl)pyrazole, DMU 10103  
N NH
MeO OMe  
Brown crystals (0.99g, 93%), mp 77-79oC; H (CDCl3) 3.85 (6H, s, 2 x OCH3), 6.69 (1H, s, 
Ar-H, C4-H), 6.98 (4H, d, Ar-H), 7.65 (4H, d, Ar-H); m/z (CI, NH3)
+ 281 ([M+H]+, 100%); 
max (KBr) /cm-1 3300 (N-H). 
 








Brown crystals (0.99g, 73%), mp 101-103oC; H (CDCl3) 3.90 (3H, s, OCH3), 3.94 (6H, s, 2 
x OCH3), 6.02 (2H, s, OCH2O), 6.70 (1H, s, Ar-H, C4-H) 6.89 (1H, d, Ar-H), 6.97 (2H, s, 
Ar-H), 7.15-7.20 (2H, m, Ar-H); C (CDCl3) 29.7, 55.9, 60.9, 99.1, 101.3, 102.6, 106.0, 
108.5, 119.2, 127.1, 137.9, 147.6, 148.0, 153.4; m/z (CI, NH3)
+ 355 ([M+H]+, 100%); max 













Brown crystals (0.81g, 66%), mp 109-111oC; H (CDCl3) 3.85 (3H, s, OCH3), 3.95 (3H, s, 
OCH3), 6.00 (2H, s, OCH2O), 6.68 (1H, s, Ar-H, C4-H), 6.80 (1H, d, Ar-H), 6.88 (1H, d, Ar-
H), 7.10-7.19 (2H, m, Ar-H), 7.22 (2H, d, Ar-H); C (CDCl3) 55.9, 56.0, 99.4, 101.3, 106.3, 
108.6, 109.0, 111.5, 118.2, 119.4, 148.2, 149.3; m/z (CI, NH3)
+ Found 325.1181, C18H16N2O4 
requires 325.1183; m/z (CI, NH3)
+ 325 ([M+H]+, 100%); max (KBr) /cm-1 3325 (N-H).    
 








Brown solid (0.95g, 70%), mp 140-142oC; H (CDCl3) 3.91 (3H, s, OCH3), 3.92 (3H, s, 
OCH3), 3.97 (3H, s, OCH3), 6.00 (2H, s, CH2O2), 6.74 (1H, s, Ar-H), 6.78 (1H, d, Ar-H), 
6.88 (1H, d, Ar-H), 7.33-7.39 (3H, m, Ar-H); C (CDCl3) 56.1, 61.0, 61.2, 99.3, 101.1, 106.3, 
108.2, 108.4, 108.5, 115.8, 119.3, 122.3, 127.8, 141.8, 142.5, 147.3, 148.0, 150.8, 153.8; m/z 
[Electrospray]+ 355 ([M+H]+, 100%); max (KBr) /cm-1 3420 (N-H). 
 









Brown crystals (0.89g, 72%), mp 169-171oC; H (CDCl3) 3.87 (3H, s, OCH3), 3.98 (3H, s, 
OCH3), 6.00 (2H, s, CH2O2), 6.57-6.63 (2H, m, Ar-H), 6.73 (1H, s, Ar-H), 6.88 (1H, d, Ar-
H), 7.32-7.39 (2H, m, Ar-H), 7.62 (1H, d, Ar-H); C (CDCl3) 55.5, 55.8, 98.6, 99.0, 101.0, 
105.7, 106.3, 108.4, 110.9, 119.3, 128.0, 128.8, 142.0, 147.2, 147.9, 152.0, 157.1, 160.8; m/z 
(CI, NH3)
+  Found 325.1183, C18H17N402 requires 325.1183; (CI, NH3)
+ 325 ([M+H]+, 
100%); max (KBr) /cm-1 3380 (N-H). 
 






Brown crystals (0.90g, 73%), mp 154-156oC; H (CDCl3) 3.85 (3H, s, OCH3), 3.96 (3H, s, 
OCH3), 6.00 (2H, s, CH2O2), 6.82 (1H, s, Ar-H), 6.84-6.89 (1H, m, Ar-H), 6.97 (1H, d, Ar-
H), 7.24 (1H, d, Ar-H), 7.35 (1H, dd, Ar-H), 7.38 (1H, s, Ar-H); C (CDCl3) 55.8, 56.3, 99.6, 
101.1, 106.3, 108.5, 112.8, 113.2, 114.2, 118.3, 119.3, 127.8, 141.9, 147.3, 148.0, 150.3, 
154.0; m/z (CI, NH3)
+ 325 ([M+H]+, 100%); max (KBr) /cm-1 3425 (N-H). 
 





Brown crystals (0.90g, 70%), mp 135-137oC; H (CDCl3) 3.85 (3H, s, OCH3), 3.94 (3H, s, 
OCH3), 6.86 (1H, d, Ar-H), 6.88 (1H, d, Ar-H), 6.96 (2H, d, Ar-H), 7.19 (1H, s, Ar-H), 7.45 
(2H, d, Ar-H); C (CDCl3) 55.9, 56.4, 58.4, 103.9, 113.0, 113.4, 114.3, 120.9, 144.7, 150.9, 
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153.9; m/z (CI, NH3)
+ Found 341.1493, C19H21N2O4 requires 341.1139; (CI, NH3)
+ 341 
([M+H]+, 100%); max (KBr) /cm-1 3425 (N-H). 
 





Brown oily residue (0.66g, 67%); H (CDCl3) 3.84 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.96 
(3H, s, OCH3), 6.85-6.88 (2H, m, Ar-H), 6.97 (3H, d, Ar-H), 7.27 (1H, s, Ar-H), 7.75 (2H, d, 
Ar-H); C (CDCl3) 55.3, 55.8, 56.3, 99.5, 112.8, 113.2, 114.0, 114.1, 118.5, 126.2, 126.9, 
142.0, 150.3, 151.1, 154.0, 159.4; m/z (Electrospray)+ Found 311.1389, C18H18N2O3 requires 
311.1390; m/z (Electrospray)+ 311 ([M+H]+, 100%); max (neat) /cm-1 3298 (N-H).  
 






Brown crystals (0.85g, 87%), mp 71-73oC; H (CDCl3) 3.75 (6H, s, OCH3), 3.81 (3H, s, 
OCH3), 6.41 (1H, s, Ar-H), 6.67 (1H, s, Ar-H), 6.86-6.89 (4H, m, Ar-H), 7.58 (2H, s, Ar-H); 
C (CDCl3) 55.3, 99.6, 100.5, 103.7, 114.3, 123.6, 126.9, 133.6, 159.7, 161.1; m/z 
(Electrospray)+ Found 311.1390, C18H18N2O3 requires 311.1390; m/z (Electrospray)
+ 311 










Brown crystals (0.78g, 70%), mp 136-138oC; H (CDCl3) 3.90 (3H, s, OCH3), 5.98 (2H, s, 
OCH2O), 6.68 (1H, s, Ar-H, C4-H), 6.80 (1H, d, Ar-H), 6.88 (1H, d, Ar-H), 7.10-7.19 (2H, 
m, Ar-H), 7.22 (2H, d, Ar-H); m/z (Electrospray)+ Found 325.1181, C18H16N2O4 requires 
325.1183; m/z (Electrospray)+ 325 ([M+H]+, 100%); max (KBr) /cm-1 3325 (N-H).    
 





Brown crystals (0.87g, 65%), mp 74-76oC; H (CDCl3) 1.00 (3H, t, CH3), 1.52 (2H, q, CH2), 
1.74-1.83 (2H, m, CH2), 3.90 (3H, s, OCH3), 3.92 (3H, s, OCH3), 4.0 (2H, t, CH2), 6.70 (1H, 
s, Ar-H), 6.89-6.98 (3H, m, Ar-H), 7.39 (2H, d, Ar-H), 7.60 (2H, d, Ar-H); C (CDCl3) 13.9, 
19.3, 31.3, 55.6, 55.8, 67.7, 98.6, 108.6, 111.1, 114.5, 118.2, 123.5, 124.7, 126.8, 147.8, 
148.8, 149.0, 149.2, 159.1; m/z (Electrospray)+ Found 353.1854, C18H18N2O3 requires 
353.1851; m/z (Electrospray)+ 353 ([M+H]+, 100%)max (KBr) /cm-1 3328 (N-H). 
 







Brown crystals (0.78g, 66%), mp 75-77oC; H (CDCl3) 3.86 (3H, s, OCH3), 3.92 (3H, s, 
OCH3), 3.96 (3H, s, OCH3), 6.70 (1H, s, Ar-H), 6.90-7.00 (3H, m, Ar-H), 7.30 (2H, d, Ar-H), 
7.63 (2H, d, Ar-H); C (CDCl3) 55.3, 55.8, 55.9, 99.0, 108.9, 111.4, 114.3, 118.3, 123.6, 
124.6, 126.9, 149.2, 159.8, 175.4; m/z (Electrospray)+ 311 ([M+H]+, 100%); max (KBr) /cm-1 
3328 (N-H). 
 





Brown crystals (1.06g, 90%), mp 126-128oC; H (CDCl3) 3.87 (3H, s, OCH3), 3.88 (3H, s, 
OCH3), 4.04 (3H, s, OCH3), 6.60-6.64 (2H, m, Ar-H), 6.79 (1H, s, Ar-H, C4-H), 6.97 (2H, d, 
Ar-H), 7.65 (1H, d, Ar-H), 7.75 (2H, d, Ar-H); C (CDCl3) 55.3, 55.5, 55.7, 98.7, 98.9, 105.6, 
110.8, 114.1, 125.7, 126.9, 128.8, 141.9, 150.2, 157.3, 159.5, 160.9, 175.5; m/z 
(Electrospray)+ 311 ([M+H]+, 100%); max (KBr) /cm-1 3315 (N-H).  
 
3-(2-methoxyphenyl)-5-(2-methoxyphenyl)pyrazole, DMU 10120 
N NHOMe OMe
 
Brown oily residue (0.69g, 73%), H (CDCl3) 3.90 (6H, s, OCH3), 7.00-7.09 (4H, m, Ar-H), 
7.18 (1H, s, Ar-H, C4-H), 7.28-7.34 (2H, m, Ar-H), 7.99 (2H, d, Ar-H); C (CDCl3) 55.7, 
103.8, 111.5, 121.2, 128.4, 128.9, 156.4; m/z (Electrospray)+ 281 ([M+H]+, 100%); max 





3-(4-chloromethoxyphenyl)-5-(4-chloromethoxyphenyl)pyrazole, DMU 10121  
N NH
Cl Cl  
Light brown crystals (0.80g, 73%), mp 240-242oC; H (CDCl3) 6.82 (1H, s, Ar-H), 7.44 (4H, 
d, Ar-H), 7.66 (4H, d, Ar-H); C (CDCl3) 55.6, 103.8, 111.6, 119.7, 121.2, 128.3, 129.2, 
143.9, 156.5, 176.0; m/z (Electrospray)+ 289 ([M+ H]+, 100, Cl-35), 291 ([M+H]+, 60%, Cl-
37); max (KBr) /cm-1 3124 (N-H). 
 





Brown oily residue (0.81g, 63%); H (CDCl3) 1.04 (3H, t, CH3), 1.84 (2H, q, CH2), 3.90 (6H, 
s, OCH3), 3.93 (2H, t, CH2), 6.70 (1H, s, Ar-H), 6.88-6.94 (3H, m, Ar-H), 7.27 (2H, s, Ar-H), 
7.59 (2H, d, Ar-H); C (CDCl3) 10.5, 18.4, 22.6, 56.0, 58.5, 69.7, 99.2, 109.0, 111.5, 115.0, 
118.3, 123.4, 124.7, 126.9, 147.7, 149.3, 159.5; m/z (Electrospray)+ 339 ([M+H]+, 100%); 
max (neat) /cm-1  3215 (N-H). 
        
9.5 General Procedure for the Synthesis of Substituted Amino-
Pyrimidines  
A solution of the chalcone (9 mmol), guanidine hydrochloride (1.29 g, 13.5 mmol) and 
aqueous potassium hydroxide (4.94 cm3, 50% w/v, 36 mmol) in ethanol (30 cm3) was heated 
at reflux for 6 h. Hydrogen peroxide solution (1.84 cm3, 50% w/v, 27 mmol) was added drop-
wise to the solution and reflux continued for 1 h. The reaction was quenched with water (40 
cm3) and the resulting mixture extracted with dichloromethane (3 x 50 cm3). The combined 
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organic extracts were dried (MgSO4) and the solvent removed in vacuo. The pyrimidine was 
purified by either recrystalisation from methanol or ethanol, or by flash chromatography on 
silica gel using ethyl acetate − hexane (6:4) as eluent. 
 




Beige crystals (0.67g, 30%), mp 119-121oC; H (CDCl3) 5.20 (2H, s, NH2), 7.44-7.54 (7H, m, 
Ar-H), 8.00-8.09 (4H, m, Ar-H); C (CDCl3) 104.4, 127.1, 128.8, 130.5, 137.8, 163.6, 166.3, 










Beige crystals (1.02 g, 31%), mp 142-144oC; H (CDCl3) 3.88 (3H, s, OCH3), 3.91 (3H, s, 
OCH3), 3.98 (3H, s, OCH3), 5.10 (2H, s, NH2), 7.00 (2H, d, Ar-H), 7.30 (2H, s, Ar-H), 7.34 
(1H, s, Ar-H, C5), 8.04 (2H, d, Ar-H); C (CDCl3) 55.4, 56.3, 61.0, 103.3, 103.8, 104.4, 
114.1, 128.6, 130.1, 133.4, 140.2, 153.5, 161.7, 163.4, 165.7; m/z (CI)+ 368 ([M+H]+ 100%), 












Light brown crystals (0.31g, 9%), mp 192-193oC; H (CDCl3) 3.91 (3H, s, OCH3), 3.98 (6H, 
s, OCH3), 5.08 (2H, s, NH2), 6.05 (2H, s, OCH2O), 6.90 (2H, d, Ar-H), 7.30 (3H, d, Ar-H), 
7.59 (1H, s, Ar-H, C5), 7.62 (1H, d, Ar-H); m/z (Electrospray)+ 382 ([M+H]+ 100%); max 
(KBr) /cm-1 3360 (N-H). 
 
2-amino-4-(3,4-methylenedioxyphenyl)-6-(3,4-methylenedioxyphenyl)- 







Off white crystals (0.99g, 33%), mp 222-224oC; H (DMSO-d6) 5.46 (2H, s, NH2), 6.04 (4H, 
s, 2 x OCH2O), 6.90 (2H, d, Ar-H), 7.51 (2H, s, Ar-H), 7.58-7.67 (3H, m, Ar-H); C (DMSO-
d6) 55.0, 56.0, 60.3, 97.7, 104.7, 113.9, 128.9, 152.9, 159.0, 162.1; m/z (Cl, NH3)
+ 336 













Beige crystals (0.79g, 25%), mp 180-182oC; H (CDCl3) 3.94 (3H, s, OCH3), 4.00(3H, s, 
OCH3), 5.09 (2H, s, NH2), 6.03 (2H, s, OCH2O), 6.90 (1H, d, Ar-H), 6.94 (1H, d, Ar-H), 7.32 
(1H, s, Ar-H, C5), 7.58 (1H, s, Ar-H), 7.61 (2H, d, Ar-H), 7.69 (1H, s, Ar-H); C (CDCl3) 
56.1, 101.5, 103.0, 107.4, 108.4, 110.1, 111.0, 120.1, 121.69, 130.5, 132.2, 148.3, 149.3, 
151.2, 163.4, 165.3; m/z (Cl, NH3)











Light brown crystals (0.58g, 17%), mp 181-183oC; H (CDCl3) 3.83 (3H, s, OCH3), 3.91 (3H, 
s, OCH3), 3.93 (3H, s, OCH3), 5.04 (2H, s, NH2), 6.04 (2H, s, CH2O2), 6.80 (1H, d, Ar-H), 
6.90 (1H, d, Ar-H), 7.56-7.65 (4H, m, Ar-H); C (CDCl3) 56.1, 61.1, 61.5, 101.5, 107.4, 
107.5, 107.7, 108.4, 121.7, 125.1, 132.2, 142.5, 148.2, 149.6, 152.9, 155.2, 163.3, 164.3, 













Beige crystals (0.98g, 31%), mp 133-135oC; H (CDCl3) 3.87 (3H, s, OCH3), 3.90 (3H, s, 
OCH3), 5.02 (2H, s, NH2), 6.03 (2H, s, CH2O2), 6.55 (1H, d, Ar-H), 6.61 (1H, d, Ar-H), 6.90 
(1H, d, Ar-H), 7.53-7.61 (3H, m, Ar-H), 7.90 (1H, d, Ar-H); C (CDCl3) 55.7, 99.0, 101.4, 
105.3, 107.5, 108.0, 108.4, 121.6, 131.8, 159.2, 164.3; m/z (CI)+ 352 ([M+H]+ 100%); max 










Beige crystals (0.35g, 11%), mp 133-135oC; H (CDCl3) 3.84 (6H, s, 2 x OCH3), 5.05 (2H, s, 
NH2), 6.02 (2H, s, CH2O2), 6.89 (1H, d, Ar-H), 6.95 (2H, s, Ar-H), 7.43 (1H, s, Ar-H, C5), 













Pale yellow crystals (0.61g, 20%), mp 172-174oC; H (CDCl3) 3.89 (9H, s, 3 x OCH3), 5.12 
(2H, s, NH2), 6.60 (1H, s, Ar-H), 7.00 (2H, d, Ar-H), 7.20 (2H, s, Ar-H), 7.38 (1H, s, Ar-H, 
C5), 8.03 (2H, d, Ar-H); C (CDCl3) 60.3, 60.4, 106.9, 107.2, 110.0, 118.8, 133.6, 134.7, 










Light yellow crystals (0.92g, 32%), mp 142-144oC; H (CDCl3) 3.90 (3H, s, OCH3), 5.06 
(2H, s, NH2), 6.04 (2H, s, CH2O2), 6.90 (1H, d, Ar-H), 7.02 (1H, d, Ar-H), 7.08 (1H, t, Ar-
H), 7.42 (1H, t, Ar-H), 7.52 (1H, s, Ar-H, C5), 7.54-7.61 (2H, m, Ar-H), 7.82 (1H, d, Ar-H); 
C (CDCl3) 55.8, 101.5, 107.5, 108.4, 108.5, 111.6, 121.0, 121.7, 127.5, 130.7, 131.0, 132.3, 
148.2, 149.5, 157.6, 163.3, 164.4, 164.9; m/z (Electrospray)+ Found 322.1189, C18H15N303 










Off white crystals (0.67g, 22%), mp 145-147oC; H (CDCl3) 3.88 (3H, s, OCH3), 3.96 (3H, s, 
OCH3), 4.00 (3H, s, OCH3), 5.10 (2H, s, NH2), 6.96 (1H, d, Ar-H), 7.01 (2H, d, Ar-H), 7.39 
(1H, s, Ar-H, C5), 7.63 (1H, d, Ar-H), 7.70 (1H, s, Ar-H), 8.05 (2H, d, Ar-H); C (CDCl3) 
55.4, 55.9, 56.0, 102.8, 109.9, 110.2, 114.1, 120.1, 128.4, 128.6, 130.2, 130.6, 149.1, 151.1, 
161.6, 163.5, 165.4; m/z (Electrospray)+ 338 ([M+H]+, 100); max (KBr) /cm-1 3320 (N-H).    
 





Light yellow crystals (0.45g, 15%), mp 119-121oC; H (CDCl3) 3.88 (6H, s, 2 x OCH3), 3.90 
(3H, s, OCH3), 5.00 (2H, s, NH2), 6.56 (1H, s, Ar-H), 6.62 (1H, d, Ar-H), 6.99 (2H, d, Ar-H), 
7.60 (1H, s, Ar-H, C5), 7.90 (1H, d, Ar-H), 8.00 (2H, d, Ar-H); C (CDCl3) 55.4, 55.5, 55.7, 
99.0, 105.1, 107.9, 114.0, 120.2, 128.6, 130.6, 131.8, 159.1, 161.4, 162.3, 163.3, 164.2, 













Beige crystals (0.84g, 29%), mp 132-134oC; H (DMSO-d6) 3.84 (3H, s, OCH3), 6.12 (2H, s, 
CH2O2), 6.59 (2H, s, NH2), 7.02-7.10 (3H, m, Ar-H), 7.60 (1H, s, Ar-H, C5), 7.77-7.86 (2H, 
m, Ar-H), 8.20 (2H, d, Ar-H); C (DMSO-d6) 55.3, 94.5, 100.4, 101.5, 106.9, 108.2, 113.8, 
121.5, 128.5, 129.7, 131.6, 147.8, 149.1, 161.1, 163.8, 164.2; m/z (Electrospray)+ 322 










Beige crystals (1.01g, 32%), mp 125-127oC; H (CDCl3) 3.89 (6H, s, 2 x OCH3), 5.10 (2H, s, 
NH2), 6.05 (2H, s, CH2O2), 6.60 (1H, s, Ar-H), 6.91 (1H, d, Ar-H), 7.19 (2H, s, Ar-H), 7.33 
(1H, s, Ar-H, C5), 7.58-7.64 (2H, m, Ar-H); m/z (Electrospray)+ 352 ([M+H]+ 100%); max 













Yellow crystals (0.93g, 32%), mp 134-136oC; H (CDCl3) 3.88 (3H, s, OCH3), 5.17 (2H, s, 
NH2), 6.03 (2H, s, OCH2O), 6.90 (1H, d, Ar-H), 6.99 (2H, d, Ar-H), 7.31 (1H, d, Ar-H, C5), 
7.58 (1H, s, Ar-H), 7.60 (1H, d, Ar-H), 8.03 (2H, d, Ar-H); C (CDCl3) 55.4, 101.6, 103.8, 
107.4, 108.2, 112.2, 116.4, 119.5, 121.7, 129.8, 131.9, 139.3, 148.3, 149.7, 160.0, 163.5, 
165.5, 165.9; m/z (Electrospray)+ 322 ([M+H]+, 100); max (KBr) /cm-1 3310 (N-H). 
   
9.6 General Procedure for the Synthesis of Substituted 
Pyrimidones  
Sodium nitrite solution (1.08 cm3, 50% w/v, 7.8 mmol) was added to a refluxing solution of 
the amino-pyrimidine (1.31 mmol) in glacial acetic acid (50 cm3). After 3 h at reflux the 
solution was allowed to cool and the solvent removed in vacuo. The crude product was 
recrystallised from ethanol. 
 






Off white crystals (0.24g, 75%), mp 221-223oC; H (DMSO-d6) 7.40 (1H, s, Ar-H, C5), 7.48-
7.56 (6H, m, Ar-H), 8.13-8.18 (4H, m, Ar-H); m/z (Electrospray)+ 249 ([M+H]+ 90%); max 
(KBr) /cm-1 1750 (C=O), 3440 (N-H). 
 







Light yellow crystals (0.42g, 85%), mp 275-277oC; H (CDCl3) 3.92 (3H, s, OCH3), 3.94 
(3H, s, OCH3), 4.00 (6H, s, 2 x OCH3), 7.01 (1H, s, Ar-H, C5), 7.08 (2H, d, Ar-H), 7.30 (2H, 












Dark orange crystals (0.015g, 3%), mp 271-273oC; H (DMSO-d6) 3.74 (3H, s, OCH3), 3.90 
(6H, s, 2 x OCH3), 6.15 (2H, s, OCH2O), 7.10 (1H, d, Ar-H), 7.43 (3H, s, Ar-H), 7.76-7.85 
(2H, m, Ar-H); m/z (CI, NH3)
+ Found 383.1235, C20H19N2O6 requires 383.1238; m/z (CI, 
NH3)












Light brown crystals (0.29g, 65%), mp 296-298oC; H (DMSO-d6) 6.15 (2H, s, 2 x OCH2O), 
7.08 (2H, d, Ar-H), 7.45 (1H, s, Ar-H, C5), 7.74-7.82 (4H, m, Ar-H); m/z (CI, NH3)
+ 337 











Light brown crystals (0..33g, 72%), mp 290-292oC; H (DMSO-d6) 3.87 (3H, s, OCH3), 3.90 
(3H, s, OCH3), 6.15 (2H, s, OCH2O), 7.10 (2H, t, Ar-H), 7.42 (1H, s, Ar-H, C5), 7.70 (1H, s, 
Ar-H), 7.74-7.83 (3H, m, Ar-H); m/z [electrospray]+ 353 ([M+H]+, 79%); max (KBr) /cm-1 














Pale yellow crystals (0.42g, 84%), mp 261-263oC; H (DMSO-d6) 3.80 (6H, s, 2 x OCH3), 
3.90 (3H, s, OCH3), 6.13 (2H, s, OCH2O), 6.96 (1H, d, Ar-H), 7.05 (1H, d, Ar-H), 7.12 (1H, 
s, Ar-H, C5), 7.42 (1H, d, Ar-H), 7.65 (1H, d, Ar-H), 7.69 (1H, dd, Ar-H); C (DMSO-d6) 
56.1, 60.6, 61.3, 107.2, 108.4, 124.9, 148.0, 155.6; m/z (Electrospray)+ Found 383.1234, 
C20H18N2O6 requires 383.1236; m/z (Electrospray)
+ 353 ([M+H]+, 100%); max (KBr) /cm-1 









Orange crystals (0.39g, 84%), mp 198-200oC; H (CDCl3) 3.90 (3H, s, OCH3), 3.98 (3H, s, 
OCH3), 6.05 (2H, s, OCH2O), 6.59 (1H, d, Ar-H), 6.66 (1H, d, Ar-H), 6.87-6.94 (2H, m, Ar-
H), 7.64-7.71 (3H, m, Ar-H); C (CDCl3) 55.7, 56.1, 99.4, 101.8, 106.5, 108.1, 108.3, 123.0, 
131.1, 148.4, 150.9, 159.2, 164.1; m/z (Cl, NH3)
+ Found 353.1137, C19H17N2O5 requires 
353.1132; m/z (Cl, NH3)


















Pale yellow crystals (0.33g, 72%), mp 244-246oC; H (DMSO-d6) 4.78 (3H, s, OCH3), 4.80 
(3H, s, OCH3), 6.65 (2H, s, OCH2O), 7.05 (1H, d, Ar-H), 7.10 (1H, d, Ar-H), 7.18-7.11 (2H, 
m, Ar-H), 7.20 (1H, d, Ar-H), 7.78 (1H, s, Ar-H), 7.83 (1H, d, Ar-H); m/z (Cl, NH3)
+ Found 
353.1135, C19H17N2O5 requires 353.1132; m/z (Cl, NH3)
+ 353 ([M+H]+, 56%); max (KBr) 
/cm-1 1680 (C=O). 
 







Pale yellow crystals (0.25g, 56%), mp 231-233oC; H (DMSO-d6) 3.85 (9H, s, 3 x OCH3), 
6.70 (1H, t, Ar-H), 7.09 (2H, d, Ar-H), 7.29 (2H, d, Ar-H), 7.48 (1H, s, Ar-H, C5), 8.18 (2H, 
d, Ar-H); C (DMSO-d6) 55.5, 103.4, 105.4, 114.1, 129.5, 160.7, 162.1; m/z (CI, NH3)+ 339 










Yellow crystals (0.36g, 85%), m.p. 166-167oC; H (DMSO-d6) 3.90 (3H, s, OMe), 6.10 (2H, 
s, OCH2O), 6.90-7.10 (3H, m, Ar-H), 7.25(1H, d, Ar-H), 7.50-7.60 (1H, m, Ar-H), 7.65-7.70 
(1H, m, Ar-H), 7.8 (1H, s, Ar-H); c (DMSO-d6) 56.1, 101.6, 102.2, 107.7, 108.8, 112.3, 
120.9, 122.6, 123.2, 130.6, 132.7, 148.3, 150.6, 157.4, 158.2, 172.3; m/z [MALDI+] 322 
([M]+); max (KBr) /cm-11663 (C=O). 
 





Light brown crystals (0.35g, 78%), mp 253-255oC; H (CDCl3) 3.90 (3H, s, OCH3), 3.98 (3H, 
s, OCH3), 4.06 (3H, s, OCH3), 7.00 (1H, d, Ar-H), 7.03-7.13 (3H, m, Ar-H), 7.63 (1H, dd, 
Ar-H), 7.77 (1H, s, Ar-H, C5), 8.06 (1H, d, Ar-H); m/z (CI, NH3)
+ 339 ([M+H]+, 100%); max 



















Light yellow crystals (0.20g, 47%), mp 300-302oC; H (DMSO-d6) 3.85 (3H, s, OCH3), 6.18 
(2H, s, OCH2O), 7.06 (1H, d, Ar-H), 7.10 (2H, d, Ar-H), 7.43 (1H, s, Ar-H, C5), 7.74-7.80 
(2H, m, Ar-H), 8.18 (2H, d, Ar-H); C (DMSO-d6) 55.4, 56.0, 101.8, 107.4, 108.4, 114.1, 
122.7, 129.3, 147.9, 150.1, 162.0; m/z (Cl, NH3)
+ Found 323.1028, C18H15N2O4 requires 
323.1026; m/z (Cl, NH3)










Pale yellow crystals (0.37g, 73%), mp 272-274oC; H (DMSO-d6) 3.88 (6H, s, 2 x OCH3), 
6.13 (2H, s, OCH2O), 6.67 (1H, d, Ar-H), 7.02 (1H, d, Ar-H), 7.27 (2H, s, Ar-H), 7.42 (1H, s, 
Ar-H), 7.75-7.85 (2H, m, Ar-H); C (DMSO-d6) 55.5, 101.8, 103.5, 105.4, 107.5, 108.4, 
122.9, 148.0, 150.2, 160.7; m/z (Electrospray)+ Found 353.1135, C19H17N2O6 requires 













Pale yellow crystals (0.32g, 76%), mp 269-271oC; H (DMSO-d6) 3.86 (3H, s, OCH3), 6.15 
(2H, s, OCH2O), 7.08 (1H, d, Ar-H), 7.15 (1H, dd, Ar-H), 7.42-7.48 (2H, m, Ar-H), 7.68 (1H, 
s, Ar-H, C5), 7.72 (1H, d, Ar-H), 7.77-7.85 (2H, m, Ar-H); C (DMSO-d6) 55.4, 101.8, 107.4, 
108.4, 112.4, 117.5, 119.9, 122.8, 129.9, 148.0, 150.2, 159.6; m/z (CI, NH3)
+ 323 ([M+H]+, 
56%);  
 
9.7 General Procedure for the Synthesis of Substituted 
Morpholino-Pyrimidines  
A solution of the chalcone (1.60 mmol), 4-amidinomorpholine hydrobromide (0.50 g, 2.38 
mmol) and aqueous sodium hydroxide (0.50 cm3, 50% w/v, 6.40 mmol) in ethanol (20 cm3) 
was heated at reflux for 6h. Hydrogen peroxide solution (0.33 cm3, 50% w/v, 4.80 mmol) was 
added drop-wise to the solution and reflux continued for 1 h. The reaction was quenched with 
water (40 cm3) and the resulting mixture extracted with dichloromethane (3 x 60 cm3). The 
combined organic extracts were dried (MgSO4) and the solvent removed in vacuo. The 
morpholino-pyrimidine was purified by either recrystalisation from methanol or ethanol, or 















Yellow crystals (0.14g, 20%), mp 194-196oC; H (CDCl3) 3.86 (4H, t, 2 x CH2), 3.96 (6H, s, 
2 x OCH3), 3.98-4.04 (12H, m, 2 x OCH3, 2 x CH2), 6.80 (2H, d, Ar-H), 7.33 (1H, s, C-5), 
7.68 (2H, d, Ar-H), 7.72 (2H, d, Ar-H); C (CDCl3) 44.5, 56.0, 56.1, 67.1, 101.3, 110.1, 
110.9, 120.2, 131.0, 149.2, 151.2, 162.2, 164.6; m/z (CI)+ 438 ([M+H]+, 83%). 
 
4-(3,4-methylenedioxyphenyl)-6-(3,4-methylenedioxyphenyl)-2-








Yellow crystals (0.28g, 20%), mp 213-215oC; H (CDCl3) 3.83 (4H, t, 2 x CH2), 3.98 (4H, t, 
2 x CH2), 6.04 (2H, s, 2 x OCH2O), 6.90 (2H, d, Ar-H), 7.24 (1H, s, C-5), 7.62 (3H, s, Ar-H), 
7.64 (1H, d, Ar-H); C (CDCl3) 44.4, 67.0, 101.2, 101.5, 107.4, 108.3, 121.5, 132.5, 148.2, 













Beige crystals (0.16g, 31%), mp 135-137oC; H (CDCl3) 3.75 (4H, t, 2 x CH2), 3.82 (3H, s, 
OCH3), 3.95 (3H, s, OCH3), 3.88-3.96 (10H, m, 2 x OCH3, 2 x CH2), 6.93 (2H, d, Ar-H), 












Oily residue (0.11g, 24%); H (CDCl3) 3.81 (4H, t, 2 x CH2), 3.89 (3H, s, OCH3), 3.95 (4H, t, 
2 x CH2), 6.01 (2H, s, OCH2O), 6.89 (1H, d, Ar-H), 7.00 (1H, d, Ar-H), 7.07 (1H, t, Ar-H), 
7.39 (1H, t, Ar-H), 7.56 (1H, s, Ar-H, C-5), 7.63 (2H, d, Ar-H), 7.95 (1H, d, Ar-H); C 
(CDCl3); m/z (Electrospray
+) Found 392.1605, C22H21N3O4 requires 392.1605; m/z 











Yellow crystals (0.14g, 29%), mp 146-148oC; H (CDCl3) 3.83 (4H, t, 2 x CH2), 3.85 (3H, s, 
OCH3), 3.95 (3H, s, OCH3), 3.96-4.20 (7H, m, OCH3, 2 x CH2), 6.97 (1H, d, Ar-H), 7.00 
(2H, d, Ar-H), 7.41 (1H, s, C-5), 7.70 (2H, d, Ar-H), 8.09 (2H, d, Ar-H); C (CDCl3) 44.5, 
55.4, 56.1, 67.1, 101.1, 110.0, 110.9, 113.8, 120.2, 128.6, 130.7, 131.1, 149.1, 151.1, 161.6, 










Light yellow crystals (0.13g, 26%), mp 145-147oC; H (CDCl3) 3.82 (4H, t, 2 x CH2), 3.87 
(3H, s, 2 x OCH3), 3.90 (3H, s, OCH3), 3.96 (4H, t, 2 x CH2), 6.56 (1H, d, Ar-H), 6.62 (1H, 
dd, Ar-H), 6.98 (2H, d, Ar-H), 7.63 (1H, s, C-5), 8.02 (1H, d, Ar-H), 8.05 (2H, d, Ar-H); C 
(CDCl3) 44.5, 55.4, 55.5, 55.8, 67.1, 99.0, 105.2, 106.3, 113.7, 120.6, 128.6, 131.1, 132.0, 












Light yellow crystals (0.13g, 23%), mp 181-183oC; H (CDCl3) 3.82 (4H, t, 2 x CH2), 3.88 
(6H, s, 2 x OCH3), 3.99 (4H, t, 2 x CH2), 6.04 (2H, s, OCH2O), 6.58 (1H, t, Ar-H), 6.90 (1H, 
d, Ar-H), 7.23 (2H, d, Ar-H), 7.28 (1H, s, C-5), 7.65 (2H, d, Ar-H); C (CDCl3) 44.5, 55.5, 
67.0, 101.5, 101.9, 102.2, 105.4, 107.4, 108.3, 121.6, 140.4, 148.2, 149.7, 161.1, 162.1, 
164.6, 164.9; m/z (Electrospray)+  422.1709, C23H23N3O5 requires 422.1710 m/z 
(Electrospray)+ 422 ([M+H], 100%). 
 





Light yellow crystals (0.12g, 36%), mp 121-123oC; H (CDCl3) 3.84 (4H, t, CH2), 4.02 (4H, 
t, CH2), 7.44 (1H, s, C-5), 7.46-7.52 (6H, m, Ar-H), 8.08-8.15 (4H, m, Ar-H); C (CDCl3); 
m/z (Electrospray)+ Found 318.1604, C20H19N3O requires 318.1601; m/z (Electrospray)
+ 318 
([M+H], 100%). 
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9.8 General Procedure for the Synthesis of Morpholino-
Hydrochloride 
S-methylisothiourea sulphate (5 g, 0.018 mol) and morpholine (3.14 ml, 0.036 mol) was 
stirred in water under reflux for 5 mins. A solution of aqueous barium chloride (11.24 cm3, 
50% w/v, 0.027 mol) was added and the reaction continued to stir under reflux for 1h. Once 
cool, the mixture was filtered through kieselguhr giving a colourless solution. The solvent 
was removed in vacuo leaving a white gum which was recrystallised from a mixture of 
ethanol and acetone (50:50). The product was obtained as white crystals which were collected 
by filtration.  
 







White crystals (0.15g, 5%), mp 190-192oC; H (DMSO-d6) 3.52 (4H, t, 2 x CH2), 3.83 (4H, t, 
2 x CH2); C (DMSO-d6); m/z (Electrospray)+ 165 ([M]+, 100%). 
 
9.9 General Procedure for the Synthesis of 
Dimethylethylenediamino-Guanidine Hydrochloride 
S-methylisothiourea sulphate (5 g, 0.018 mol) and N,N-dimethylethylenediamine (3.93 ml, 
0.036 mols) was stirred in water under reflux for 5 minutes. A solution of aqueous barium 
chloride (11.24 cm3, 50% w/v, 0.027 mol) was added and the reaction continued to stir under 








solution. The solvent was removed in vacuo leaving a white gum which was recrystallised 
from a mixture of ethanol and acetone (50:50). The product was obtained as white crystals 
which were collected by filtration.  
 








White crystals (0.21g, 7%), mp 221-223oC; H (DMSO-d6) 2.39 (6H, s, 2 x CH3), 2.78 (2H, t, 
CH2), 3.39 (2H, t, CH2); C (D2O) 36.5, 43.3, 55.6; m/z (Electrospray)+ 166 ([M]+, 29%); 
max (KBr) /cm-1 1600, 3470 (1o N-H), 3300 (2o N-H). 
 
9.10 General procedure for the synthesis of substituted 
dimethylethylenediamino-pyrimidines  
A solution of the chalcone (1.6 mmol), guanidinium-dimethylethyleneamine chloride (2.4 
mmol) and aqueous sodium hydroxide (0.51 cm3, 50% w/v, 6.4 mmol) in ethanol (10 cm3) 
was heated at reflux for 24 h. The reaction was quenched with water (40 cm3) and the organic 
mixture extracted with dichloromethane (3 x 50 cm3). The combined organic extracts were 
dried (MgSO4) and the solvent removed in vacuo. The morpholino-pyrimidine was purified 


















Light brown oil (0.26g, 39%), H (CDCl3) 2.66 (6H, s, 2 x CH3), 3.07 (2H, t, CH2), 3.82-3.92 
(8H, m, CH2, 2 x OCH3), 5.87 (1H, s, broad, NH), 6.03 (2H, s, OCH2O), 6.56 (1H, d, Ar-H), 
6.62 (1H, dd, Ar-H), 6.89 (1H, d, Ar-H), 7.57-7.60 (3H, m, Ar-H, C5-H), 7.95 (1H, d, Ar-H); 
C (CDCl3) 29.4, 29.7, 31.9, 38.0, 55.5, 55.8, 57.8, 98.9, 101.4, 105.2, 107.4, 108.3, 120.1, 
121.6, 131.2, 132.5, 148.1, 149.4, 159.3, 162.4; m/z (Electrospray)+ 423.2026; m/z 
(Electrospray)+ 423 ([M+H]+, 100%). 
 





Light brown oil (0.14g, 42%), H (CDCl3) 2.41 (6H, s, 2 x CH3), 2.74 (2H, t, CH2), 3.77 (2H, 
q, CH2), 5.77 (1H, s, broad, NH), 7.43 (1H, s, C5-H), 7.47-7.53 (6H, m, Ar-H), 8.05-8.14 
(4H, m, Ar-H); C (CDCl3) 38.9, 45.1, 58.3, 102.9, 127.1, 128.7, 130.3, 138.1, 162.9; m/z 













Brown oil (0.15g, 29%), H (CDCl3) 2.38 (6H, s, 2 x CH3), 2.70 (2H, t, CH2), 3.70 (2H, q, 
CH2), 3.90 (3H, s, OCH3), 5.64 (1H, s, broad, NH), 6.03 (2H, s, OCH2O), 6.89 (1H, d, Ar-H), 
7.01 (1H, d, Ar-H), 7.08 (1H, t, Ar-H), 7.40 (1H, t, Ar-H), 7.50 (1H, s, C5-H), 7.63 (2H, d, 
Ar-H), 7.90 (1H, d, Ar-H); m/z (Electrospray)+ Found 393.1923, C22H24N4O3 requires 
393.1921; m/z (Electrospray)+ 393 ([M+H]+, 100%). 
 
9.11 General Procedure for the Synthesis of 2-Methyl-4-(2,4-
Dimethoxyphenyl)-6-(3,4-Methylenedioxyphenyl)Pyrimidine 
A solution of DMU 407 (6.4 mmol), acetamidine hydrochloride (9.6 mmol) and aqueous 
potassium hydroxide (2.90 cm3, 50% w/v, 25.6 mmol) in ethanol (25 cm3) was heated at 
reflux for 6 h. Hydrogen peroxide solution (1.31 cm3, 50% w/v, 19.2 mmol) was added drop-
wise to the solution and reflux continued for 1 h. The reaction was quenched with water (40 
cm3) and the resulting mixture extracted with dichloromethane (3 x 50 cm3). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo. The methyl-












Yellow crystals (0.09g, 10%), mp 127-129oC; H (CDCl3) 2.80 (3H, s, CH3), 3.88 (3H, s, 
OCH3), 3.90 (3H, s, OCH3), 6.05 (2H, s, CH2O2), 6.60 (1H, d, Ar-H), 6.67 (1H, dd, Ar-H), 
6.95 (1H, d, Ar-H), 7.60-7.69 (2H, m, Ar-H), 8.01 (2H, d, Ar-H); C (CDCl3) 55.5, 55.7, 
99.0, 101.5, 105.4, 107.6, 108.5, 110.9, 113.5, 119.9, 121.8, 132.2, 132.4, 148.3, 149.6, 
159.3, 162.5, 162.9, 167.7; m/z (Electrospray)+ Found 351.1333, C20H18N2O4 requires 
351.1339; m/z (Electrospray)+ 351 ([M+H]+, 100).  
 
9.12 General Procedure for the Synthesis of 4-(2,4-
Dimethoxyphenyl)-6-(3,4-Methylenedioxyphenyl)Pyrimidine 
A solution of DMU 407 (9.62 mmol), formamidine hydrochloride (14.4 mmol) and aqueous 
potassium hydroxide (4.31 cm3, 50% w/v, 38.5 mmol) in ethanol (30 cm3) was heated at 
reflux for 6 h. Hydrogen peroxide solution (1.96 cm3, 50% w/v, 28.9 mmol) was added drop-
wise to the solution and reflux continued for 1 h. The reaction was quenched with water (40 
cm3) and the resulting mixture extracted with dichloromethane (3 x 50 cm3). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo. The pyrimidine was 


















Brown crystals (0.32g, 10%), mp 132-134oC; H (CDCl3) 3.88 (3H, s, OCH3), 3.95 (3H, s, 
OCH3), 6.08 (2H, s, CH2O2), 6.58 (1H, d, Ar-H), 6.68 (1H, dd, Ar-H), 6.94 (1H, d, Ar-H), 
7.64 (1H, d, Ar-H), 7.69 (1H, d, Ar-H), 8.08 (1H, d, Ar-H), 8.25 (1H, s, Ar-H), 9.20 (1H, s, 
Ar-H); C (CDCl3) 55.5, 55.7, 99.0, 101.5, 105.4, 107.6, 108.5, 110.9, 113.5, 121.8, 132.4, 
149.6, 159.3, 162.9, 167.7; m/z (Electrospray)+ Found 337.1184, C19H16N2O4 requires 
337.1183; m/z (Electrospray)+ 337 ([M+H]+, 100). 
 
 
9.13 General procedure for the synthesis of 4-(2, 4-
dimethoxyphenyl)-6-(3, 4-dihydroxyphenyl)-2-amino-pyrimidine 
A solution of the pyrimidine (0.57 mmol) and boron trichloride (1.71 mmol) in 
dichloromethane (60 cm3) was stirred at -5oC under nitrogen for 24 h. The reaction was 
quenched with water (50 cm3) and the resulting mixture extracted with ethyl acetate (3 x 50 
cm3). The combined organic extracts were dried (MgSO4) and the solvent removed in vacuo. 
The dihydroxy-pyrimidine was purified by flash chromatography on silica gel using 


















Brown oil (0.033g, 17%), H (CDCl3) 3.84 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.40 (2H, s, 
NH2), 6.65 (1H, dd, Ar-H), 6.68 (1H, d, Ar-H), 6.85 (1H, d, Ar-H), 7.37-7.61 (1H, dd, Ar-H), 
7.46 (1H, d, C5-H), 7.53 (1H, d, Ar-H), 7.89 (1H, d, Ar-H), 9.25 (1H, s, broad, OH), 9.44 
(1H, s, broad, OH); m/z (Electrospray+) 340.1290, C18H17N3O4 requires 340.1292; m/z 
(Electrospray+) 340 ([M+H]+, 100). 
 
9.14 General procedure for the Synthesis of DMU 10500 
A solution of 4-hydroxy-2-methoxybenzaldehyde (16 mmol) and pyridinium ρ-toluene 
sulfonate (0.38 mmol) in dichloromethane (30 ml) was stirred at room temperature for 0.5 h. 
This was followed by drop-wise addition of 3,4-dihydro-2H-pyran (4.08 ml) in 
dichloromethane (15 ml) and stirring continued for 24 h. The reaction was quenched with 
water (30 cm3) and the resulting mixture extracted with dichloromethane (3 x 50 cm3). The 
combined organic extracts were dried (MgSO4) and the solvent removed in vacuo. The 
protected benzaldehyde was purified by flash chromatography on silica gel using 
dichloromethane – methanol as eluent. 
 










Yellow oil (1.83g, 49%), H (CDCl3) 3.90 (3H, s, OCH3), 5.55 (1H, t, cyclic-H), 6.63 (1H, s, 
Ar-H), 6.70 (1H, d, Ar-H), 7.80 (1H, d, Ar-H), 10.30 (1H, s, CH); C (CDCl3); m/z 
(electrospray)+ Found 237.1119, C13H16O4 requires 237.1121; m/z (electrospray)
+ 237 ([M+ 
H]+, 38%).  
 
9.15 General procedure for the synthesis of the DMU 10501 
A solution of 2-(methoxy-4-tetrahydropyran-2-yloxy)-benzaldehyde (7.8 mmol), 3, 4-
(methylenedioxy)-acetophenone (7.8 mmol) and aqueous sodium hydroxide (2.50 cm3, 50% 
w/v, 31.2 mmol) in methanol (30 ml) was stirred at room temperature for 24 h. Once 
complete (as indicated by TLC) the reaction was quenched with water (50 cm3) and the 
resulting mixture was extracted with dichloromethane (3 x 40 cm3).  The organic extracts 
were dried (MgSO4) and the solvent removed in vacuo.  The crude was purified by flash 
chromatography on silica gel using ethyl acetate – hexane as eluent. 
 
(E)-1-(3,4-methylenedioxyphenyl)-3-(2-methoxy-4-tetrahydropyran-2-









Yellow oil (2.30g, 77%), H (CDCl3) 3.90 (3H, s, OCH3), 5.50 (1H, t, cyclic-H), 6.05 (2H, s, 
OCH2O), 6.64 (1H, d, Ar-H), 6.70 (1H, dd, Ar-H), 6.89 (1H, d, J=12, C=C-H), 7.48 (1H, s, 
Ar-H), 7.53 (1H, d, Ar-H), 7.54 (1H, d, J=12, C=C-H), 7.63 (1H, dd, Ar-H), 8.03 (1H, d, Ar-
H); C (CDCl3) 18.3, 18.5, 25.1, 30.2, 50.7, 55.6, 58.3, 62.0, 96.3, 100.3, 101.7, 107.8, 108.0, 
108.2, 117.8, 120.3, 124.5, 130.7, 133.6, 140.1, 148.1, 151.3, 160.3, 189.1; m/z 
(Electrospray)+  383 ([M+H]+, 100).   
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9.16 General Procedure for the Synthesis of DMU 10502 
A solution of the protected chalcone (3.4 mmol), guanidine hydrochloride (5.1 mmol) and 
aqueous sodium hydroxide (1.08 cm3, 50% w/v, 13.6 mmol) in ethanol (15 cm3) was heated 
at reflux for 24 h. The reaction was quenched with water (40 cm3) and the resulting mixture 
extracted with dichloromethane (3 x 50 cm3). The combined organic extracts were dried 
(MgSO4) and the solvent removed in vacuo. The protected pyrimidine was purified by flash 
chromatography on silica gel using ethyl acetate − hexane (4:6) as eluent. 
 
2-amino-4-(3,4-methylenedioxyphenyl)-6-(2-methoxy-4-tetrahydropyran-2-








Yellow oil (0.025g, 3%), H (CDCl3) 3.90 (3H, s, OCH3), 5.00 (2H, s, broad, NH2), 5.52 (1H, 
t, Cyclic-H), 6.03 (2H, s, OCH2O), 6.72 (1H, d, Ar-H), 6.78 (1H, dd, Ar-H), 6.90 (1H, d, Ar-
H), 7.55 (1H, d, Ar-H), 7.5 (1H, d, Ar-H), 7.58 (1H, dd, Ar-H), 7.87 (1H, d, Ar-H); C 
(CDCl3); m/z (Electrospray)
+ Found 422.1710, C22H22N3O5 requires 422.1710; m/z 






10.1 MTT Assay 
To harvest the adhered cells, medium was aspirated and 1mL of a 1% trypsin-EDTA solution 
was added and the cells were gently agitated for 30 seconds.  The trypsin-EDTA solution was 
removed and immediately replaced by a further 1mL aliquot of trypsin-EDTA solution. The 
cells were incubated at 37°C for approximately 5 minutes or until the cells were visibly non-
adherent.  The resultant cell suspension was placed in a sterile container with 5mL of fresh 
medium. To determine the density of the cell suspension, 100µL was added to 100µL of a 
trypan-blue solution (0.4%) and the number of viable cells was determined using a Neubauer 
haemocytometer (depth 0.1mm, 1/400mm2).  The cell suspension was diluted with medium to 
produce a cell count of 2x103 cells.mL-1 and 100µL aliquots were dispensed into sterile, 96-
well microtitre plates.  With the exception of the MCF7 cells, all plates were incubated for 24 
hours prior to the addition of the compounds of interest.   
For the MCF7 cells, after allowing approximately 4 hours for cells to adhere, 100µL of 
medium containing TCDD (from 100mM stock in DMSO) or medium with 0.2% (v/v) 
DMSO only as a control was added to each well containing cells to give a final concentration 
of 10nM TCDD and 0.1% (v/v) DMSO, for 24 hours to induce CYP expression. The medium 
was then aspirated and 100µL of fresh medium was subsequently added.  
Compounds requiring screening were added to the cells in ten-fold serial dilutions in warm 
medium (37°C), under subdued light, from an appropriate stock (in DMSO). Final 
concentrations were of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and 0.0003μM (in 
quadruplicate). The final concentration of DMSO did not exceed 0.1% (v/v). The cells were 
then allowed to grow on for 96 hours to attain 80-90% confluence in the control wells. 
After 96 hours, 50µL of 2mg.mL-1 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide in sterile phosphate buffer) was added to each well and incubated at  
37°C for 2 hours. All medium was then aspirated and the product (reduced purple formazan) 
was solubilized with 150µL DMSO. Plates were vortexed and the absorbance at 540nm 
determined using a Molecular Devices SpectraMax M5 plate reader with SoftMax® Pro 
software, version 4.8. 
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Relative toxicities of each compound within each cell line were evaluated by determining 
IC50 values (50% of growth inhibition).  Results were expressed as a percentage of the control 
value versus the negative logarithm of the molar drug concentration range using GraphPad 
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